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“Man is a little germ that lives on an unimportant rock ball that revolves 
about an insignificant star on the outer edges of one of the smaller 
galaxies. But on the other hand if you think about that for a few minutes… 
I am absolutely amazed to discover myself on this rock ball rotating 
around a spherical fire. It’s a very odd situation! And the more I look at 
things, I cannot get rid of the feeling that existence is quite weird.” 
“And then more so, when this so-called insignificant little creature has 
inside his skull a neurological contraption that is able to center itself in the 
midst of these incredible expanses of galaxies and start measuring the 
whole thing. That is quite extraordinary!” 
 
Alan Watts (1915 – 1973), Philosopher 
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Summary 
The fixation of inorganic carbon and the conversion to organic molecules is a prerequisite for life and 
the foundation of the carbon cycle on Earth. Since the industrial revolution, this carbon cycle has 
become imbalanced and consequently the atmospheric carbon dioxide (CO2) concentration is 
increasing and is a major cause of global warming. On the other hand, atmospheric CO2 can also be 
considered an important carbon feedstock of the future. Human society has not yet come up with a 
viable solution to convert this inorganic CO2 back into reduced carbon compounds and is still relying 
on natural CO2 fixation. In contrast, nature has evolved multiple solutions to reduce CO2 and 
incorporate it into organic molecules. The involved pathways differ in their cofactor requirements and 
are often limited to anoxic conditions. The most common oxygen tolerant CO2 fixation pathway is the 
Calvin-Benson-Bassham (CBB) cycle found in plants, algae and many prokaryotes. Its central 
carboxylase Ribulose-1,5-bisphosphate carboxylase/oxygenase (RubisCO) is a fairly slow catalyst, 
which also performs a side reaction with oxygen. This leads to an energetically wasteful process called 
photorespiration that results in the loss of already fixed carbon. Many attempts have been made to 
improve the carboxylation reaction of RubisCO directly or to redesign the photorespiration pathway 
to a more energy efficient process. The emerging field of synthetic biology offers an alternative 
approach by designing novel pathways for the fixation of CO2. This approach additionally includes the 
design and engineering of enzymes enabling molecular conversions not found in nature. Although, 
several such artificial pathways have been designed, none of them have been realized so far. This 
reveals an existing gap between the design and the realization and implementation of such a synthetic 
CO2 fixation pathway. 
In this work we designed several synthetic oxygen-tolerant CO2 fixation pathways in a bottom-up 
approach, by freely combining feasible enzyme reactions. The pathways were designed around an 
efficient central carboxylase from the family of enoyl-CoA carboxylases/reductases. Some members of 
this family belong to the most efficient carboxylases known so far, do not accept oxygen as a substrate 
and only require the ubiquitous cofactor NADPH. 
The theoretical analysis of thermodynamic and energetic properties of the designed pathways for CO2 
fixation also showed that they are comparable or even more energy efficient than naturally occurring 
oxygen-tolerant CO2-fixing pathways. We were able to realize two of these cycles in vitro and 
investigated their efficiencies for the fixation of inorganic CO2 into organic molecules. The results 
narrowed the gap between theoretical design and in vivo transplantation. The following results were 
achieved: 
1. First, the Crotonyl-CoA/EThylmalonyl-CoA/Hydroxybutyryl-CoA (CETCH) cycle was established 
in vitro and its CO2 fixation efficiency was increased in several rounds of optimization, including 
the principle of metabolic proofreading to recycle undesired side products. The current version 
CETCH 5.4 is a reaction network of 17 enzymes originating from nine different organisms of all 
three domains of life, including three rationally engineered enzymes. It is energized by ATP- 
and NADPH-regeneration modules and converts CO2 into organic molecules at a rate of 5 nmol 
CO2 min-1 mg-1 protein. A stepwise incorporation of 13CO2 into the cycle intermediates 
confirmed a continuous operation of the cycle for multiple rounds of conversion. The CETCH 
cycle expands the solution space beyond the six naturally evolved CO2 fixation pathways by a 
seventh, man-made alternative that is thermodynamically more efficient than the CBB cycle 
of plants. 
 
2. Second, the HydrOxyPropionyl-CoA/Acrylyl-CoA (HOPAC) cycle was established in vitro and its 
turnover number was increased over several rounds of optimization. The current version 
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HOPAC 4.1 is a reaction network of 15 enzymes originating from eight different organisms 
(including bacteria and archaea). We also applied rational active site engineering to improve 
enzymes towards desired reactions. A stepwise incorporation of 13CO2 into the cycle 
intermediates confirms a continuous operation for multiple rounds of conversion. The HOPAC 
cycle is the second synthetic CO2 fixation cycle established in vitro, but still requires more 
optimization to reach the level of the CETCH cycle. Nevertheless, it increases the available 
options for future applications and allows the parallel optimization of both pathways (HOPAC 
and CETCH) and their comparison. 
 
3. The methylsuccinyl-CoA dehydrogenase (Mcd) from R. sphaeroides was a crucial component 
for the construction of the CETCH and the HOPAC cycle. This enzyme belongs to the family of 
flavin dependent acyl-CoA dehydrogenases, which catalyze the α-,β-carbon bond desaturation 
of acyl-CoA thioesters. The electrons from the oxidation reactions are naturally transferred to 
the membrane bound electron transport chain via electron transfer flavoproteins (ETF). In the 
CETCH cycle, we engineered the enzyme towards using molecular oxygen as a direct electron 
acceptor and in the HOPAC cycle the side reactivity was exploited to convert succinyl-CoA to 
fumaryl-CoA. In turn, to elucidate the enzyme’s substrate specificity and the engineered 
oxidase activity, we crystallized the protein and obtained a high resolution structure. It is the 
first protein structure of an acyl-CoA dehydrogenase converting an α-methyl branched γ-
carboxylic acid CoA thioester. The enzyme also possesses an unusual N-terminal ~170 residue 
extension and we were able to assign a tertiary structure and function to this domain. 
 
In summary, this study laid the foundation for the development of artificial pathways for the fixation 
of CO2. We demonstrated that it is possible to convert inorganic CO2 into organic molecules via two 
synthetic pathways in vitro. These results narrow the gap between theoretical design of synthetic CO2 
fixation pathways and their application in vivo. Additionally, we solved the crystal structure of 
methylsuccinyl-CoA dehydrogenase, revealing a novel fold for a structural domain that is unique 
among the well described family of acyl-CoA dehydrogenases.  
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Zusammenfassung 
Die Fixierung von anorganischem Kohlenstoff und dessen Umwandlung in organische Moleküle bildet 
die Grundlage des Kohlenstoffkreislaufs und ist notwendig für das gesamte Leben auf der Erde. Seit 
der industriellen Revolution ist dieser Kreislauf jedoch gestört und als Konsequenz messen wir einen 
stetigen Anstieg der Konzentration an Kohlenstoffdioxid (CO2) in der Atmosphäre. Dieser Anstieg ist 
unteranderem einer der Hauptgründe für die Klimaerwärmung. Jedoch kann dieses CO2 auch als eine 
wichtige Kohlenstoffquelle der Zukunft betrachtet werden. Unsere Gesellschaft hat allerdings bis 
heute keinen optimalen Prozess gefunden, um dieses anorganische Molekül zurück zu gewinnen und 
ist weiterhin auf natürlich Prozesse angewiesen. Die Natur hat mehrere Stoffwechselwege evolviert, 
um CO2 zu reduzieren und wieder in organische Moleküle einzubauen. Viele dieser Stoffwechselwege 
sind jedoch nur unter anaeroben Bedingungen funktionsfähig. Der meist verbreitete 
sauerstofftolerante Stoffwechselweg zur Fixierung von CO2 ist der Calvin-Benson-Bassham (CBB) 
Zyklus, der in Pflanzen, Algen und Mikroorganismen vorkommt. Die zentrale Carboxylase Ribulose-1,5-
Bisphosphat-Carboxylase/Oxygenase (RubisCO) ist jedoch ein vergleichbar langsamer Katalysator und 
besitzt eine intrinsische Seitenreaktion mit Sauerstoff. Diese Seitenreaktion führt zu einem energetisch 
ungünstigen Prozess, welcher Photorespiration genannt wird. Photorespiration führt unteranderem zu 
dem Verlust von fixiertem CO2 und reduziert damit die Gesamteffizienz der Photosynthese. Viele 
Versuche wurden bereits unternommen, die RubisCO selbst oder den Prozess der Photorespiration zu 
verbessern. Die aufkommende Disziplin der synthetischen Biologie bietet einen neuen Ansatz, in dem 
komplett neue Stoffwechselwege zur Fixierung von CO2 entworfen werden. Dieser Ansatz beinhaltet 
auch das konstruieren (engineering) und entwickeln von Enzymen, um neue Reaktionen zu 
ermöglichen. Solche künstliche Stoffwechselwege wurden schon in früheren Untersuchungen 
entworfen, aber keiner konnte bisher verwirklicht werden. Dies veranschaulicht eine bestehende 
Lücke zwischen dem Entwerfen von synthetischer CO2 Fixierung und dessen tatsächlicher Umsetzen 
und Anwenden. 
Ziel dieser Arbeit war es mehrere sauerstofftolerante und synthetische Stoffwechselwege zur CO2 
Fixierung zu entwickeln, indem enzymatische Reaktionen kombiniert wurden. Das zentrale Enzym 
dieser künstlichen Prozesse stammt aus der Familie der Enoyl-CoA-Carboxylasen/Reduktasen, da diese 
zu den effizientesten Carboxylasen zählen, die bisher bekannt sind. Zudem besitzen sie keine 
Seitenreaktion mit Sauerstoff und benötigen für die Katalyse nur den ubiquitären Cofaktor NADPH. 
Die theoretische Analyse dieser neuen künstlichen Stoffwechselwege zeigte eine vergleichbare oder 
sogar bessere Energieeffizienz gegenüber natürlichen sauerstofftoleranten Prozessen zur CO2 
Fixierung. Von diesen theoretischen Konstrukten, konnten wir zwei Stoffwechselwege in vitro 
realisieren und deren CO2 Fixierungseffizienz analysieren. Diese Resultate verkleinern die bestehende 
Lücke zwischen theoretischem Entwerfen und der Etablierung künstlicher CO2 Fixierung in vivo. Die 
folgenden Resultate wurden erreicht: 
1. Erstens wurde der Crotonyl-CoA/EThylmalonyl-CoA/Hydroxybutyryl-CoA (CETCH) Zyklus in 
vitro realisiert und die CO2 Fixierungseffizienz wurde in mehreren Schritten optimiert. Dies 
beinhaltete auch das Prinzip des metabolic proofreading, um Nebenprodukte zu recyceln. Die 
aktuelle Version CETCH 5.4 ist ein Reaktionsnetzwerk, bestehend aus 17 Enzymen von neun 
verschiedenen Organismen aus allen Domänen des Lebens. Zudem wurden drei Enzyme 
engineered, um bestimmte Reaktion zu katalysieren. Der Stoffwechselweg wird durch ATP- 
und NADPH-Regenerationssysteme angetrieben und wandelt 5 nmol CO2 min-1 mg-1 Protein 
um. Die schrittweise Inkorporation von 13CO2 in die Intermediate zeigte, dass der Zyklus sich 
für mehrere Runden drehte. Der CETCH Zyklus erweitert die sechs natürlich evolvierten 
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Lösungen zur Fixierung von CO2 um eine Siebente, von Menschenhand geschaffene. Zudem ist 
dieser Zyklus thermodynamisch sogar energieeffizienter als der CBB Zyklus von Pflanzen. 
 
2. Zweitens wurde der HydrOxyPropionyl-CoA/Acrylyl-CoA (HOPAC) Zyklus in vitro realisiert und 
die CO2 Fixierungseffizienz wurde schrittweise optimiert. Die aktuelle Version HOPAC 4.1 ist 
ein Reaktionsnetzwerk bestehend aus 15 Enzymen von acht verschiedenen Organismen 
(Bakterien und Archaeen). Unteranderem wurde für den HOPAC Zyklus das rationale 
Entwickeln (engineering) von Enzymen benutzt, um die Katalyse von gewünschten Reaktionen 
zu ermöglichen. Die schrittweise Inkorporation von 13CO2 in die Intermediate bestätigte auch 
für diesen Zyklus, dass mehrere Reaktionsrunden aufrechterhalten werden konnten. Der 
HOPAC Zyklus ist der zweite künstliche Stoffwechselweg zur CO2 Fixierung, der in vitro etabliert 
wurde, jedoch bedarf dieser noch weiterer Optimierungen im Vergleicht zum CETCH Zyklus. 
Der HOPAC Zyklus erweitert die Verfügbarkeit von möglichen Optionen für zukünftige 
Anwendungen und erlaubt die parallele Weiterentwicklung beider Zyklen (CETCH und HOPAC) 
und deren Vergleich.  
 
3. Die Methylsuccinyl-CoA-Dehydrogenase (Mcd) von R. sphaeroides war eine wichtige 
Komponente für die Funktionsfähigkeit des CETCH und HOPAC Zyklus. Dieses Enzym gehört 
zur Familie der flavin abhängigen Acyl-CoA-Dehydrogenasen, welche die α-,β-
Kohlenstoffbindung von Acyl-CoA-Thioestern desaturieren. Die Elektronen aus der 
katalysierten Oxidationsreaktion werden im Organismus via einem elektronen-
transferierenden Flavoprotein (ETF) zur Elektronentransportkette transportiert. Im CETCH 
Zyklus wurde dieses Enzym zu einer Oxidase engineered, um Sauerstoff als direkten 
Elektronenakzeptor zu verwenden und im HOPAC Zyklus wurde die intrinsische Seitenreaktion 
mit Succinyl-CoA ausgenutzt. Um die Substratspezifität und die eingebaute Oxidaseaktivität 
besser zu verstehen, wurde dieses Protein kristallisiert und eine hochauflösende Struktur 
gelöst. Es ist die erste Struktur einer Acyl-CoA-Dehydrogenase, die einen α-Methyl verzweigten 
γ-Carbonsäure CoA Thioester akzeptiert. Dieses Enzym enthält im Gegensatz zu anderen Acyl-
CoA-Dehydrogenasen eine N-terminale ~170 Aminosäure lange Erweiterung und wir konnten 
dieser Domäne eine tertiäre Struktur und Funktion zuordnen. 
Zusammengefasst legt diese Arbeit den Grundstein für die Entwicklung von künstlichen 
Stoffwechselwegen zur Fixierung von CO2. Wir konnten in vitro zeigen, dass es möglich ist 
anorganisches CO2 mit Hilfe von zwei synthetischen Stoffwechselwegen in organische Moleküle zu 
überführen. Die Resultate dieser Arbeit schmälern die Lücke zwischen theoretischem Entwerfen von 
künstlichen Prozessen für die CO2 Fixierung und deren Umsetzung in vivo. Zusätzlich wurde eine neue 
Struktur in der bereits gut erforschten Familie der Acyl-CoA-Dehydrogenasen gelöst. 
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1. Introduction 
 Carbon dioxide in the atmosphere 
In recent years, atmospheric carbon dioxide (CO2) has become a main focus of interest, because it is 
the primary anthropogenic greenhouse gas released by the human economical thrive. Burning fossil 
fuels releases the CO2 that was sequestered by nature over several geological eras millions of years 
ago. Since the industrial revolution, the concentration of CO2 rose from 280 ppm to 400 ppm today 
and the annual anthropogenic release of ~36 Gt of CO2 is expected to rise further (Fig. 1). The 
accumulation of CO2 in the atmosphere correlates undeniably with the experienced rise of the global 
temperature (1). Human society and economy has a very high demand for energy and fossil fuels will 
still be the main source for years until more ecological technologies are developed and viable. Hence, 
fighting global warming will be one of the major and most difficult tasks in the future. 
Whereas the CO2 in the atmosphere poses a threat to our society, it is also considered as an important 
carbon feedstock for the future. The sustainable capture and utilization of CO2 will be crucial to realize 
a green economy that is independent from petrochemical sources. Yet, compared to the 
anthropogenic release of CO2, our capabilities to recapture or reuse atmospheric CO2 are still limited. 
Chemistry still struggles with developing catalysts and processes that allow the conversion of CO2 
under mild conditions into a multi-carbon, value-added product in a carbon-neutral, let alone carbon-
beneficial, sustainable way (2-4). In contrast, natural autotrophic carbon fixation annually transforms 
gigatons of inorganic CO2 into biomass. More than 90% is converted via the Calvin-Benson-Bassham 
(CBB) cycle by plants, algae and microorganisms. The remainder is converted through alternative CO2 
fixation pathways (5, 6). Despite the existence of diverse natural solutions for carbon fixation, the 
biotechnological application of these enzymes and pathways is limited and proved challenging so far 
(7, 8). Additionally, biological CO2 fixation mainly delivers biomass and not a dedicated product. In turn, 
the obtained biomass needs further processing to yield a useful product (e.g. biofuels) (9). 
 
Fig. 1 Annual mean of CO2-concentration in the atmosphere. In green are the annual mean measured in the Law Dome Ice 
Core (10) and in red are the data measured on Mauna Loa, Hawaii by the National Oceanic & Atmospheric Administration 
(NOAA)/ Earth System Research Laboratory (ERSL). www.esrl.noaa.gov/gmd/ccgg/trends/ 
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 Diversity of natural carbon fixation pathways 
The fixation of inorganic carbon and the conversion to organic molecules is a prerequisite for life and 
a vital part in the carbon cycle on our planet. The most prominent CO2 fixation pathway in nature, is 
the CBB cycle, which is responsible for the autotrophic growth of plants, algae, cyanobacteria and 
many other bacterial species. Although this pathway seems to be a late invention during evolution 
compared to some other CO2 fixation pathways (11, 12), it was very successful and able to spread in 
nature. This pathway was first discovered in the late 1940s and is described in a series of publications 
by the group of Melvin Calvin (13-15). The ribulose-1,5-bisphosphate carboxylase/oxygenase 
(RubisCO) is the key enzyme of the CBB cycle and catalyzes the carboxylation of ribulose 1,5-
bisphosphate and produces two molecules of 3-phosphoglycerate (Fig. 2). This intermediate is 
phosphorylated to 1,3-bisphosphoglycerate before it is reduced to glyceraldehyde 3-phosphate. 
Whereas one glyceraldehyde 3-phosphate is used for biosynthesis, five of these C3 molecules are 
recycled via the pentose phosphate pathway to yield three C5 compounds (ribulose 5-phsophate). 
Subsequent phosphorylation of the ribulose 5-phosphate by phosphoribulokinase (PRK) regenerates 
the carboxylation substrate. Consequently, three cycles are required to produce one molecule of 
glyceraldehyde 3-phosphate and regenerate the CO2 accepting intermediate. The vast success of the 
CBB cycle in evolution can be partially accounted for by the fact that all its enzymes are oxygen tolerant 
(5). However, in the presence of molecular oxygen RubisCO also exhibits an oxygenase activity, which 
produces the toxic side product 2-phosphoglycerate (16). Photorespiration is a wasteful detoxifying 
process in organisms to prevent the accumulation of the side product and recycle it to 3-
phosphoglycerate. Since this pathway involves a decarboxylation step, CO2 fixation efficiency of the 
organism is reduced (17, 18). 
 
Fig. 2 Simplified scheme of the CBB cycle. Note, that not all individual enzymatic conversions are shown. The two key enzymes 
are ribulose-5-phosphate kinase (phosphoribulokinase, PRK) and ribulose-1,5,-bisphosphate carboxylase/oxygenase 
(RubisCO). Glyceraldehyde-3-phosphate is withdrawn and my enter gluconeogenesis or glycolysis for further conversion. 
  
Introduction 
9 
 
After the discovery of the CBB cycle, it was assumed to be the only carbon fixation pathway, which fit 
with the central biological dogma of biochemical unity of life at that time (19). But this dogma only 
stood for two decades because several alternative CO2 fixation pathways have been discovered to 
date. These pathways are adapted to the environmental conditions given by a certain habitat to allow 
efficient fixation of inorganic CO2 (5). 
Already in the 1960s, the reductive citric acid (rTCA) cycle was discovered as an alternative CO2 fixation 
pathway (20). The name already implies, that the pathway reverses the reactions of the oxidative citric 
acid cycle (Krebs cycle) and forms acetyl-coenzyme A (CoA) from two molecules of CO2 (Fig. 3). 
Subsequently, acetyl-CoA is reductively carboxylated to pyruvate by a ferredoxin-dependent pyruvate 
synthase. Three enzymes are characteristic for this cycle and enable reversed flux through the 
pathway. Succinate dehydrogenase is replaced by fumarate reductase, the nicotinamide dinucleotide 
(NAD+)-dependent 2-oxoglutarate dehydrogenase is replaced by 2-oxoglutarate:ferredoxin 
oxidoreductase (21) and the citrate synthase is replaced by adenosine triphosphate (ATP) citrate lyase 
(22). These enzymes support the reversion of the Krebs cycle, but the overall conversion from succinate 
to acetyl-CoA is still endergonic (ΔG°´ +27 kJ) (6). Although, the rTCA cycle is quite energy efficient, it 
needs reduced ferredoxin to drive the system thermodynamically. Conclusively, the pathway is 
restricted to anaerobic organisms. 
 
Fig. 3 Simplified scheme of the rTCA cycle adapted from (6). Note, that not all individual enzymatic conversions are shown. 
The key enzymes are ATP-citrate lyase, 2-oxoglutarate:ferredoxin oxidoreductase and fumarate reductase. The carboxylation 
reactions are catalyzed by isocitrate dehydrogenase, 2-oxoglutarate:ferredoxin oxidoreductase and pyruvate:ferredoxin 
oxidoreductase (pyruvate synthase). 
Moreover, the reductive acetyl-CoA pathway (Wood-Ljungdahl pathway) is found in acetogenic 
bacteria and methanogenic archaea, which live close to the thermodynamic limit, and requires the 
least input of ATP among all known CO2-fixing pathways. It is not only used for the fixation of CO2, but 
also for the conservation of energy (23-25). The genomic reconstruction of LUCA (last universal 
common ancestor) predicts that this pathway already operated at the beginning of life (26). In this 
pathway, acetyl-CoA is produced as the primary assimilation product from two molecules of CO2 (Fig. 
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4). The first molecule of CO2 is reduced to carbon monoxide and binds to the nickel containing Fe-S 
cluster of the key enzyme, CO dehydrogenase/acetyl-CoA synthase. In acetogens, the second CO2 
molecule is reduced to formate and coupled to the cofactor tetrahydrofolate (H4F). Subsequently, the 
formyl-H4F is further reduced to methyl-H4F and the methyl group is also transferred to the CO 
dehydrogenase/acetyl-CoA synthase, and acetyl-CoA is formed (27). Subsequently, acetyl-CoA can be 
carboxylated by pyruvate synthase to form pyruvate. Despite its high energy efficiency, this pathway 
is only functional under strictly anaerobic conditions, as it utilizes highly oxygen-sensitive metal 
co-factors and reduced ferredoxin. Therefore, it is only found in a limited number of anaerobic 
organisms.  
 
Fig. 4 Simplified scheme of the reductive acetyl-CoA pathway (Wood-Ljungdahl pathway) adapted from (6). One CO2 is 
reduced to a methyl group bound on a carrier molecule. This reaction sequence differs in acetogens and methanogens 
(indicated by a blue or red box), because different reductants and coenzymes are applied. A second CO2 molecule is reduced 
to a nickel bound carbon monoxide in the active site of CO dehydrogenase/acetyl-CoA-synthase. This enzyme also combines 
the reduced methyl group with CO to form acetyl-CoA. Acetyl-CoA can be further reductively carboxylated to pyruvate. The 
CO2 fixing enzymes are formate dehydrogenase, formyl-methanofuran dehydrogenase, CO dehydrogenase/acetyl-CoA-
synthase, pyruvate:ferredoxin oxidoreductase. MFR: methanofuran; H4F: tetrahydrofolate; H4PT: tetrahydropterin (H4F is 
present in acetogens and H4PT in methanogens). 
 
The following three CO2 fixation pathways have been elucidated in the laboratory of Georg Fuchs and 
are often termed Fuchs cycles I, II and III. 
The first hints towards the 3-hydroxypropionate (3HP) bi-cycle were already published in the late 1980s 
(28). Yet, it took another 20 years to elucidate the full reaction sequence of the pathway. Two 
metabolic cycles are involved for the fixation of CO2 (Fig. 5). In the first cycle acetyl-CoA is carboxylated 
to malonyl-CoA by acetyl-CoA carboxylase. The reduction of malonyl-CoA to propionyl-CoA is catalyzed 
by a bi-functional malonyl-CoA reductase (29) and a tri-functional propionyl-CoA synthase (30). 
Subsequently, propionyl-CoA is carboxylated to methylmalonyl-CoA by propionyl-CoA carboxylase 
(Pcc) and isomerized to succinyl-CoA. The oxidation of succinyl-CoA to malyl-CoA proceeds via the free 
carboxylic acids. A CoA transfer from succinyl-CoA to malate by succinyl-CoA:(S)-malate-CoA 
transferase leads to the formation (S)-malyl-CoA. The latter is then cleaved into acetyl-CoA and 
glyoxylate. In the second cycle, acetyl-CoA is again carboxylated followed by reduction to propionyl-
CoA (identical to the first cycle), however, propionyl-CoA is now condensed with glyoxylate (the 
product of the first cycle) to form β-methylmalyl-CoA. After a series of C5-transformations, (S)-
citramalyl-CoA is formed and subsequently cleaved into acetyl-CoA and pyruvate. All condensation and 
cleavage reactions are catalyzed by one tri-functional malyl-CoA/β-methylmalyl-CoA/citramalyl-CoA 
lyase (31-33). Interestingly the whole pathway involves 19 reactions, but requires only 13 enzymes to 
catalyze them, none of which are oxygen sensitive. Considering also the more efficient carboxylases 
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than RubisCO, it is interesting, that this pathway was less successful during evolution and appears to 
be restricted to Chloroflexaceae. 
 
 
Fig. 5 Simplified scheme of the 3HP bi-cycle adapted from (6). Note, that not all individual enzymatic conversions are shown. 
The key enzymes are the bifunctional malonyl-CoA reductase, trifunctional propionyl-CoA synthase and the malyl-CoA/β-
methylmalyl-CoA/citramalyl-CoA lyase. The carboxylation reactions are catalyzed by acetyl-CoA carboxylase and propionyl-
CoA carboxylase. In the first cycle (left) one molecule of glyoxylate is produced, which is used in the second cycle (right) to 
produce pyruvate. 
 
The 3-hydroxypropionate/4-hydroxybutyrate (3HP/4HB) cycle for CO2 fixation operates in autotrophic 
thermoacidophilic Crenarchaeota and mesophilic Thaumarchaeota (5, 34, 35). The first part of the 
cycle is identical to the 3HP bi-cycle and converts acetyl-CoA with two carboxylation steps to succinyl-
CoA via propionyl-CoA (Fig. 6). However, the key enzymes for the reduction of malonyl-CoA to 
propionyl-CoA are not homologous in archaea and Chloroflexaceae, suggesting an independent and 
convergent evolution of the two pathways (33, 35, 36). The second part of the cycle converts succinyl-
CoA to 4-hydroxybutyryl-CoA via 4-hydroxybutyrate. The key enzyme 4-hydroxybutyryl-CoA 
dehydratase catalyzes the dehydration to crotonyl-CoA, which is eventually oxidized to acetoacetyl-
CoA. Subsequent cleavage of acetoacetyl-CoA yields two molecules of acetyl-CoA, closing the cycle. All 
enzymes are oxygen tolerant and the pathway can be found in aerobic as well as anaerobic organisms. 
Although the key enzyme (4-hydroxybutyryl-CoA dehydratase), is a radical enzyme and homologs in 
clostridia are susceptible to inactivation by molecular oxygen, the archaeal enzymes seem to be 
sufficiently oxygen insensitive (34). 
The last natural CO2 fixation cycle discovered is the dicarboxylate/4-hydroxybutyrate (DC/4HB) cycle 
and operates in archaea as well (37). Similar to the pathways described before, acetyl-CoA is also 
carboxylated twice to yield succinyl-CoA (Fig. 6). However, a different reaction sequence with two 
different carboxylases is used. Unlike before, acetyl-CoA is first reductively carboxylated by pyruvate 
synthase, to produce pyruvate. Subsequently, pyruvate is activated to phosphoenol pyruvate (PEP) and 
further carboxylated to oxaloacetate by PEP carboxylase. After the conversion to succinyl-CoA, two 
molecules of acetyl-CoA are produced via 4-hydroxybutyrate as described for the 3HP/4HB cycle. Since 
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the enzymes and electron carriers of the DC/4HB cycle are susceptible to oxygen, this pathway is 
restricted to anaerobic archaea. 
 
 
Fig. 6 Simplified scheme of the 3HP/4HB cycle (red) and the DC/4HB cycle (blue) adapted from (6). Note, that not all 
individual enzymatic conversions are shown. The key enzyme is the 4-hydroxybutyryl-CoA dehydratase. While the 3HP/4HB 
cycle depends on biotin dependent acyl-CoA carboxylases, the DC/4HB cycle catalyzes the carboxylation reactions via 
pyruvate:ferredoxin oxidoreductase and the phosphoenolpyruvate carboxylase. Both cycles convert succinyl-CoA to two 
acetyl-CoA via 4-hydroxybutyrate. 
 
Conclusively, many different strategies to fix CO2 for autotrophic growth have evolved in nature, of 
which six have been discovered so far. Each pathway evolved in a specific environment, thus 
representing an adaptation to a certain ecological niche. The occurrence of a particular pathway in an 
organism is highly dependent on the physiological conditions, such as energy requirements and type 
of reducing equivalents used for the reduction of the CO2. Further determinants are their requirements 
for special cofactors, metals and especially their tolerance towards molecular oxygen. 
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Table 1 Pathways for autotrophic carbon fixation, adapted from (36) 
Pathway 
ATP equival-
ents for 
synthesis of 
one pyruvate 
Reductants for 
synthesis of on 
pyruvate 
(10 [H]) 
CO2-fixing enzymes Key enzymes 
Oxygen 
tolerant 
Calvin-Benson-
Bassham cycle 
 
7 5 NAD(P)H RubisCO (CO2) RubisCO, 
phosphoribulo-kinase 
Yes 
Reductive citric 
acid cycle 
2-3 2 NAD(P)H, 
1 NADH or an 
unknown donor 
of fumarate 
reductase, 
2 ferredoxin 
2-Oxoglutarate 
synthase (CO2), 
isocitrate 
dehydrogenase (CO2) or  
2-oxoglutarate 
carboxylase (HCO3-), 
pyruvate synthase (CO2) 
 
2-Oxoglutarate 
synthase, 
ATP citrate lyase 
No 
Reductive acetyl-
CoA pathway 
~1 NAD(P)H, 
Ferredoxin, 
F420-H2 in 
Euryarchaeota 
CO dehydroge-
nase/Acetyl-CoA 
synthase (CO2), 
formate dehydroge-
nase (CO2), 
Pyruvate synthase (CO2) 
 
CO dehydrogenase/ 
Acetyl-CoA synthase 
and enzymes reducing 
CO2 to methyl-H4F 
No 
3-Hydroxypropio-
nate bi-cycle 
7 NAD(P)H, but 1 
quinone is 
reduced by 
succinate 
dehydrogenase 
 
Acetyl-CoA and 
propionyl-CoA 
carboxylase (HCO3-) 
Malonyl-CoA reductase, 
propionyl-CoA 
synthase, 
malyl-CoA lyase 
 
Yes 
3-Hydroxypropio-
nate/4-hydroxy-
butyrate cycle 
9 NAD(P)H, but 1 
quinone is 
reduced by 
succinate 
dehydrogenase 
Acetyl-CoA and 
propionyl-CoA 
carboxylase (HCO3-) 
Acetyl-CoA/propio- 
nyl-CoA carboxylase, 
enzymes reducing 
malonyl-CoA to 
propionyl-CoA, 
4-hydroxybutyryl-CoA 
dehydratase 
 
Yes 
Dicarboxylate/4-
hydroxybutyrate 
cycle 
5 2-3 ferredoxin 
1-2 NAD(P)H, 1 
unknown donor 
of fumarate 
reductase 
 
Pyruvate synthase 
(CO2), PEP carboxylase 
(HCO3-) 
4-Hydroxybutyryl-CoA 
dehydratase 
No 
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 Carboxylases in nature 
Carboxylases are the key enzymes of all CO2-fixing pathways and are among the most important 
enzymes in the biosphere. Since they catalyze the incorporation of inorganic CO2 into organic 
molecules, they are crucial for the carbon cycle and supply all life on earth with reduced carbon 
compounds. Although, all carboxylases transfer a CO2 molecule to an organic substrate, they differ in 
the underlying mechanism, as well as co-substrates and cofactors used (38). Carboxylases are not only 
function in autotropic pathways, where the carbon fixation reaction delivers the initial precursor for 
all biomass formed in a cell (as discussed above); they serve a broad range of physiologically relevant 
functions (39). 
(i) Carboxylases can be found in assimilatory pathways, where they are important for the 
functionalization of inert substrates such as phenol, acetophenone, epoxypropane or acetone (40-42) 
as an alternative to oxygen-dependent activation in anaerobic organisms. Additionally, by-fixation of 
CO2 can occur in assimilatory pathways, where substrates are converted to central metabolites by 
carboxylation. For example, the shortest odd-numbered acyl-CoA ester, propionyl-CoA (C3), cannot be 
metabolized by classical β-oxidation and is therefore carboxylated to (2S)-methylmalonyl-CoA for 
assimilation via succinyl-CoA (C4) (43). Furthermore, the assimilation of acetate, even-numbered fatty 
acids, alkanes, alcohols, esters and the bacterial storage polymer polyhydroxybutyrate (PHA) occurs 
with an initial conversion to acetyl-CoA. In turn, acetyl-CoA (C2) is transformed into metabolites of 
greater complexity (C3 and C4) via carboxylation reactions. Anaerobic organisms are able to directly 
carboxylate acetyl-CoA to pyruvate via pyruvate:ferredoxin oxidoreductase, the same enzyme found 
in the rTCA cycle, DC/4HB cycle and reductive acetyl-CoA pathway (44). On the other hand, aerobic 
organisms are known to assimilate acetyl-CoA via the glyoxylate cycle, methylaspartate pathway and 
the ethylmalonyl-CoA pathway (45-47). Interestingly, the methylaspartate pathway comprises the 
carboxylation of propionyl-CoA, but a preceding decarboxylation step results in an overall neutral 
carbon yield. In contrast, the ethylmalonyl-CoA pathway applies two carboxylation reactions to convert 
three molecules of acetyl-CoA into two C4 molecules (succinyl-CoA and malate), resulting in a positive 
carbon yield within this pathway. Note that one of these carboxylation reactions is performed by a 
nicotinamide dinucleotide phosphate (NADPH) dependent enoyl-CoA carboxylase, crotonyl-CoA 
carboxylase/reductase (Ccr). 
(ii) Carboxylases can also be found in other anaplerotic pathways, which are essential to maintain the 
function of central metabolism. The most important anaplerotic reaction is the replenishing of the TCA 
cycle intermediate, oxaloacetate, from pyruvate (48). The conversion involves either the carboxylation 
by PEP carboxylase or the biotin-dependent pyruvate carboxylase. Notably, the ethylmalonyl-CoA and 
methylaspartate pathway are also anaplerotic pathways and there is a functional overlap between 
assimilatory and anaplerotic carboxylases in some organisms.  
(iii) In biosynthetic pathways, specific building blocks for the cells are generated. Carboxylases are 
involved in the essential biosynthesis of fatty acids, by providing activated acyl-CoA esters (49). Acetyl-
CoA is carboxylated to malonyl-CoA by a biotin-dependent acetyl-CoA carboxylase and subsequent 
decarboxylation yields a reactive enolate that acts as a nucleophile for the extension of the growing 
carbon chain in a Claisen condensation-like reaction. Furthermore, carboxylases are providing 
substrates for the phylogenetically related polyketide synthases. The most common extender units 
methylmalonyl-CoA and ethylmalonyl-CoA are formed by a biotin-dependent Pcc or NADPH-
dependent Ccr (50). Homologues of Ccr form the class of carboxylating enoyl-thioester reductase (ECR) 
are known to accept a broad range of substrates, providing a diverse spectrum of polyketide extender 
units (51, 52). 
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(iv) Finally, carboxylases are important for balancing the redox state in a cell by using CO2 as electron 
acceptor. For example, the CBB cycle with RubisCO is absolutely essential in purple non-sulfur bacteria 
during anaerobic photoheterotrophic growth and acts as electron sink (53, 54). But not only the CBB 
cycle has been found to be important in redox balancing, also the ethylmalonyl-CoA pathway that uses 
reductive carboxylation serves as an electron sink in R. sphaeroides under photoheterotrophic 
conditions (55). 
Conclusively, nature evolved many ways to catalyze the fixation of CO2 into organic matter not only for 
autotrophic growth, but for many diverse physiologically important processes. CO2 is readily available 
in the atmosphere as gas or dissolved in water as bicarbonate (HCO3-) and is effectively used as simple 
C1 extension in biosynthetic pathways. While nature has found many mechanisms to reduce and 
incorporate CO2 under mild conditions, our technology and chemistry is still lacking behind in making 
efficient use of this molecule. The increasing concentration of carbon dioxide in the atmosphere 
requires new methods to cope with this greenhouse gas and nature provides a multitude of solutions 
for this problem. Understanding, applying and improving naturally evolved CO2 fixation in organic 
chemistry, biotechnology and synthetic biology is therefore an important scientific task. 
 Improving natural carbon fixation 
In the past, several possibilities to improve and apply biological CO2 fixation mechanisms have been 
explored. Initial attempts focused on the key enzyme, RubisCO, since the CO2 fixation rate of the CBB 
cycle is restricted by low activity of the carboxylase (1 –10 s-1) (56). In a cell, sufficient flux is achieved 
by high expression levels of RubisCO, which can account for up to 50% of soluble protein (57). 
Moreover, RubisCO accepts molecular oxygen as substrate, which leads to photorespiration and in 
turn to the loss of ammonia (NH3) and carbon dioxide (see above). This oxygenation reaction of the 
enzyme occurs under ambient conditions approximately every fifth turn over. Therefore, RubisCO was 
subjected to directed evolution or engineering towards higher reaction rates with increased CO2/O2 
specificity (58-60). These attempts were met with limited success, because it became apparent that 
there is an inherent trade-off between activity and specificity. RubisCOs with a higher turnover rate 
show even less specificity towards CO2, resulting in a higher oxygenation rate (61, 62). In nature, 
certain organisms evolved different CO2-concentration mechanisms (CCM) to optimize the operational 
conditions for RubisCO and decrease the oxygenation side reaction (63). Accordingly, different 
attempts focused on these CCMs, by either mimicking the C4-plants mechanism for CO2 concentration 
(64) or expressing carboxysome proteins for the generation of a heterologous CO2-fixing organelle (65). 
Further strategies aim to decrease the deleterious side effects of the oxygenation reaction, by 
improving/replacing the photorespiration pathway (56). A recently published study even proposed a 
synthetic photorespiration route based on the 3HP bi-cycle. Compared to the canonical pathway, this 
synthetic solution prevents not only the loss of ammonia, but results in the additional fixation of CO2 
via different carboxylases (66). Another attempt involves the transplantation of natural CO2 fixation 
pathways into heterologous host organisms. Nevertheless, the introduction of the 3HP bi-cycle into E. 
coli (67) or the introduction of the natural 3HP/4HB cycle into P. furiosus (68) were less successful. The 
most successful transplantation so far involves the heterologous operation of the CBB cycle in E. coli, 
which required the introduction of three genes. (69). This genetically modified organsim was able to 
drive the heterologous CBB cycle with reducing equivalents and ATP derived from the oxidation of 
pyruvate in the TCA cycle. In this strain, a substantial amount of biomass is still produced from 
pyruvate, but sugar phosphates are exclusively generated from CO2 via the implemented CBB cycle. 
Initially, no growth of the so-called hemi-autotrophic organism could be observed and it was decided 
to evolve the strain under constant selective pressure. Xylose enabled the continuous operation of the 
heterologous CBB cycle and the population evolved towards growth on pyruvate and CO2 after about 
Introduction 
16 
 
50 days. Interestingly, genome sequencing revealed mutations of enzymes at branching points of the 
CBB cycle and the authors concluded that fine-tuning of the carbon flux between the carbon fixation 
cycle and biosynthetic pathways was crucial. They also determined that almost 35% of cellular carbon 
originated from carbon dioxide. Despite this semi-autotrophic growth and the fact that the organism 
applies the “inefficient” CBB cycle, this study is a major step towards transplanting CO2 fixation 
pathways into heterotrophic organisms. This study also lays a foundation for future attempts to 
introduce more efficient or artificial CO2 fixation pathways into heterologous hosts. 
In contrast to these efforts, the emerging field of synthetic biology provides an even more radical 
approach, by creating completely artificial CO2-fixing pathways. Since nature offers many different 
solutions for the fixation of inorganic CO2, completely novel routes can be designed around efficient 
carboxylases. Previous efforts have been made to understand and describe the thermodynamics and 
kinetics of central carbon metabolism and also the stability of autocatalytic cycles (70-72). These 
findings provide the foundation for the design of novel pathways. The free combination of different 
enzymatic reactions, including a more efficient carboxylase than RubisCO, leads to kinetically and 
thermodynamically favored pathways. Several such synthetic routes for CO2 fixation have already been 
theoretically and computationally considered, by using the entire repertoire of approximately 5000 
metabolic enzymes described so far (73). In this study, the authors followed a constraint-based 
modeling approach to design thermodynamically feasible pathways based on the efficient carbon 
fixation enzyme PEP carboxylase. These designed synthetic pathways were calculated to be 
approximately 2-3 times faster than the CBB cycle. It is a very intriguing idea to design artificial CO2-
fixing pathways with superior thermodynamics and kinetics, compared to the naturally evolved 
solutions. Nevertheless, the strong focus on the computational analysis and the in silico design was not 
followed up by the assembly of a synthetic carbon fixation route in vitro or in vivo so far.  
We decided to take a slightly different approach to design artificial CO2 fixation pathways. We did not 
restrict the design on naturally occurring reactions, but more on biochemically feasible conversions 
(i.e. falling into one of the standard E.C. reaction classes) and reactions, which require simple cofactors, 
such as CoA, NAD(P)H, ATP, or flavin adenosine dinucleotide (FAD). Conclusively, this design principle 
includes not yet discovered or unprecedented reactions and permits a more extended solution space. 
Nevertheless, these yet unknown reactions could be achieved by enzyme engineering and evolution. 
Comparable to the previously described approach, we designed our pathways around an efficient 
central carboxylase. In this case, we decided to base our synthetic CO2 fixation pathway on the 
carboxylation reaction catalyzed by CoA-dependent carboxylases and in particular enoyl-CoA 
carboxylase/reductases (ECRs), since they show favorable catalytic properties in comparison to other 
carboxylases. 
As aforementioned, none of such designed artificial CO2 fixation pathways have been realized so far, 
emphasizing an existing gap between theoretical design and experimental realization in synthetic 
biology. A common problem is the attempt to assemble a synthetic pathway directly into a living 
organism. Often, there is a lack of understanding the complex interplay of the artificial pathway with 
the host organism that leads to undesired effects, such as side-reactions and toxicity. Therefore, the 
realization of synthetic pathways requires a different strategy, which allows to understand, test and 
optimize it in a cell free environment (74-76). A prime example is the research field of synthetic 
biochemistry, which focuses on biologically produced compounds in cell free systems via synthetic 
pathways (77, 78). This approach offers the advantage that only the production of the desired 
compound is important without considering the survivability of an organism and could lead to higher 
rates and yields than in production strains (77, 78). Yet, the stability of such a synthetic system is highly 
dependent on the regeneration and balancing of energy and redox equivalents (79, 80). These 
achievements prove that the in vitro approach is a viable platform for the development of synthetic 
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metabolic pathways. Therefore, we aim to narrow the existing gap in the field of synthetic CO2 fixation, 
by first realizing artificial pathways in vitro. This allows the prior testing, optimization and investigation 
before an in vivo application is attempted. 
 
 Aim of this study 
A general aim of this study was to design efficient artificial pathways for the fixation of CO2 based on 
the highly efficient carboxylation reaction of enoyl-CoA carboxylase/reductase (52). Following the 
approach of synthetic biochemistry, we focused on the experimental proof of these artificial pathways 
in vitro. 
1.5.1. Design of synthetic CO2 fixation 
In the beginning several possible pathways were designed by using a principle called metabolic 
retrosynthesis. After considering different carboxylases, our designs were constructed around the 
highly efficient carboxylation reaction performed by the class of ECR. Given a certain ECR carboxylation 
reaction as starting point, molecular conversions from the standard reaction classes defined by the 
Enzyme Commission (including other carboxylation reactions) were used to regenerate the starting 
substrate. Notably, the designs were not restricted to known enzymes, but rather to reactions that are 
biochemically feasible. Additionally, the fixed CO2 was channeled into a primary assimilation product 
via a dedicated output reaction. With this design principle, several prospective cycles were obtained 
and further analyzed for thermodynamic and energetic properties. The most promising candidates 
were selected for their realization, testing and optimization in a defined cell free environment. 
1.5.2. Realization of synthetic CO2 fixation 
Furthermore, this study focused not only on the theoretical design, but approached the realization and 
optimization of the artificial CO2 fixation cycles in a reductionist approach by assembling the artificial 
pathway from its principle components in vitro. Two promising candidates from the design phase, the 
Crotonyl-CoA/EThylmalyonyl-CoA/Hydroxybutyryl-CoA (CETCH) cycle and the Hydroxypropionyl-
CoA/Acrylyl-CoA (HOPAC) cycle, were realized in a cell free environment with purified enzymes. Both 
pathways were improved stepwise in their CO2 fixation efficiency within the boundaries of the in vitro 
system. 
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2. Theoretical design and analysis of synthetic CO2 fixation cycles 
 Metabolic retrosynthesis 
A known bottleneck in natural CO2 fixation is the efficiency of the carboxylating enzyme in a given 
pathway (34, 81, 82). To identify a suitable carboxylase as the core reaction for the synthetic pathways, 
we first compared the different biochemical and kinetic properties of all known major classes of 
carboxylating enzymes (83) (Table 2 and Fig. 7).  
Table 2 Comparison of different carboxylase classes.  
Carboxylase class 
Oxygen 
sensitivity 
Catalytic efficiency kcat KM-1 
(M-1 s-1) [a] 
vmax 
(U mg-1) 
Enoyl-CoA reductases/ carboxylases (ECRs) No 7.0 ± 5.1  105 [b],[d] 130 [e] 
Acetyl-CoA carboxylase  No 4.9 ± 3.7  105 [c] 18 [e] 
RubisCO 
No, but side reaction 
with oxygen 
2.9 ± 1.1  105 [c] 3.5 [e] 
Propionyl-CoA carboxylase No 1.6 ± 1.6  105  [c] 30 [e] 
PEP carboxykinase No 1.2 ± 1.1  105 [c] 39 [e] 
2-oxoglutarate carboxylase No 0.6 ± 0.7  105 [c] 15 [e] 
Pyruvate carboxylase No 0.4 ± 0.4  105 [c] 30 [e] 
Methylcrotonyl-CoA carboxylase No 0.3 ± 0.3  105 [c] 6 [e] 
2-Keto acid synthases Yes -- -- 
[a] kcat /KM–values are given in respect to the carboxylation substrate of each carboxylase, for individual data, see Fig. 7 below. 
[b] from Peter et al. 2015 (52) and (84). [c] from the BRENDA database Chang et al. 2015 (85); http://www.brenda-
enzymes.org/). Taken into account were only entries that provided kcat and KM measurements for the same enzyme in the 
same study. [d] Note that ECRs include enzymes from primary and secondary metabolism. Only enzymes from primary 
metabolism were evaluated. [e] from Bar-Even A. et al. 2010 (73). Specific activity are given for saturating CO2/HCO3- 
concentrations. 
 
Fig. 7 Catalytic efficiencies of individual enzymes within a given class of carboxylases different classes of carboxylases. Each 
dot represents the parameter of an individual enzyme according to the sources used in Table 2.  
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From this analysis, we decided to design our synthetic CO2 fixation pathways around the carboxylation 
reaction catalyzed by CoA-dependent carboxylases and in particular enoyl-CoA carboxylase/reductases 
(ECRs), since they show favorable catalytic properties in comparison to other carboxylases. ECRs are a 
recently discovered class of carboxylases, which are important in primary central metabolism but can 
also be found in secondary metabolism (47). Notably, this class of enzymes has not been discovered in 
any pathway for autotrophic growth so far. Compared to RubisCO and other carboxylases, ECRs span 
a broad substrate spectrum (52), which enables the design of multiple synthetic pathways starting 
from different carboxylation substrates. This increases the possibilities to design an efficient CO2 
fixation cycle. Additionally, these enzymes are preferable, because they are oxygen-insensitive, do not 
accept oxygen as substrate, require only the ubiquitous cofactor NADPH for the reduction, and catalyze 
the fixation of CO2 with high catalytic efficiency (Table 2 and Fig. 7) (38).  
According to the initial analysis of the central carboxylation reaction, we designed several theoretical 
CO2 fixation pathways, in a process we termed metabolic retrosynthesis. Comparable to chemical 
retrosynthesis, where a reaction sequence for the formation of a product is planned beforehand, we 
assembled a theoretical metabolic pathway from possible enzymatic catalyzed reactions applying the 
following constrains. Starting from a given central ECR reaction, the initial substrate is regenerated in 
the pathway to allow continuous cycling. In contrast to earlier approaches, we did not restrict our 
design to known enzymes (73, 86), but rather considered all reactions that seemed biochemically 
feasible (i.e. fall into one of the standard E.C. reaction classes) and required simple cofactors, such as 
CoA, NAD(P)H, ATP, or flavin adenosine dinucleotide (FAD). Additionally, the fixed CO2 is channeled 
into a product via a dedicated output reaction. Following this metabolic retrosynthesis approach, we 
obtained several prospective cycles, of which the Crotonyl-CoA/EThylmalonyl-CoA/ 
4-Hydroxybutyryl-CoA (CETCH), HydrOxyPropionyl-CoA/Acrylyl-CoA (HOPAC), Crotonyl-CoA/ 
HYdroxyethylmalonyl-CoA/MEthymalonyl-CoA (CHYME), CRotonyl-CoA/ACEtoacetate (CRACE), 
FUmaryl-CoA/MEthylmalonyl-CoA/Succinyl-CoA (FUMES), Hydroxycrotonyl-CoA/ITaconyl-CoA/ 
MEthylmalonyl-CoA (HITME) and HYdroxycrotonyl-CoA/Propionyl-CoA/Acetyl-CoA (HYPA) cycle were 
considered further (Fig. 8).  
 Analysis of thermodynamic and enzymatic properties 
Next, we examined the theoretical drafts for certain properties. First, we evaluated the 
thermodynamic feasibility of these theoretical cycles, by calculating the Gibbs free energy profiles 
under standard and biologically relevant conditions (Fig. 8 and chapter 8.1). This verified that the 
reaction sequence is driven in the direction of CO2 fixation and no endergonic barrier is incorporated 
in the system. Although, some reaction in the pathways require the input of energy, they are coupled 
to exergonic steps to preserve the thermodynamic driving force. Another important factor is the 
availability of enzymes to catalyze the intendent reactions. Therefore, we searched bioinformatic 
databases for enzymes that are able sustain our drafts. For the CETCH and the HOPAC cycle we were 
able to identify potential enzyme candidates for each reaction. With the approach of synthetic biology 
we can choose from the vast diversity of enzymes in nature and considering further characterization 
of homologs, even more suitable enzymes can be obtained for the operation of the pathway. On the 
contrary, for some of the designed CO2 fixation cycles we could not identify a candidate for each 
reaction. Nevertheless, the field of enzyme design and engineering offers great potential to fill these 
gaps, by obtaining novel biologically catalyzed reactions (87). 
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Fig. 8 Topology and thermodynamic profiles of seven selected synthetic CO2 fixation cycles. 
Depicted are seven promising synthetic CO2 fixation cycles that were conceived by metabolic 
retrosynthesis. (A) CETCH cycle, (B) HOPAC cycle, (C) CHYME cycle, (D) CRACE cycle, (E) FUMES 
cycle, (F) HITME cycle, and (G) HYPA cycle.  
The theoretical cycles were drafted based on a given ECR reaction (#1 in each reaction 
scheme). Note that the stereochemistry of individual reactions (i.e., the requirement for 
epimerases and racemases) was not taken into account at the design stage, but only during 
the realization phase. 
The Gibbs free energy profile of these theoretical cycles is shown at the center of the 
respective pathway. The Gibbs free energy profiles were based on calculations and 
estimations using the eQuilibrator software (88) (http://equilibrator.weizmann.ac.il/) or other 
sources (indicated in the tables in chapter 8.1). Shown in dark red are the summarized Gibbs 
free energies along the individual reactions for ΔrG’ at pH 7.8, ionic strength I = 0.2, and 
assuming the following metabolite concentrations: substrates (CoA ester, acids, aldehydes) = 
0.2 mM; products (CoA ester, acids, aldehydes) = 0.2 mM; free CoA = 0.5 mM; Quinone / 
Quinol (2[H]) = 0.1 mM; ATP = 1.2 mM; ADP = 0.6 mM; AMP = 0.2 mM; NADPH = 3.6 mM; 
NADP+ = 0.4 mM. Shown in light red is the summarized ΔrG’m (assuming a concentration of 1 
mM for each metabolite) as comparison.  
The overall reaction summarized from the individual reaction steps is given below each cycle.  
An evaluation of enzyme candidates available to realize the theoretical cycles is also given. 
Reactions for which potential candidates could be identified are highlighted in green boxes 
and reactions for which obvious candidate enzymes were missing according to bioinformatic 
analysis and database queries are shown in grey boxes. 
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 Analysis of energetic properties 
We assessed the energetic cost of the synthetic drafts and natural CO2 fixation pathway, by estimating 
the presumable ATP- and NAD(P)H-consumption of each cycle for the conversion of CO2 into its 
primary fixation product. First, we derived the overall reaction stoichiometry of each cycle and added 
the number of NAD(P)H, ATP and FADH2 required or generated during the conversion of CO2 into the 
respective primary CO2 fixation product. 
CETCH cycle: 2 CO2 + 3 NAD(P)H + 2 ATP + FAD    glyoxylate + 3 NAD(P)+ + 2 ADP + 2 Pi + FADH2 
HOPAC cycle: 2 CO2 + 3 NAD(P)H + 2 ATP + FAD    glyoxylate + 3 NAD(P)+ + 2 ADP + 2 Pi + FADH2 
CHYME cycle: 2 CO2 + 6 NAD(P)H + 3 ATP + FAD    acetaldehyde + 6 NAD(P)+ + 3 ADP + 3 Pi + FADH2 
CRACE cycle: 2 CO2 + 4 NAD(P)H + 3 ATP    acetyl-CoA + 4 NAD(P)+ + 3 ADP + 3 Pi 
FUMES cycle: 2 CO2 + 3 NAD(P)H + 2 ATP + FAD    glyoxylate + 3 NAD(P)+ + 2 ADP + 2 Pi + FADH2 
HITME cycle: 2 CO2 + 3 NAD(P)H + 2 ATP + FAD    glyoxylate + 3 NAD(P)+ + 2 ADP + 2 Pi + FADH2 
HYPA cycle: 3 CO2 + 6 NAD(P)H + 4 ATP + FAD    pyruvate + 6 NAD(P)+ + 4 ADP + 4 Pi + FADH2 
CBB cycle: 3 CO2 + 6 NAD(P)H + 9 ATP    3-phosphoglyceraldehyde + 6 NAD(P)+ + 9 ADP + 9 Pi 
3HP bi-cycle: 3 HCO3- + 6 NAD(P)H + 5 ATP + FAD    pyruvate + 6 NAD(P)+ + 3 ADP + 3 Pi + 2 AMP + 4 PPi + FADH2 
3HP/4HB cycle: 2 HCO3- + 4 NAD(P)H + 4 ATP    acetyl-CoA + 4 NAD(P)+ + 4 ADP + 2 Pi 
To allow for comparison between the synthetic cycles and their naturally existing aero tolerant 
counterparts, we then normalized all pathways against a common multi-carbon product, either 
phosphoglycerate or acetyl-CoA and added the additional NAD(P)H, ATP and FADH2 required or 
generated during these conversions. The results are listed in Table 3.  
The CETCH, HOPAC, FUMES and HITME cycles that generate glyoxylate as primary CO2 fixation product 
were normalized against phosphoglycerate according to the following scheme (89):  
CETCH, HOPAC, FUMES, HITME cycles: 2 glyoxylate to phosphoglycerate 
(1) 2 glyoxylate    tartronic semialdehyde + CO2     (glyoxylate carboligase) 
(2) tartronic semialdeyhde + NADH    glycerate + NAD+    (tartronic semialdehyde reductase) 
(3) glycerate + ATP    3-phosphoglycerate + ADP + Pi    (glycerate kinase) 
The CHYME cycle that generates acetaldehyde as primary CO2 fixation product, was normalized against 
acetyl-CoA according to the following scheme: 
CHYME cycle: acetaldehyde to acetyl-CoA 
(1) acetaldehyde + CoA + NADP+    acetyl-CoA + NADPH    (acylating dehydrogenase) 
The HYPA cycle that generates pyruvate as primary CO2 fixation product, was normalized against 
acetyl-CoA according to the following scheme: 
HYPA cycle: pyruvate to acetyl-CoA 
(1) pyruvate + CoA + NADP+    acetyl-CoA + CO2 + NADPH    (pyruvate dehydrogenase) 
The CBB cycle that generates 3-phosphoglyceraldehyde as primary CO2 fixation product was 
normalized against acetyl-CoA and phosphoglycerate according to the following schemes (34): 
CBB cycle: phosphoglyceraldehyde to phosphoglycerate: 
(1) phosphoglyceraldehyde + Pi + NAD+    1,3-bisphosphoglycerate + NADH  (glyceraldehyde-3-P dehydrogenase) 
(2) 1,3-bisphosphoglycerate + ADP    ATP + 3-phosphoglycerate   (phosphoglycerate kinase) 
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CBB cycle phosphoglyceraldehyde to acetyl-CoA: 
(1) phosphoglyceraldehyde + Pi + NAD+    1,3-bisphosphogylcerate + NADH (glyceraldehyde-3-P dehydrogenase) 
(2) 1,3-bisphosphoglycerate + ADP    3-phosphoglycerate+ ATP   (phosphoglycerate kinase) 
(3) 3-phosphoglycerate    2-phosphoglycerate     (phosphoglycerate mutase) 
(4) 2-phosphoglycerate + H2O    PEP      (enolase) 
(5) PEP + ADP    pyruvate + ATP       (pyruvate kinase) 
(6) pyruvate + CoA + NADP+    acetyl-CoA + CO2 + NADPH    (pyruvate dehydrogenase) 
The 3HP bi-cycle that generates pyruvate as primary CO2 fixation product was normalized against 
acetyl-CoA and phosphoglycerate according to the following schemes (34). 
3HP bi-cycle: pyruvate to phosphoglycerate: 
(1) pyruvate + ATP    PEP + AMP + PPi      (pyruvate:phosphate dikinase) 
(2) PEP  2-phosphoglycerate + H2O      (enolase) 
3HP bi-cycle: pyruvate to acetyl-CoA 
(1) pyruvate + CoA + NADP+    acetyl-CoA + CO2  + NADPH    (pyruvate dehydrogenase) 
The 3HP/4HB cycle that generates acetyl-CoA as primary CO2 fixation product was normalized against 
phosphoglycerate according to the following scheme (34): 
3HP/4HB cycle: acetyl-CoA to phosphoglycerate: 
(1) acetyl-CoA + CO2 + ATP    malonyl-CoA + ADP + Pi    (acetyl-CoA carboxylase) 
(2) malonyl-CoA + 2 NADPH    3-hydroxypropionate + CoA + 2 NADP+   (malonyl-CoA reductase) 
(3) 3-HP + CoA + NADPH + ATP    propionyl-CoA + NADP+ + ADP + Pi + H2O (propionyl-CoA synthase) 
(4) propionyl-CoA + CO2 + ATP    methylmalonyl-CoA + ADP + Pi   (propionyl-CoA carboxylase) 
(5) methylmalonyl-CoA    succinyl-CoA      (methylmal.-CoA mutase) 
(6) succinyl-CoA + GDP + Pi    succinate + CoA + GTP     (succinyl-CoA synthase) 
(7) succinate + FAD+    fumarate + FADH2     (succinate dehydrogenase) 
(8) fumarate + H2O    malate       (fumarase) 
(9) malate + NAD+    oxaloacetate + NADH     (malate dehydrogenase) 
(10) oxaloacetate + ATP    PEP + CO2 + ADP    (PEP carboxykinase) 
(11) PEP    2-phosphoglycerate + H2O      (enolase) 
To calculate the ATP equivalents required per CO2-molecule converted into 3-phosphoglycerate or 
acetyl-CoA, we converted all NAD(P)H and FADH2 into ATP equivalents, assuming a P/O ratio of 2.5 
NAD(P)H and 1.5 for FADH2 (90). Additionally, all AMP-forming reactions were taken into account with 
two ATP equivalents (Table 3). To account for different P/O ratios for NAD(P)H reported in the 
literature (90), we also calculated the ATP equivalents required per CO2-molecule converted into 3-
phosphoglycerate and acetyl-CoA for a changing P/O ratio in comparison to natural oxygen tolerant 
pathway (especially the CBB cycle) (Fig. 9). 
Furthermore, the photons required per CO2-molecule converted into 3-phosphoglycerate in a 
theoretical photosynthetic process was calculated. First, we accounted for the amount of photons in a 
linear electron flow process to generate the number of ferredoxins and NAD(P)H molecules required, 
assuming a coupled stoichiometry of 4 photons per 1 NAD(P)H and 1.28 ATP generated (91). If FADH2 
was formed through a given pathway, the energy of FADH2 is conserved on the level of the 
plastoquinone pool by assuming a stoichiometry of 2 photons (and no ATP) to generate 1 NADPH from 
FADH2. If the number of ATP molecules generated through the coupled linear electron flow was not 
sufficient, the extra ATP required was calculated from a cyclic electron flow process with a 
stoichiometry of 2 photons per 1.71 ATP generated (91). The additional number of ATP-molecules left 
from the overall process was also determined (Table 3 and Fig. 10). 
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Table 3 Comparison of synthetic CO2 fixation cycles with known naturally evolved, aero-tolerant CO2 fixation pathways.  
Normalized to 3-phosphoglycerate as fixation product 
Pathway Primary CO2- 
fixation product 
Normalized CO2 
fixation product 
ΣNAD(P)H ΣATP ΣFADH2 ATP equiv. 
per CO2 
Photons per CO2 
(additional ATP molecules left) [a] 
CETCH cycle glyoxylate 3-phosphoglycerate -7 -5 2 -6.5 24 (+ 1.4 ATP) 
HOPAC cycle glyoxylate 3-phosphoglycerate -7 -5 2 -6.5 24 (+ 1.4 ATP) 
FUMES cycle glyoxylate 3-phosphoglycerate -7 -5 2 -6.5 24 (+ 1.4 ATP) 
HITME cycle  glyoxylate 3-phosphoglycerate -7 -5 2 -6.5 24 (+ 1.4 ATP) 
CBB cycle (without O2)  3P-glyceraldehyde 3-phosphoglycerate -5 -8 0 -6.8 22 (+0.1 ATP) 
CBB cycle (with O2) [b] 3P-glyceraldehyde 3-phosphoglycerate -7 -12 0 -9.9 33 (+0.2 ATP) 
3HP bi-cycle pyruvate 3-phosphoglycerate -6 -9 1 -7.5 26 (+0.8 ATP) 
3HP/4HB cycle [c] acetyl-CoA 3-phosphoglycerate -6 -7 1 -6.8 23 (+0.3 ATP) 
CETCH 5.4 (as realized) glyoxylate 3-phosphoglycerate -9 -3 4 -6.5 [d] /-8.5[e] 28 (+3.4 ATP) 
 HOPAC 4.1 (as realized) glyoxylate 3-phosphoglycerate -7 -5 2 -6.5 24 (+ 1.4 ATP) 
 
Normalized to acetyl-CoA as fixation product 
Pathway Primary CO2- 
fixation product 
Normalized CO2 
fixation product 
ΣNAD(P)H ΣATP ΣFADH2 ATP equiv. 
per CO2 
Photons per CO2 
(additional ATP molecules left) [a] 
CHYME cycle acetaldehyde acetyl-CoA -5 -3 1 -7.0 18 (+ 2.1 ATP). 
CRACE cycle  acetyl-CoA acetyl-CoA -4 -3 0 -6.5 16 (+ 2.1 ATP) 
HYPA cycle  pyruvate acetyl-CoA -5 -4 1 -7.5 18 (+ 1.1 ATP) 
CBB cycle (without O2)  3P-glyceraldehyde acetyl-CoA -4 -7 0 -8.5 19 (+ 0.7 ATP) 
CBB cycle (with O2) [b] 3P-glyceraldehyde acetyl-CoA -6 -11 0 -13 30 (+ 0.8 ATP) 
3HP bi-cycle  pyruvate acetyl-CoA -5 -7 1 -9.0 21 (+ 0.7 ATP) 
3HP/4HB cycle [c]  acetyl-CoA acetyl-CoA -4 -4 0 -7.0 16 (+ 1.1 ATP) 
 
To calculate the ATP equivalents required per CO2-molecule converted into 3-phosphoglycerate or acetyl-CoA, we converted all NAD(P)H and FADH2 into ATP equivalents, assuming a P/O ratio of 
2.5 NAD(P)H, 1.5 for FADH2.and 3 for ferredoxin. Additionally, every AMP-forming reaction was accounted for two ATP equivalents. [a] These calculations consider the conservation of electrons 
from additional FADH2 generated through a given pathway. [b] Assuming a photorespiration rate of 20% and additional -0.4 ferredoxin per phosphoglycerate. [c] Calculation for the more energy 
efficient 3HP/4HB cycle from Thaumarchaeota. [d] Calculations for CETCH 5.4, where the electrons from the two oxidase reactions could be conserved. [e] This calculation does not consider the 
conservation of additional FADH2 created in CETCH 5.4. 
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Fig. 9 Comparison of ATP equivalents required per CO2 converted into phosphoglycerate or acetyl-CoA in respect to a 
changing P/O ratio. Comparison of the ATP equivalents required per CO2 fixed (y-axis) in respect to different P/O ratios (x-
axis), with some experimentally reported P/O ratios indicated on the x-axis. The efficiency of the CBB cycle was calculate with 
and without photorespiration indicated by the blue and red area respectively. (A) ATP equivalents per CO2 fixed into 
phosphoglycerate for theoretical CETCH, HOPAC , HITME, and FUMES cycle drafts, as well as the experimentally realized 
CETCH 5.4 cycle compared to natural oxygen tolerant carbon fixation cycles. (B) ATP equivalents per CO2 fixed into acetyl-
CoA for theoretical CHYME, CRACE, and HYPA cycle drafts compared to natural oxygen tolerant carbon fixation cycles. 
 
 
Fig. 10 Photons required per phosphoglycerate or acetyl-CoA molecule formed from CO2 in a photosynthetically-coupled 
process. Shown are the total number of photons required for the formation of phosphoglycerate (A) and acetyl-CoA (B) for 
the theoretical cycle drafts, as well as the experimentally realized CETCH 5.4 cycle in comparison to natural oxygen tolerant 
CO2 fixation pathways (left y-axis and filled bars). In case of all synthetic cycles, linear electron flow alone would be sufficient 
to generate all NADPH and ATP required. Through the fixed stoichiometry of 1:1.28 per 4 photons in linear electron flow, ATP 
is produced in excess compared to NADPH for these cycles. In case of the natural cycles, linear electron flow alone is not 
sufficient to produce all ATP required. The additional ATP needed is generated through cyclic electron flow (at a stoichiometry 
of 1.71 ATP per 2 photons). ATP produced in excess after all photons are taken into account for linear and cyclic electron flow 
are indicated in the patterned bars (right y-axis). 
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In summary, the energetic calculations and analysis showed, that the synthetic pathways are in general 
comparable or even more energy efficient than natural occurring oxygen tolerant CO2 fixation 
pathways. Especially, if the cycles are compared to the CBB cycle, all pathways are superior, due to the 
fact, that RubisCO incorporates molecular oxygen and energy is lost in photorespiration. For example, 
the CETCH, HOPAC, FUMES and HITME cycle require 1/3 ATP less per CO2 per phosphoglycerate formed 
from CO2 compared to the CBB under oxygenic conditions. This also corresponds to at least nine 
photons less per phosphoglycerate in a theoretical photosynthetic process (Table 3). Conclusively, 
these results suggested that our synthetic cycles could provide very promising solutions to a more 
efficient C-C bond formation under aerobic conditions that compete with (and eventually surpass) any 
known naturally existing solution. 
In the first phase of this study, we designed seven promising synthetic pathways for the fixation of CO2. 
As a proof of principle, we strongly focused on realizing some of these candidates in vitro. This 
intermediate step between a direct in vivo transplantation, allows the analysis and optimization of CO2 
fixation capabilities in a controlled cell-free environment. Additionally, this will serve as a proof that 
the metabolic retrosynthesis approach is a viable option for the design of functional and novel CO2 
fixation pathways. From the seven promising pathway designs, the CETCH and HOPAC cycle were 
considered further for the in vitro realization. For both pathways, the intended enzymatic reactions 
can already be found in bioinformatics databases. As aforementioned, the missing reactions could be 
obtained by enzyme engineering or directed evolution. This would require the initial development of 
novel catalysts. The CETCH and HOPAC cycle did not require initial enzyme engineering and we could 
focus on the assembly of the pathway in vitro.  
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3. Realization of the CETCH cycle 
From the theoretical drafts, we first aimed at realizing one of these synthetic cycles. To that end we 
searched bioinformatics databases for enzymes that could sustain the theoretical CETCH cycle (Fig. 
11). We were able to identify one or more potential enzyme candidates for each reaction of the CETCH 
cycle. These candidates were expressed and characterized to select a final set of 12 enzymes, each 
with a specific activity >1 U mg-1 protein (at 250 µM substrate concentration), that could catalyze the 
proposed reaction sequence of the CETCH cycle (Table 4). 
 
Table 4 List of enzymes considered, tested, characterized and used to realize the CETCH cycle.  
Rxn Abb. Enzyme full name Name Organism 
vmax 
(U mg-1) 
KM 
(mM) 
Source of 
kinetic data 
1 Pco propionyl-CoA oxidase Pco A. thaliana 12 0.044 This work 
1 Acx4 acyl-CoA oxidase Acx4 A. thaliana 39 0.013 This work 
12 Pcc propionyl-CoA carboxylase PccAB M. extorquens 24 0.1. This work 
2+8 Ccr crotonyl-CoA carboxylase/reductase Ccr M. extorquens 110 0.17 This work 
2+8 Ccr crotonyl-CoA carboxylase/reductase CcrR152A M. extorquens 85 0.82 This work 
2+8 Ccr crotonyl-CoA carboxylase/reductase Ccr K. setae 21 0.01 Peter (84) 
2+8 Ccr crotonyl-CoA carboxylase/reductase Ccr L. borgpetersenii 75 0.07 Peter (84)  
3+9 Epi emC/mmC epimerase Epi R. sphaeroides 440 0.08 Erb et al. 2008 (92) 
3 Mcm methylmalonyl-CoA mutase Mcm R. sphaeroides 20 0.14 Erb et al. 2009 (92) 
4 Scr succinyl-CoA reductase SucD C. kluyveri 29 0.003 Söhling et al. 1993 (93) 
5 Ssr succinic semialdehyde reductase AKR7a2 H. sapiens 3.9 0.013 This work 
5 Ssr sulfolactaldehyde reductase YihU E. coli 2 26.7 This work 
6 Hbs 4-hydroxybutyryl-CoA synthetase Nmar0206 N. maritimus 2 0.19 Könneke et al. 2014 (34) 
6 Hbs 3-hydroxypropionyl-CoA synthetase Nmar1309 N. maritimus 3 28 Könneke et al. 2014 (34) 
6 Hbs medium-chain fatty acid CoA ligase AlkK P. putida 4 69.7 This work 
7 Hbd 4-hydroxybutyryl-CoA dehydratase Nmar0207 N. maritimus 26 0.06 Könneke et al. 2014 (34) 
7 Hbd 4-hydroxybutyryl-CoA dehydratase AbfD C.aminobutyricum 19 0.06 Könneke et al., 2014 (34) 
9 Ecm ethylmalonyl-CoA mutase Ecm R. sphaeroides 7 0.06 Erb et al. 2008 (92) 
10 Mco methylsuccinyl-CoA oxidase Mco R. sphaeroides. 0.1 0.03 This work 
10 Mcd methylsuccinyl-CoA dehydrogenase Mcd R. sphaeroides 6 0.04 Erb et al. 2009 (94) 
11 Mch mesaconyl-CoA hydratase Mch R. sphaeroides 1500 n.d. Zarzycki et al. 2008 (95) 
12 Mcl β-methylmalyl-CoA lyase Mcl1 R. sphaeroides 5 0.01 Erb et al. 2010 (96) 
13 Mas malate synthase GlcB E. coli 36 0.021 Anstrom et al. 2003 (97) 
14 Mct malyl-CoA thioesterase Mcl2 R. sphaeroides 200 0.09 Erb et al. 2010 (96) 
15 Fdh formate dehydrogenase (D221A) Fdh M. vaccae 1.4 0.37 Hoelsch et al. 2013 (98) 
16 Pkk polyphosphate kinase Pkk2 S. meliloti 12 0.032 Nocek et al. 2008 (99) 
17 Kat katalase KatE E. coli 11740 86.5 Sevinc et al. 1995 (100) 
18 Gcl Glyoxylate carboligase [a] Gcl E. coli 18 0.9 Kaplun et al. 2008 (101) 
19 Gar Tartronate semialdehyde reductase[a] GarR E. coli 410 [b] 0.2 [b] Gotto et al. 1961 (102) 
20 Glk Glycerate kinase [a] GlxK E. coli 960 138 This work 
The reaction numbering is according to (Fig. 17, Fig. 18, Fig. 19, Fig. 21 and Fig. 22). Whereas reactions from 1 to 12 represent 
the core sequence of the CETCH cycle, reactions from 13 to 20 are additional enzymes introduced over the process of 
optimization and for the conversion of the primary substrate. Highlighted in green are those enzymes used in the final version 
of CETCH 5.4. [a] These enzymes were tested as proof-of-principle that they could convert glyoxylate into phosphoglycerate, 
demonstrating a potential connection with central carbon metabolism and allowing for the thermodynamic comparison of 
CETCH with the CBB. [b] Values for Pseudomonas ovalis enzymes 
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Fig. 11 Topology of the CETCHcycle from the initial design phase. Enzyme names are abbreviated according to Table 4.  
 
 CETCH 1.0 (discontinuous/stepwise reconstitution) 
To demonstrate feasibility of the CETCH cycle, we first reconstituted its central CO2 fixation reaction 
sequence stepwise. We provided cofactors and the chemically synthesized intermediate propionyl-
CoA in a buffer containing NaHCO3 as a source of CO2. To this mixture, Pcc was added first, followed 
by the subsequent and stepwise addition of the other eleven enzymes required for the assembly of 
the pathway. HPLC-MS analysis demonstrated the stepwise transformation of propionyl-CoA into key 
intermediates of the pathway (Fig. 12), indicating that this first version of the CETCH cycle (CETCH 1.0) 
was in principle functional. 
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Fig. 12 Stepwise reconstitution of the CETCH cycle. (A) Reconstitution scheme of the CETCH cycle. Enzyme names are 
abbreviated according to Table 4. The CETCH cycle was reconstituted in five individual steps through the subsequent addition 
of one or multiple enzymes, as indicated for each step. (B) HPLC-MS analysis of the reaction mixture from step 0 (before 
addition of Pcc) to step 5 (after all enzymes were added). Shown are the extracted high resolution-MS traces of individual 
intermediates, confirming their stepwise formation. Color coding of intermediates is according to panel (A). (C) Fractional 
peak areas of these key intermediates (in total ion counts) from step 0 to 5, coloring according to panel (A). 
  
Realization of the CETCH cycle 
34 
 
 CETCH 1.0 (continuous cycling is blocked on the level of Mcd) 
After we had demonstrated the individual reactions of the CETCH cycle (CETCH 1.0) in a discontinuous 
fashion and stepwise, we aimed at establishing a continuous operating cycle that could fix CO2 in 
multiple turns. Additionally, by using 13C labeled bicarbonate (NaH13CO3), incorporation into the 
intermediates occurs according to the numbers of turns and enables the analysis of the continuous 
operation of the synthetic cycle (Fig. 13). In a first attempt, we provided all enzymes, cofactors 
(NADPH, ATP and CoA) and the artificial electron acceptor ferrocenium (100 µM) from the beginning 
and started the cycle by addition of propionyl-CoA (Fig. 14A). However, under these continuous 
operation conditions, CETCH 1.0 was not functional, as demonstrated by intermediate detection and 
13C-labeling on HPLC-MS. The conversion of CoA-ester intermediates stopped at the level of 
methylsuccinyl-CoA, indicating that the methylsuccinyl-CoA dehydrogenase (Mcd) reaction was rate 
limiting (Rxn #10, Fig. 14B-C). Mcd belongs to the family of FAD-dependent acyl-CoA dehydrogenases 
(ACD), which are naturally coupled via electron transfer flavoproteins to the membrane bound 
ubiquinone pool (via electron transfer flavoprotein:ubiquinone oxidoreductase) and eventually to the 
respiratory chain. In the CETCH 1.0 we added the artificial electron acceptor ferrocenium together with 
the enzyme to replace this complicated electron transfer cascade. However, under continuous 
operation the use of ferrocenium with Mcd was not possible. The maximum ferrocenium 
concentration in the assay was limited to 0.1 mM, causing protein precipitation at higher 
concentrations. Moreover, ferrocenium has an unfavorable redox behavior under the assay conditions 
(i.e. it reacts spontaneously with NADPH, free CoA and has a slow re-oxidation rate (103)) preventing 
the effective cycling of CETCH 1.0.  
 
Realization of the CETCH cycle 
35 
 
 
Fig. 13 Expected 13C-label incorporation of the CETCH cycle from 13CO2. Shown is the expected labeling pattern for each turn 
of the CETCH cycle in its final version 5.4 (but is essentially the same for all other versions). The cycle features two CO2-
incorporation steps per turn shown in blue and red dots. The carbon incorporated into the C4-acceptor crotonyl-CoA is shown 
in blue. This carbon ends up in the output molecule glyoxylate during each turn. The carbon incorporated into the C3-acceptor 
propionyl-CoA (CETCH 1.0 to 4.0) or acrylyl-CoA (CETCH 5.0 to 5.4) is shown in red. This label stays with the acceptor molecule 
during each turn of the cycle (indicated by a darker red color). Note that the CETCH cycle includes carbon skeleton-rearranging 
steps catalyzed by mutases, resulting in a complex labeling pattern.  
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Fig. 14 CETCH 1.0 (continuous cycling is blocked on the level of Mcd). (A) Topology of the CETCH cycle version 1.0, operated 
in continuous mode. Enzyme names are abbreviated according to Table 4. (B) Dynamics of key intermediates of CETCH 1.0 
over 90 minutes. Shown are the total levels (ion counts) and fractional labeling pattern of six different CoA esters with color-
coding according to (A). Fractional labeling showed that the cycle was not turning and that CoA esters accumulated at the 
level of methylsuccinyl-CoA, indicating that it was stalled at the level of Mcd (Rxn #10). (C) Level and fractional labeling pattern 
of methylsuccinyl-CoA.  
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 CETCH 2.0 (engineering of Mcd to Mco allows multiple turning) 
In CETCH 2.0 we aimed at overcoming the limitation caused by Mcd by engineering the enzyme to 
directly use molecular oxygen as electron acceptor. Modeling of Mcd onto the structure of short-chain 
acyl-CoA dehydrogenase from Homo sapiens (38% amino acid identity, 68% coverage, PDB ID: 2VIG) 
indicated a negatively charged, narrow pocket opposite of the redox active N5 of the isoalloxazine ring 
of the FAD cofactor. The same FAD pocket appeared to be wider in acyl-CoA oxidases (e.g., short chain 
acyl-CoA oxidase 4 from A. thaliana, PDB ID: 2IX5) that are able to reoxidize the FAD cofactor with 
oxygen (Fig. 16A). A sequence alignment, comparing dehydrogenases with oxidases, revealed a 
conserved threonine (Thr317 in Mcd), which is replaced by a glycine in oxidases. The structural model 
showed, that the Thr315 is in proximity to the N5 of the isoalloxazine ring of the FAD cofactor (Fig. 15). 
We assumed that this residue could modulate the electrochemical potential of the FAD and might also 
prevent the active binding of molecular oxygen. Introduction of a Thr317Gly mutation into Mcd from 
R. sphaeroides already supported initial oxidase activity (Fig. 16 and Table 5). Next, at the position of 
Glu377 in Mcd, the oxidases poses a conserved asparagine, which is also close to the FAD cofactor in 
the active site and might be involved in the oxidase activity (Fig. 15 and Fig. 16A). Introduction of the 
single Glu377Asn mutation showed very low oxidase activity and in combination with the Thr317Gly 
mutation (T317G, E377N), oxidase activity was lower than of the single Thr317Gly variant (Fig. 16 and 
Table 5). Additionally, we investigated the Trp315 of Mcd, since it is positioned in the active site tunnel 
and mutations might contribute to the solvation of the active site and change the accessibility for 
molecular oxygen (Fig. 16A). A single mutation of Trp315Ala catalyzed no reaction with oxygen, but a 
Trp315Phe mutation showed very low oxidase activity (Fig. 16B). The combination of the Trp315Phe 
with the Thr317Gly mutation (W315F, T317G) increased the oxidase activity, compared to the single 
Thr317Gly variant. Interestingly, the additional Glu377Asn mutation (W315F, T317G, E377N) increased 
the reaction rate with oxygen further, even though it showed a negative effect in the double variant 
(T317G, E377N) (Fig. 16C and Table 5). Conclusively, three point mutations (T317G, E377N, W315F) 
allowed us to convert methylsuccinyl-CoA dehydrogenase into a functional methylsuccinyl-CoA 
oxidase (Mco) that catalyzed the oxidation of methylsuccinyl-CoA with a vmax of 97.3 ± 5.4 mU mg-1 and 
at an apparent KM of 27.4 ± 5.0 µM. 
 
 
Fig. 15 Sequence alignment of different ACDs and oxidases. (i) Represents ACD from different organisms. (ii) Represents 
homologs from the butyryl-CoA dehydrogenases from the anaerobic living M. elsdenii, which is known to have an intrinsic 
oxidase activity (104). (iii) Represents different acyl-CoA oxidases. Trp315 (from Mcd) is conserved in dehydrogenases as well 
as oxidases. This residue is positioned in the active site tunnel and replacing it by a phenylalanine (as found in anaerobic 
dehydrogenases) might enable solvation of the active site. Thr315 (from Mcd) is a conserved active site residue amongst 
dehydrogenases and is in proximity to the N5 of the FAD cofactor. This residue is replaced by a glycine in oxidases. Glu377 is 
close to the active site and the FAD cofactor, while some dehydrogenases poses a glutamate, the oxidases show a conserved 
asparagine. 
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Fig. 16 Structure guided engineering of Mcd into Mco. (A) Active site comparison of the human short-chain acyl-CoA 
dehydrogenase (PDB ID: 2VIG, green backbone) with a model of Mcd from Rhodobacter sphaeroides (blue backbone, modeled 
by the SWISS-MODEL server with 2VIG as template) and the short-chain acyl-CoA oxidase 4 from Arabidopsis thaliana (PDB 
ID: 2IX5, orange backbone). The three residues that were targeted to introduce oxidase activity into Mcd are highlighted. (B) 
HPLC-MS based analysis of wild-type and different single active-site variants for oxidation of methylsuccinyl-CoA into 
mesaconyl-CoA with molecular oxygen as electron acceptor. The screen identified three substitutions (W315F, T317G and 
E377N) that were combined into double and triple variants. (C) Michaelis-Menten graphs of single, double and triple variants 
characterized in more detail. The triple variant showed the best kinetic parameters (see also Table 5).  
Table 5 Kinetic parameters for the Mcd variants.  
Mutation e- acceptor vmax (mU mg-1) apparent KM (µM) 
wt [a] ferrocenium 6000 20 
wt O2 No activity [b] 
Thr317Gly O2 27.7 ± 0.7 30.0 ± 2.5 
Trp315Ala O2 No activity [b] 
Trp315Phe O2 Low activity [b] 
Glu377Asn O2 Low activity [b] 
Thr317Gly, Glu377Asn O2 10.4 ± 0.3 39.9 ± 3.3 
Thr317Gly, Trp315Phe O2 37.8 ± 2.0 7.6 ± 2.5 
Thr317Gly, Glu377Asn, Trp315Phe O2 97.3 ± 5.4 27.4 ± 5.0 
[a] values were taken from Erb et al. 2009 (94). [b] Kinetic parameters were not determined, due to low product formation rate 
observed in the HPLC based analysis (Fig. 16B)  
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When we replaced Mcd by the engineered oxidase (Mco) in CETCH 2.0, fractional labeling of CoA-
esters showed that the 13CO2 is stepwise incorporated and the majority of propionyl-CoA was labelled 
once after 5 minutes and twice after 30 minutes. This indicates, that the majority of propionyl-CoA was 
already turn over twice in the pathway after 30 min. Although the total amount of intermediates in 
the cycle decreased over time, these experiments demonstrated that CETCH 2.0 could in principle turn 
several times (Fig. 17). 
 
Fig. 17 CETCH 2.0 (replacing Mcd by Mco allows multiple turning). (A) Topology of the CETCH cycle version 2.0. Enzyme 
names are abbreviated according to Table 4. Mcd was replaced by Mco (boxed in red) (B) Dynamics of key intermediates of 
CETCH 2.0 over 90 minutes. Shown are the total levels (ion counts) and fractional labeling pattern of six different CoA ester 
with color-coding according to (A). Replacing Mcd by Mco allowed to operate the cycle beyond rxn #10 and for multiple turns. 
(C) Level and fractional labeling pattern of methylsuccinyl-CoA (compared to CETCH 1.0, Fig. 14).  
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 CETCH 3.0 (read-out module and NADPH regeneration) 
For CETCH 3.0 we implemented a read-out module to directly quantify CO2 fixation (Fig. 18A). Starting 
from propionyl-CoA, the CETCH cycle converts two molecules of CO2 per turn into one molecule of 
glyoxylate. To measure glyoxylate formation we used a malate synthase (Mas) from Escherichia coli, 
which condenses glyoxylate with externally added acetyl-CoA to yield malate. Additionally, we 
introduced a NADPH regeneration module to continuously replenish the NADPH-pool (Fig. 18A). To 
that end, we added an engineered formate dehydrogenase from Mycobacterium vaccae (98), which 
could directly operate in the formate-based buffer system. HPLC-MS quantification of the malate 
produced from the CETCH 3.0 cycle, yielded 0.3 fixed CO2-molecules per propionyl-CoA acceptor 
molecule over 90 min (Fig. 22C). CoA ester analysis showed that ethylmalonyl-CoA, methylmalonyl-
CoA, malonyl-CoA and malyl-CoA accumulated over time in CETCH 3.0 (Fig. 18B-C). The accumulation 
of the two alkylmalonyl-CoA ester suggested that the coenzyme B12-dependent mutase reactions in 
the cycle were affected. Buildup of malyl-CoA, which is not a direct intermediate of the CETCH cycle, 
indicated a side reaction of the acetyl-CoA pool with glyoxylate, presumably catalyzed by β-
methylmalyl-CoA lyase (Mcl), which is known to possess this activity intrinsically (96). This side reaction 
leads to a loss of malate production, since the primary assimilation product (glyoxylate) is converted 
into a different output molecule. The accumulation of malonyl-CoA is presumably caused because 
propionyl-CoA carboxylase (Pcc) is able to carboxylate acetyl-CoA with a low activity (Fig. 18). 
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Fig. 18 CETCH 3.0 (read-out module and NADPH regeneration). (A) Topology of the CETCH cycle version 3.0. Enzyme names 
are abbreviated according to Table 4. The newly added enzymes Fdh (NADPH-regeneration) and Mas (read-out module) 
converting the primary CO2 fixation product glyoxylate into malate are boxed in red. (B) Dynamics of key intermediates of 
CETCH 3.0 over 90 minutes. Shown are the total levels (ion counts) and fractional labelling pattern of six different CoA esters 
with color-coding according to (A). (C) Level and fractional labeling pattern of malyl-CoA and malonyl-CoA, which are dead-
end metabolites that accumulated over time. 
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 CETCH 4.0 (proof reading & protection from oxidative damage) 
In CETCH 4.0, we took care of the unwanted malyl-CoA formation observed in CETCH 3.0. We added 
malyl-CoA thioesterase (Mct) from Rhodobacter sphaeroides that catalyzes the specific hydrolysis of 
malyl-CoA into malate and CoA (Fig. 19A). We reasoned that Mct would act as a metabolic proof 
reading-enzyme that frees the CoA bound malate deriving from the unwanted side reactivity of Mcl. 
We also addressed the mutase reactions that were apparently limiting in CETCH 3.0 by adding 0.1 mM 
coenzyme B12, 5 mM ascorbic acid and catalase (Kat) from E. coli to protect B12, as well as other 
coenzymes, cofactors, intermediates and proteins from oxidative damage and radical oxygen species 
(such as H2O2, produced by Mco). With these changes, we could increase efficiency of CETCH 4.0 by a 
factor of five to 1.5 fixed CO2 equivalents per acceptor molecule within 30 min (Fig. 22C), after which 
CO2 fixation leveled off. CoA ester analysis still showed an accumulation of malonyl-CoA, which was 
accompanied by an unexpected high ATP-hydrolysis and acetyl-CoA consumption rate (Fig. 19C). We 
suspected that malonyl-CoA formation was caused by Pcc, which is known to accept acetyl-CoA besides 
propionyl-CoA (105). This side activity of Pcc apparently depleted the acetyl-CoA pool within short time 
and caused the unproductive hydrolysis of ATP, preventing a more efficient cycling of CETCH 4.0.  
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Fig. 19 CETCH 4.0 (proof reading by Mct prevents malyl-CoA build-up) (A) Topology of the CETCH cycle version 4.0. Enzyme 
names are abbreviated according to Table 4. The newly added enzymes Kat (H2O2 protection) and Mct (malyl-CoA proof-
reading) are boxed in red. (B) Dynamics of key intermediates of CETCH 4.0 over 90 minutes. Shown are the total levels (ion 
counts) and fractional labelling pattern of six different CoA ester with color-coding according to (A). (C) Level and fractional 
labeling pattern of malyl-CoA and malonyl-CoA. While build-up of the malyl-CoA was efficiently prevented through application 
of Mct (compared to CETCH 3.0, Fig. 18), malonyl-CoA still accumulated over time. 
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 CETCH 5.0 (reaction sequence redesign & addition of ATP regeneration) 
For CETCH 5.0, we concentrated on eliminating the unwanted side production of malonyl-CoA, as well 
as maintaining a stable ATP-pool. The side reaction of Pcc with acetyl-CoA resulted not only in the 
production of malonyl-CoA, but more importantly lead to an undesired hydrolysis of ATP. First, we 
redesigned the core sequence of the CETCH cycle to become independent of the promiscuous Pcc. 
Realizing that Ccr also accepts acrylyl-CoA as non-native substrate we drafted an alternative reaction 
sequence that would allow us to form methylmalonyl-CoA from propionyl-CoA via reductive 
carboxylation of acrylyl-CoA (Fig. 21A). 
So far, no enzyme is known that would specifically oxidize propionyl-CoA into acrylyl-CoA. We thus 
screened different oxidases for an activity with propionyl-CoA and identified a short-chain acyl-CoA 
oxidase 4 (Acx4) from Arabidopsis thaliana that catalyzed the oxidation of propionyl-CoA with a 
catalytic efficiency of kcat KM-1 = 2.4106 M-1 s-1 (kcat = 30.8 ± 1 s-1, KM = 13 ± 1 μM). Unfortunately, the 
enzyme also oxidized 4-hydroxybutyryl-CoA, another intermediate of the CETCH cycle, with a similar 
catalytic efficiency of kcat KM-1 = 6.9 105 M-1 s-1 (kcat = 9.7 ± 0.2 s-1; KM = 14 ± 1 μM). To decrease the 
unwanted side-reactivity of Acx4 with 4-hydroxybutyryl-CoA, we engineered the enzyme towards 
higher substrate specificity. The structure of Acx4 revealed an active site pocket, which is large enough 
to accept different short-chain acyl-CoA esters (106) (Fig. 20A). We argued, that mutations, decreasing 
the overall size of this active site pocket, would be sufficient to enable the enzyme to discriminate the 
short propionyl-CoA (C3) from the longer 4-hydroxybutyryl-CoA (C4 with an additional hydroxyl group). 
Therefore we targeted several residues lining the cavity. Eventually, a Thr134Leu mutation in Acx4 
allowed us to lower the activity of the enzyme with 4-hydroxybutyryl-CoA by two orders of magnitude 
to a kcat KM-1 = 1.3  103 M-1 s-1 (kcat = 0.3 ± 0.02 s-1; KM = 239 ± 44 μM) while the reaction of the 
engineered enzyme with propionyl-CoA was only affected by a factor of ten at a 
kcat KM-1 = 2.2  105 M-1 s-1 (kcat = 9.8 ± 0.4 s-1; KM = 44 ± 5 μM). In summary, our engineered, propionyl-
CoA oxidase (Pco) showed a strongly improved discrimination factor of 180 between the desired 
oxidation of propionyl-CoA and the unwanted side-reaction with 4-hydroxybutyryl-CoA (Fig. 20 and 
Table 6). Note that Pco additionally serves a proof reading function in the CETCH cycle. Ccr possess a 
very low reduction reaction besides its reductive carboxylation reaction, which could lead to a loss of 
intermediates from the cycle over time (through the reduction of acrylyl-CoA to propionyl-CoA). Pco 
could work against this loss by recycling propionyl-CoA to acrylyl-CoA. 
In assays with the Pco/Ccr combination instead of Pcc, formation of malonyl-CoA was not detectable 
anymore and ATP hydrolysis rate was strongly decreased, indicating the successful implementation of 
the Pco/Ccr bypass (Fig. 21C). However, we realized that the reaction of 4-hydroxybutyryl-CoA 
synthetase (Hbs) operates close to the thermodynamic equilibrium (ΔrG’ = 10 kJ mol-1) and thus is very 
sensitive to changes in the ATP and ADP + Pi concentrations. We reasoned that it might not be sufficient 
to decrease ATP hydrolysis, but to actively maintain a high ATP concentration in the assay to keep the 
thermodynamic driving force intact. We tested different ATP-regeneration/addition systems with the 
CETCH core sequence. Of the systems tested, a polyphosphate transferase from Sinorhizobium meliloti 
(99) worked most reliably. In summary, the Pco/Ccr combination together with the ATP-regeneration 
system increased the efficiency of the cycle to 4.3 CO2-equivalents per acceptor molecule over a 
running time of 90 min (Fig. 22C). 
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Fig. 20 Engineering of Acx4 towards a specific propionyl-CoA oxidase (Pco). The short-chain oxidase 4 (ACX4) from A. 
thaliana was engineered towards desired substrate (propionyl-CoA) specificity, because we detected activity with 
4-hydroxybutyryl-CoA. (A) The active site structure (PDB ID: 2IX5) shows a large substrate binding pocket, which is surrounded 
by the residues Thr134, Thr137, Val138 and Val291 (106). These residues were mutated to more bulky ones with the intention 
to close the active site and enable the discrimination of the larger 4-hydroxybutyryl-CoA (C4 with additional hydroxyl group) 
from the shorter propionyl-CoA (C3) (B) Michaelis-Menten kinetics of all characterized variants with propionyl-CoA as 
substrate. (C) Michaelis-Menten kinetics of all characterized variants with 4-hydroxybutyryl-CoA as substrate. 
 
Table 6 Kinetic data of all Acx4 variants analyzed.  
 propiony-CoA 4-hydroxybutyryl-CoA  
 
vmax 
(U mg-1) 
app. KM 
(µM) 
vmax 
(U mg-1) 
app. KM 
(µM) 
kcat KM-1 (propionyl-CoA) / 
kcat KM-1 (4-hydroxybutyryl-CoA) 
wt 38.9 ± 1.0 12.5 ± 1.3 12.2 ± 0.2 13.6 ± 1.2 4 
L137F 3.0 ± 0.1 7.0 ± 0.7 1.90 ± 0.05 38.0 ± 3.4 9 
V138L 3.0 ± 0.1 59.2 ± 4.7 0.14 ±0.01 63 ± 20 23 
V138I n.d. n.d.  
V291I 8.9 ± 0.3 65.4 ± 6.0 2.73 ± 0.14 225 ± 29 12 
V291L n.d. n.d.  
V291F n.d. n.d.  
T134I 5.1 ± 0.3 148 ± 16 0.18 ± 0.01 182 ± 38 34 
T134L 12.3 ± 0.5 43.7 ± 5.3 0.38 ± 0.03 239 ± 45 180 
n.d.: no detectable activity 
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Fig. 21 CETCH 5.0 (reaction sequence redesign & ATP regeneration). (A) Topology of the CETCH cycle version 5.0. Enzyme 
names are abbreviated according to Table 4. The newly added enzymes, Pkk (ATP regeneration) and the Pco/Ccr combination 
(replacing promiscuous Pcc) are boxed in red. (B) Dynamics of key intermediates of CETCH 55.0 over 90 minutes. Shown are 
the total levels (ion counts) and fractional labelling pattern of six different CoA esters with color-coding according to (A). (C) 
Level and fractional labeling pattern of malonyl-CoA. The build-up of the dead-end metabolite malonyl-CoA (compare to 
CETCH 4.0, Fig. 19) was effectively prevented through these changes. 
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 CETCH 5.1-5.4 (further improvements). 
In further versions of the CETCH cycle (CETCH 5.1-5.4), we tested the influence of minor variations of 
the assay onto CO2 fixation efficiency. In CETCH 5.1, we tested the influence of different Ccr homologs 
onto CO2 fixation efficiency. We substituted a mutated Ccr used so far (Methylobacterium extorquens; 
Arg152Ala; kcat = 70 s-1; KM,crotonyl-CoA= 820 µM) by the wt enzyme from M. extorquens (kcat = 90 s-1; 
KM,crotonyl-CoA= 180 µM), a Ccr from Kitasatospora setae (kcat = 17 s-1 ; KM,crotonyl-CoA= 11 µM), as well as a 
Ccr from Leptospira borgpetersenii (kcat= 57 s-1 ; KM,crotonyl-CoA= 65 µM). The use of either of these 
alternative Ccrs improved CO2 fixation efficiency to about 5.1 fixed CO2-equivalents and we used the 
M. extorquens wt enzyme in the following. In CETCH 5.2, we added 10 mM calcium to the assay, 
reasoning that calcium precipitates inorganic phosphate that accumulated over time and might 
interfere with the Hbs reaction, which operates close to the thermodynamic equilibrium (see above). 
However, addition of calcium did not increase CO2 fixation efficiency. In CETCH 5.3, we exchanged the 
tris(hydroxymethyl)aminomethane (Tris) buffer used to store the purified proteins with a MOPS-based 
buffer system. We intended to reduce the final concentration of Tris in the assay, because we 
speculated that the Tris could react with the succinic semialdehyde intermediate (trapping the 
semialdehyde as Tris-succinic imine adduct). However, this alternation did not change CO2 fixation 
efficiency. In CETCH 5.4, we exchanged the ammonium-formate reaction buffer used so far with a 
100 mM MOPS KCl buffer (pH 7.5), which eventually increased efficiency of the cycle to a maximum of 
5.4 fixed CO2-equivalents per acceptor molecule over 90 min (Fig. 22).  
 CETCH 5.4 (additional features and limitations) 
So far, all versions of the CETCH cycle were tested in buffer containing 50 mM HCO3-. HCO3- was 
equilibrated with carbonic anhydrase to provide dissolved CO2 in the assay. To investigate the ability 
of CETCH 5.4 to directly fix atmospheric CO2, we quantified malate production rate of the cycle in 
presence and absence of HCO3- in the buffer. Omitting HCO3- from the buffer reduced the maximal 
malate production rate to approximately 73% (70% and 75%, n=2) compared to the positive control 
(i.e., buffer with 50 mM HCO3-). This experiment showed that CETCH 5.4 is able to fix atmospheric CO2 
but suggests that under the chosen experimental conditions transfer of atmospheric CO2 into solution 
becomes limiting. For CETCH 5.4, we also reinvestigated the requirement for catalase, coenzyme B12 
and ascorbic acid as protecting additives. We tested the influence of the three factors on malate 
production by running the cycle in the absence of each of these compounds. While omitting coenzyme 
B12 and ascorbic acid did not show significant differences, the absence of catalase lowered malate 
production by about 55% (57% and 54%, n =2), indicating that an active catalase is important for an 
operational CETCH cycle. Finally, we turned our attention to the fact that malate production in CETCH 
5.4 started to plateau around 90 min, reaching a final concentration of about 500-600 µM malate, 
questioning what factor limits conversion of CO2 into malate. When we added a fresh batch of 
propionyl-CoA or ATP to a plateaued CETCH cycle, malate production by the cycle could not be 
restarted. Likewise, when we added the four enzymes that were suspected to be the most instable in 
the CETCH enzyme mix (i.e., succinyl-CoA reductase, Scr; methylmalonyl-CoA mutase, Mcm; 
ethylmalonyl-CoA mutase, Ecm and 4-hydroxybutyryl-CoA synthetase, Hbs), to the enzyme assay at 
15, 30, 60, and 90 min, production of malate could not be increased. Finally, and most interestingly, 
when we started a cycle in the presence of 500 µM malate, the cycle did not accumulate significant 
amounts of additional malate, while in the control experiment (without malate addition from the 
beginning), the cycle was operating normally. These experiments suggested that it is neither enzyme 
activity nor substrate supply that limits CO2 fixation in version 5.4 of the CETCH cycle, but that it is 
rather product inhibition by the formed malate. 
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Fig. 22 CETCH 5.4 (further improvements). (A) Topology of the CETCH cycle (version 5.4), including proofreading and cofactor 
regenerating enzymes. Enzyme names are abbreviated according to Table 4. (B) Dynamics of key intermediates of CETCH 5.4 
over 90 minutes. Shown are the levels of six different intermediates, as well as their fractional labeling patterns from the 
incorporation of 13CO2 for each turn of the cycle. Intermediate coloring according to panel A. (C) Left x-axis: CO2 fixation 
efficiency of the CETCH cycle over the course of its optimization. CO2 fixation efficiency is defined as the CO2-equivalents fixed 
per acceptor molecule in the cycle (i.e. starting amount of propionyl-CoA). Right x-axis: Absolute malate concentration formed 
over the course of 90 minutes in CETCH 5.4. The final assay (0.52 ml) contained 2.3 mg ml-1 protein of cycle core enzymes plus 
0.8 mg ml-1 auxiliary enzymes and produced 540 μM malate over 90 min, which corresponds to 1080 μM fixed CO2. 
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 Conclusions 
Over the course of the optimization, CO2 fixation efficiency in the CETCH cycle improved by almost a 
factor of 20 until version 5.4 (Fig. 22). In its current form, CETCH 5.4 represents an in vitro enzyme 
network that is able to fix CO2 at a rate of 5 nmol-1 mg-1 of core cycle protein. This is notably comparable 
to the very scarce literature on attempts to measure the complete CBB cycle in vitro (107).  
The synthetic pathway comprises reaction sequences, which are also part of natural occurring 
pathways (i.e. ethylmalonyl-CoA pathway, 3HP/4HB cycle and anaerobic succinate degradation 
pathway). Nevertheless, with the approach of synthetic biology, we considered the vast diversity of 
enzymes in nature, which might not be found within these natural pathways. 
In total, the 13 core reactions together with the readout module, auxiliary proofreading and cofactor 
regeneration processes are catalyzed by 17 enzymes from nine different organisms and all three 
domains of life, including bacteria, archaea, plants and humans. This also includes the engineering of 
three enzymes towards a desired reaction. 
The combination of such diverse enzymes into a synthetic pathway poses the challenge that these 
enzymes face metabolites to which they were never exposed in their native metabolic context, causing 
undesired side-reactions. Inspired by biology we pursued different strategies to overcome this 
problem. We replaced the original reaction sequence to circumvent problematic reactions, applied 
enzyme engineering to minimize side reactions of promiscuous enzymes, and introduced metabolic 
proofreading enzymes to correct for the formation of side products. The first two strategies have been 
applied before in biotechnology and synthetic biology to improve productivity (108, 109). In contrast, 
the concept of metabolic proofreading has only been considered in few cases for synthetic pathway 
design (77), although it exists apparently also in naturally evolved pathways (110). We believe that this 
design principle should be considered more systematically for metabolic engineering in the future.  
The redesign of the reaction sequence for the CETCH cycle from version 5.0 on, solely depends on the 
reductive carboxylation reaction of Ccr. This reallocation of the efficient carboxylase as key reaction in 
a CO2-fixing pathway goes beyond simply improving or reshuffling naturally existing autotrophic CO2 
fixation enzymes and pathways. The first successful in vitro reconstitution of a synthetic enzymatic 
network for the conversion of CO2 into organic products in vitro opens the door for several future 
applications (further discussed in chapter 6) 
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4. Realization of the HOPAC cycle 
The HOPAC cycle is the second feasible candidate pathway resulting from our metabolic retrosynthesis 
approach. From the theoretical draft, we aimed at realizing this synthetic cycle in vitro. To that end we 
searched the available databases for enzymes that could sustain the theoretical HOPAC cycle (Fig. 23). 
We were able to identify one or more potential enzyme candidates for each reaction of the HOPAC 
cycle. These candidates were expressed and characterized to select a final set of 10 enzymes that were 
able to catalyze the proposed reaction sequence of the HOPAC cycle (Table 7). 
 
Table 7 List of enzymes considered, tested, characterized and used to realize the HOPAC cycle.  
Rxn Abb. Enzyme full name Name Organism 
vmax 
(U mg-1) 
KM 
(mM) 
Source of 
kinetic data 
1 mPc propionyl-CoA carboxylase Pcc βD407I M. extorquens 1.1 0.9 This work 
1 Pcc propionyl-CoA carboxylase Pcc M. extorquens 0.1 1.3 This work 
2 Mcr malonyl-CoA reductase Mcr C. aurantiacus 10[c] 0.03 Huegler et al. (2002) (29) 
3 Hps 3-hydroxypropionyl-CoA synthetase Nmar1309 N. maritimus 0.6 1.2 Könneke et al. 2014 (34) 
3+4 tPcs propionyl-CoA synthase (truncated) tPcs Erythrobacter 1.3[d] 0.2[d] Bernhardsgrütter et al. (2017) (111) 
3+4 tPcs propionyl-CoA synthase (truncated) tPcs C. aurantiacus 4[c] [d] 0.02[d] Alber et. al. (2002) (30) 
4 Ech (R)-specific enoyl-CoA hydratase PhaJ P. aeruginosa 6200[e] 0.03[e] Fukui et al. (1989) (112) 
5 Ccr crotonyl-CoA carboxylase/reductase Ccr M. extorquens 16[f] 0.5[f] Erb et. al. (2009) (38) 
6 Mcm methylmalonyl-CoA mutase Mcm R. sphaeroides 20 0.14 Erb et al. (2009) (92) 
7 Mcd methylsuccinyl-CoA dehydrogenase Mcd R. sphaeroides 0.3[g] 0.14[g] This work 
7 Gdh Glutaryl-CoA dehydrogenase Gdh D. multivorans no activity [g] This work 
8 Mch mesaconyl-CoA hydratase Mch R. sphaeroides 1500[h] n.d. Zarzycki et al. (2008) (95) 
8 Hpd 3-hydroxypropionyl-CoA dehydratase Msed2001 M. sedula 150[i] 0.06[i] Teufel et. al. (2009) (113) 
9 Mcl malyl-CoA lyase Mcl1 R. sphaeroides 5 0.01 Erb et al. 2010 (96) 
10+13 Smt succinyl-CoA:malyl-CoA transferase SmtAB C. aurantiacus 7.5[c] 0.5 Friedmann et al. (2006) (114) 
11 Sdh succinate dehydrogenase SdhA E. coli n.d. n.d.  
12 Fuh fumarate hydratase FumA E. coli 1900 0.5 Lussenburg et. al. (2013) (115) 
14 Etf electron transfer flavoprotein EtfAB R. sphaeroides n.d. n.d.  
15 Fdh formate dehydrogenase (D221A) Fdh M. vaccae 1.4 0.37 Hoelsch et al. (2013) (98) 
16 Pkk polyphosphate kinase Pkk2 S. meliloti 12 0.032 Nocek et al. (2008) (99) 
17 Kat katalase KatE E. coli 11740 86.5 Sevinc et al. (1995) (100) 
18 Sod superoxide dismutase SodB E. coli n.d. n.d.  
15 Gcl glyoxylate carboligase [a] Gcl E. coli 18 0.9 Kaplun et al. (2008) (101) 
16 Gar tartronate semialdehyde reductase[a] GarR E. coli 410[b] 0.2[b] Gotto et al. (1961) (102) 
17 Glk glycerate kinase [a] GlxK E. coli 960 138 This work 
The reaction numbering is according to (Fig. 23, Fig. 29, Fig. 32, Fig. 33, Fig. 34 and Fig. 35). The reactions from 1 to 9 represent 
the core sequence of the HOPAC cycle. Highlighted in green are those enzymes used in the final version of HOPAC 4.1. n.d. 
not determined. [a] These enzymes would convert glyoxylate into phosphoglycerate, as a potential connection of the HOPAC 
cycle with central carbon metabolism. [b] Values for Pseudomonas ovalis enzymes. [c] Values determined at 55°C. [d] Values for 
the overall reaction of all three domains to propionyl-CoA. The reaction rate for the truncated (only synthetase and hydratase) 
of C. aurantiacus is 0.5 U mg-1 at 45°C (30). [e] Values for crotonyl-CoA from A. caviae. [f] Values from R. sphaeroides. [g] Values 
for succinyl-CoA. [h] Values for mesaconyl-CoA. [i] Values determined at 65°C. 
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 Initial considerations 
To find suitable enzymes for all steps in the HOPAC cycle, we investigated certain reactions in more 
detail prior to the assembly of the whole cycle. The studies of these candidate enzymes are 
summarized in the following chapters (chapter 4.1.1 to 4.1.4) 
 
Fig. 23 Topology of the HOPAC cycle from the initial design phase. Enzyme names are abbreviated according to Table 7. The 
enzymes for reactions #3, #4, #7, #8 and #14 will be discussed in chapters 4.1.1 to 4.1.4. The reaction sequence includes an 
alternative route bypassing the membrane bound succinate dehydrogenase (Sdh, reaction #12). Instead, a direct oxidation 
of succinyl-CoA to fumaryl-CoA, followed by a hydration to malyl-CoA is shown (reactions #7 and #8).  
 
4.1.1. Formation of 3-hydroxypropionyl-CoA 
The ATP dependent formation of 3-hydroxypropionyl-CoA from 3-hydroxypropionate and CoA (Fig. 23 
reaction #3) is limited by the availability of suitable enzyme candidates. This reaction is found in 
autotrophic CO2 fixation pathways of archaea (e.g. Metallosphaera sedula or Nitrosopumilus 
maritimus) or bacteria (Chloroflexus aurantiacus) (30, 34, 95). The propionyl-CoA synthase (Pcs) from 
C. aurantiacus consists of three domains (synthetase, dehydratase and reductase) converting 3-
hydroxypropionate and CoA into propionyl-CoA with 3-hydroxypropionyl-CoA and acrylyl-CoA as 
intermediates. The Michaelis-Menten kinetics parameters for the synthetase domain were previously 
determined (Km for 3-hydroxypropionate of 15 µM and a vmax of 4 U mg-1 at 55°C) (30). This enzyme is 
of interest, because it was previously shown that the cleavage of the reductase domain creates a 
shortened Pcs producing and releasing acrylyl-CoA, thus combining two of the reactions in the HOPAC 
cycle (Fig. 23 reaction #3 and #4) (30, 116). Recently, a homolog of the Pcs was found in Erythrobacter 
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sp. NAP1. The enzyme was characterized with favorable kinetic parameters compared to the Pcs from 
C. aurantiacus (Km for 3-hydroxypropionate of 200 µM and a vmax of 1.3 U mg-1 at 30°C) and the protein 
structure was solved (111). The information from the crystal structure and the previously described 
truncation site (from C. aurantiacus) were used to remove the reductase domain of the Pcs from 
Erythrobacter. Nevertheless, all these truncated enzymes (stop codon after Glu1428 or Val1214) were 
inactive. We then tried to cleave off the dehydratase domain as well, to obtain an AMP-forming 3-
hydroxypropionyl-CoA synthetase (stop codon after Asn881 or Ser900). Again, these further truncated 
enzymes showed no activity. 
Eventually, we decided to use the ADP-forming 3-hydroxypropionyl-CoA synthetase (Nmar1309) from 
N. maritimus for the development of the HOPAC cycle. This enzyme was described to perform under 
mesophilic conditions with an apparent Km for 3-hydroxypropionate of 1.2 ± 0.2 mM and a vmax of 
0.59 ± 0.03 U mg-1(34). Additionally, the application of an ADP-forming synthetase reduces the ATP 
equivalents required for the reaction sequence, however, rendering the synthetase reaction 
reversible. 
 
4.1.2. Oxidation of succinyl-CoA  
The original design considered a reaction sequence including succinate as an intermediate, which is 
oxidized by the succinate dehydrogenase to fumarate (Fig. 23 reaction #12). This enzyme is naturally 
part of the tricarboxylic acid (TCA) cycle and is comprised of four different subunits (SdhA, SdhB, SdhC, 
SdhD). SdhA contains the catalytic active site, whereas SdhB is responsible for the electron transfer 
and together with SdhC and SdhD for the reduction of ubiquinone. Moreover, the SdhC and SdhD are 
membrane bound (117). This complexity of the enzyme is not suitable for a cell-free development and 
testing of the HOPAC cycle. Nevertheless, the catalytic subunit (SdhA) was express and purified from 
E. coli. Although it was obtained in a soluble form, no activity with different electron acceptors could 
be observed. 
Therefore, a new reaction sequence was designed to circumvent the membrane bound SdhA reaction. 
This solution involves the direct oxidation of succinyl-CoA to fumaryl-CoA, which is then subsequently 
hydrated to malyl-CoA (Fig. 29 reactions #7 and #8). The oxidation reaction of succinyl-CoA is not 
naturally catalyzed by any known enzyme so far. Initially, we tested the non-decarboxylating glutaryl-
CoA dehydrogenase from Desulfococcous multivorans, which catalyzes the oxidation of glutaryl-CoA 
(C5 carboxylic acid CoA thioester) to glutaconyl-CoA (118). Unfortunately, this enzyme showed no 
activity with succinyl-CoA (C4 carboxylic acid CoA thioester). Therefore, the best candidate for this 
reaction step was a (2S)-methylsuccinyl-CoA dehydrogenase (Mcd) found in alphaproteobacteria (e.g. 
R. sphaeroides, P. denitrificans or M. extorquens) and actinobacteria (e.g. Streptomyces spp., Frankia 
spp.). This enzyme specifically catalyzes the FAD dependent oxidation of methylsuccinyl-CoA to 
mesaconyl-CoA and was already used as an engineered version (methylsuccinyl-CoA oxidase, Mco) in 
the CETCH cycle (Fig. 22 reaction #10). Even though the enzyme is highly specific towards 
methylsuccinyl-CoA, it also accepts succinyl-CoA with approximately 0.5% of the relative activity for 
the natural substrate (94). Mcd evolved towards a high specificity for the additional methyl group of 
methylsuccinyl-CoA to prevent the side reaction with the central carbon metabolism intermediate 
succinyl-CoA. We therefore focused on rational site-directed mutagenesis of the Mcd from R. 
sphaeroides (RsMcd) to change the substrate specificity and obtain a potential candidate enzyme for 
the oxidation of succinyl-CoA in vitro. The enzyme has a 22-34% identity to other acyl-CoA 
dehydrogenases (ACDs), if only theC-termianl ~390 amino acids are considered, because Mcd contains 
an unusual N-terminal extension of ~170 amino acids. Moreover, homology modeling of RsMcd onto 
the structure of the short-chain acyl-CoA dehydrogenase from Homo sapiens (38% amino acid identity, 
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68% coverage, PDB ID: 2VIG) showed no conclusive mechanism for substrate binding (especially for 
the carboxylic acid of succinyl-CoA) and did not allow for rational design of the active site. Therefore, 
we attempted to obtain a crystallize structure for the Mcd. We were able to solve the structure of a 
close homolog from P. denitrificans (PdMcd; 88% identity in the C-terminal catalytic domain to RsMcd) 
at a resolution of 1.37 Å. Although, PdMcd was crystallized in the presence of mesaconyl-CoA only FAD 
was found to be bound in the active site; theobserved weak electron density did not allow the 
modelling of a CoA ester in the active site (see chapter 5). 
Nevertheless, the solved structure allowed rational active site engineering on RsMcd, to increase the 
desired side activity towards succinyl-CoA as substrate. The difference between the natural and the 
desired substrate is the methyl branch at the C2 position. Although the missing methyl group in 
succinyl-CoA poses less steric hindrance, the wild type enzyme is able to efficiently distinguish between 
succinyl-CoA and (2S)-methylsuccinyl-CoA. An alanine at position 282 (285 in PdMcd) allows for the 
accommodation of the C2-methyl group of modeled fitted methylsuccinyl-CoA molecule (Fig. 24A). In 
comparison, the isobutyryl-CoA dehydrogenase from H. sapiens (PDB ID: 2RX0) also forms a cavity 
between Tyr136 and Ile103 to accommodate the branched C2-methyl group (Fig. 24B). This enzyme 
shows again reduced or no activity for the unbranched acyl-CoA esters (propionyl-CoA and butyryl-
CoA respectively). It is assumed, that the wider cavity allows unbranched substrates to adapt a non-
productive conformation (119). Closing this cavity with larger residues at this position could force the 
non-branched substrate to bind in a more productive conformation. In comparison, the glutaryl-CoA 
dehydrogenase from D. multivorans (PDB ID: 3MPI) catalyzes the oxidation of the unbranched glutaryl-
CoA (C5 carboxylic acid) and the cavity at the C2 position is occupied by the more steric Phe126. 
Therefore, we mutated the Ala282 of the RsMcd (Ala285 in PdMcd) to bulkier non-polar residues (Phe, 
Leu, Ileu and Val). Only the Ala282Val variant showed slightly improved product formation rates (Fig. 
25), whereas all other variants were inactive (see also chapter 5).  
At this point, we decided that further engineering of Mcd would be required, to obtain a more efficient 
enzyme for the oxidation of succinyl-CoA. In turn, we applied the wild type enzyme from R. sphaeroides 
for the initial realization of the HOPAC cycle, despite its low activity. This enzyme could be replaced in 
the future by an advanced engineered and more active succinyl-CoA dehydrogenase. 
 
Fig. 24 Active site structure of different acyl-CoA dehydrogenases. (A) Active site of methylsuccinyl-CoA dehydrogenase from 
P. denitrificans. The (2S)-methylsuccinyl-CoA is modeled into the structure according to glutaryl-CoA in panel (C). The C2 
methyl group is positioned in the cavity formed by Ala285 (between Phe287 and Arg272). (B) Active site of isobutyryl-CoA 
dehydrogenase from H. sapiens (PDB ID: 2RX0). The C2 methyl group of the product is positioned in the cavity between Tyr136 
and Ile103. (C) Active site of glutaryl-CoA dehydrogenase (PDB ID: 3MPI). The enzyme catalyzes the oxidation of glutaryl-CoA 
(unbranched C5 carboxylic acid CoA ester, compared to branched C4 carboxylic acid CoA ester in Mcd) and at the C2 position 
of the substrate, the Phe126 prevents the formation of a cavity and the Arg87 forms a bidentate hydrogen bond to the 
carboxylic acid of glutaryl-CoA. 
Realization of the HOPAC cycle 
55 
 
 
Fig. 25 Fumaryl-CoA formation by either wild type or mutated Mcd (Ala282Val) from R. sphaeroides. The assay was 
performed with ferrocenium as electron acceptor (1.8 mM) and the enzyme concentration was 2 µM. (A) HPLC-MS analysis 
for the fumaryl-CoA formation of the wild type RsMcd. (B) HPLC-MS analysis of the Ala282Val variant of Mcd for the formation 
of fumaryl-CoA. 
 
4.1.3. Electron acceptor for the oxidation of succinyl-CoA 
Since the reaction catalyzed by Mcd is an oxidation, an electron acceptor was required for the in vitro 
conditions. As discussed for the CETCH cycle, artificial electron acceptors are not well suited for a 
complex in vitro system. In turn, Mcd was engineered into an oxidase (Mco) to accept molecular 
oxygen as terminal electron acceptor. We tested Mco (Mcd Trp315Phe, Thr317Gly and Glu377Asn) for 
the conversion of succinyl-CoA to fumaryl-CoA with oxygen as electron acceptor. We also included the 
mutation of Thr317Gly, which was crucial for implementing basal oxidase activity into the 
dehydrogenase. Although, the conversion of succinyl-CoA by Mco with oxygen was detected, the 
product formation over time was decreased to an insufficient level (Fig. 26). 
 
Fig. 26 HPLC-MS chromatograms for the production of fumaryl-CoA (m/z=866) from succinyl-CoA. For the positive control, 
ferrocenium hexafluorophosphate was used as electron acceptor, whereas none was used in the negative control. Mcd 
(Thr319Gly) contains a crucial mutation to implement a basal oxidase activity into Mcd. Mco is the engineered version of Mcd 
from the CETCH cycle and shows a reduced product formation rate compared to the wild type enzyme. 
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The natural electron acceptor of Mcd is an electron transfer flavoprotein (ETF), which shuttles the 
electrons from the oxidation reaction to the membrane-bound respiratory chain to conserve the 
energy. ETFs are soluble heterodimeric FAD-containing proteins and act as single electron acceptors 
for different acyl-CoA dehydrogenases (120). It has been shown, that ETFs interact naturally with 
molecular oxygen and are a source of superoxide and hydrogen peroxide in solution (121). Hence, ETF 
was a potential electron acceptor for the oxidation of succinyl-CoA by Mcd and could additionally be 
reoxidized by molecular oxygen. The produced superoxide and hydrogen peroxide could be removed 
by superoxide dismutase (Sod) and catalase (Kat). We were able to show, that ETF from R. sphaeroides 
was able to act as an electron acceptor for the oxidation of succinyl-CoA and the product formation 
was dependent on the ETF concentration (Fig. 27A). This indicated that the reoxidation of ETF by 
molecular oxygen was likely again a limiting factor in the overall reaction. It has been reported that the 
production rate for reactive oxygen species (ROS) by ETF was increased in clinically relevant variants, 
which implied a faster recycling of the electron acceptor. The first interesting variant comprised an 
aspartate to asparagine mutation, which affected the overall stability of the protein. The second was 
an arginine to cysteine mutation at the interface between the dehydrogenase and ETF, which probably 
destabilized the complex formation between ETF and the acyl-CoA dehydrogenase leaving ETF soluble 
but also exposed to dissolved oxygen (121). We introduced these two single mutations (βAsp125Asn 
or βArg188Cys) into ETF from R. sphaeroides and analyzed the product formation by Mcd (500 µM 
succinyl-CoA, 50 µM ETF, 5 µM Mcd) with 200 mM NaCl and 200 mM KCl salt concentration (to 
destabilize complex formation further). The βArg188Cys mutation strongly reduced the capability to 
accept electrons from the succinyl-CoA oxidation and no significant difference was observed for the 
βAsp125Asn mutation (Fig. 27B). Conclusively, further investigations into the reoxidation rate of ETF 
are required and alternative mutations might increase the reaction rate with molecular oxygen. 
Consequently, we applied the ETF wild type enzyme as an electron acceptor for the initial development 
of the HOPAC cycle. 
 
Fig. 27 Assay of Mcd with succinyl-CoA as substrate and ETF as electron acceptor. (A) The concentration of ETF was titrated 
(using 5µM Mcd and 500µM succinyl-CoA) and the product formation was observed via HPLC-MS. The product formation is 
dependent on the concentration of ETF in the assay. (B) Different mutations for ETF were tested for their effect on the 
production of fumaryl-CoA. Whereas, the Asp125 is an ETF internal mutation, Arg188 is found at the interface of ETF and 
dehydrogenase. The conditions applied in this assay were: 500 µM succinyl-CoA, 50 µM ETF, 5 µM Mcd, 200 mM NaCl and 
200 mM KCl. Whereas the Arg188Cys mutation decreased product formation titer and rate, the Asp125Asn mutation had no 
effect under these conditions. 
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4.1.4. Fumaryl-CoA hydratase reaction (formation of malyl-CoA) 
The reactions sequence of the HOPAC cycle (including the alternative route via fumaryl-CoA) contains 
the dehydration of 3-hydroxypropionyl-CoA and the hydration of fumaryl-CoA (Fig. 23 reaction #4 and 
#8). These reversible reactions could possibly be catalyzed by a single enzyme, but the two substrates 
are very distinct requiring a promiscuous active site. Fumaryl-CoA is a compound, which is not common 
in any natural metabolism and we tested its conversion to malyl-CoA using mesaconyl-CoA hydratase 
(Mch) from R. sphaeroides. This enzyme naturally accepts the C2 branched mesaconyl-CoA (product of 
Mcd from methylsuccinyl-CoA). We discovered that Mch was able to accept the unbranched fumaryl-
CoA and convert it to malyl-CoA (Fig. 28A). In turn, we tested Mch for the dehydration of 3-
hydroxypropionyl-CoA to acrylyl-CoA, but the enzyme showed no activity towards this substrate. Vice 
versa, the (R)-specific enoyl-CoA hydratase (Ech) from P. aeruginosa was able to dehydrate 3-
hydroxypropionyl-CoA but shows no activity with the non-natural fumaryl-CoA (Fig. 28B). Conclusively, 
our attempt to perform the two hydration/dehydration reactions in the HOPAC cycle by a single 
enzyme was not successful. Nevertheless, we discovered suitable candidates for both reactions. 
 
Fig. 28 Assay of different hydratases in combination with the oxidation of succinyl-CoA. (A) The mesaconyl-CoA hydratase 
(Mch) from R. sphaeroides is able to accept fumaryl-CoA as substrate and catalyzed the hydration to malyl-CoA. (B) On the 
contrary, the (R)-specific enoyl-CoA hydratase (Ech) from P. aeruginosa, which is used in the HOPAC cycle for the dehydration 
of 3-hydroxypropionyl-CoA shows no malyl-CoA formation from fumaryl-CoA. 
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 HOPAC 1.0 (Pcc prevents cycling) 
After optimizing individual steps of the HOPAC cycle, we combined these results and tested the 
complete reaction sequence in a cell free environment. In the first version of the HOPAC cycle (HOPAC 
1.0) (Fig. 29), we provided all enzymes, cofactors (NADPH, ATP, CoA) at the beginning and started the 
assay by addition of 500µM acetyl-CoA. We used 13C bicarbonate (NaH13CO3) as a source of labeled 
13CO2, because the incorporation into the intermediates allows to follow the number of turns of the 
cycle (Fig. 30). However, under these conditions we could not observe any conversion of the initially 
supplied acetyl-CoA nor the incorporation of 13CO2 into intermediates by HPLC-MS. This indicated that 
the initial carboxylation of acetyl-CoA using Pcc from M. extorquens was a bottleneck in the reaction 
sequence. 
 
 
Fig. 29 HOPAC 1.0 (Pcc prevents cycling). Topology of the HOPAC 1.0 cycle. Enzyme names are abbreviated according to 
Table 7. The reaction sequence was altered from the initial design, bypassing the membrane bound succinate dehydrogenase 
(Sdh, reaction #12). Instead, a direct oxidation of succinyl-CoA to fumaryl-CoA (Mcd, reaction #7) followed by a hydration to 
malyl-CoA by mesaconyl-CoA hydratase (Mch, reaction #8) was applied. Pcc was insufficiently active with the provided 
starting substrate (acetyl-CoA) and prevented the operation of the CO2 fixation cycle. 
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Fig. 30 Expected 13C-label incorporation of the HOPAC cycle from 13CO2. Shown is the expected labeling pattern for each 
turn of the HOPAC cycle. The cycle features two CO2-incorporation steps per turn shown in blue and red dots. The carbon 
incorporated into the C3-acceptor acrylyl-CoA is shown in blue. This carbon ends up in the output molecule glyoxylate during 
each turn. The carbon incorporated into the C2-acceptor acetyl-CoA is shown in red. This label stays with the acceptor 
molecule during each turn of the cycle (indicated by a darker red color). Note that the HOPAC cycle includes a carbon skeleton-
rearranging step catalyzed by a mutase, resulting in a complex labeling pattern. 
 
 HOPAC 2.0 (Pcc variant mPc allows cycling) 
In HOPAC 2.0 we aimed at overcoming the limitations caused by the insufficient activity of Pcc with 
acetyl-CoA, by analyzing naturally occurring acetyl-CoA carboxylases (Acc). Accs can be found in most 
living organisms (including archaea, bacteria, yeast, fungi, plants animals and humans) and are 
essential for the initial step of the fatty acid biosynthesis or the production of precursors for polyketide 
synthesis. The catalyzed two-step reaction is initiated by the biotin carboxylase (BC) followed by a 
transfer of the carboxylated biotin by the biotin carboxyl carrier protein (BCCP). The product is 
eventually formed by the carboxyl transferase (CT) domain, which consist of and α and β subunit. 
Acetyl-CoA carboxylases are well conserved among different organisms, but the organization of all 
different subunits is highly variable (Fig. 31A). Most eukaryotic Accs form a single, large (>200 kDa and 
>2000 amino acids) and multi-domain enzyme on a single polypeptide. Bacterial Accs consist of 
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multiple smaller subunits (up to 4 individually expressed genes). However, the holoenzyme complex is 
often unstable and the subunits tend to dissociate under various conditions (122). The archaeal Acc 
from M. sedula consist of three subunits and each domain (BC, BCCP and CT) forms an individual 
polypeptide. These proteins can be heterologously produced in E. coli and the holoenzyme is stable, 
but the specific activity at 30°C is only around 100 mU mg-1 (123).  
The Acc from S. coelicolor consists of only two subunits, because the BC and BCCP domains are 
combined to a single polypeptide. This enzyme requires an additional protein for the complex stability 
and to obtain the maximal activity of 490 mU mg-1 with acetyl-CoA (124). Interestingly, this carboxylase 
shares the BC/BCCP subunit with a Pcc. In this case, the CT subunit from the Acc is exchanged with a 
propionyl-CoA specific CT (125). The main difference in the active site between these two CT domains 
is an aspartate to isoleucine substitution, determining the substrate specificity. Additionally, a single 
aspartate to isoleucine mutation (or vice versa) allows the inversion of substrate specificity within 
these two different CT domains (126). Accordingly, we decided to implement the same mutation at 
the homologous position in the CT domain of Pcc from M. extorquens (Asp407Ile). This enzyme has 
already been applied during the development of the CETCH cycle and can be heterologously produced 
in E. coli. Additionally, it consists of only two subunits (comparable to the Acc from S. coelicolor) and 
forms a stable holoenzyme complex. The mutation in this Pcc increased the catalytic efficiency for 
acetyl-CoA more than twelve times (wild type: 2.3 102 s-1 M-1; Asp407Ile: 2.7 103 s-1 M-1) to a vmax of 
1.15 ± 0.03 U mg-1 and a KM for acetyl-CoA of 0.92 ± 0.06 mM (Fig. 31B). 
 
Fig. 31 Comparison of different acetyl-CoA carboxylases. (A) Domain organization of Accs from different organisms. Each 
arrow represents a single poly peptide chain. Adapted from (122). Accs consist of four domains: biotin carboxylase (BC), biotin 
carboxyl carrier protein (BCCP) and the carboxyl transferase (comprising an α- and β-subunit). The Pcc from M. extorquens 
consists of two subunits, comparable to the Acc from S. coelicolor. (B) Michaelis-Menten kinetic of Pcc wt and the Asp407Ile 
variant from M. extorquens with acetyl-CoA as substrate. The variant shows an increased efficiency with acetyl-CoA. 
 
Applying this Pcc variant (mPc) from M. extorquens, we tested the second version of the HOPAC 
(HOPAC 2.0) cycle and incorporation of 13CO2 was observed after providing acetyl-CoA as starting 
substrate (250 µM). Fractional labeling of CoA-esters showed that the majority of acetyl-CoA was 
labelled once after 10 minutes and methylmalonyl-CoA is labeled up to 3 times indicating that some 
intermediates passed the cycle 1 and 1/2 times within 90 minutes. Although the total amount of 
intermediates in the cycle decreased over time, these experiments demonstrated that HOPAC 2.0 
could in principle turn several times. (Fig. 32).  
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Fig. 32 HOPAC 2.0 (Pcc variant mPc allows cycling) (A) Topology of the HOPAC cycle version 2.0. Enzyme names are 
abbreviated according to Table 7. The Asp407Ile mutation in Pcc from M. extorquens (enzyme boxed in red) increases the 
activity towards acetyl-CoA sufficiently to allow for 13CO2 incorporation by the pathway. (B) Dynamics of key intermediates 
of HOPAC 2.0 over 90 minutes. Shown are the total levels (ion counts) and fractional labelling pattern of six different CoA 
ester with color-coding according to (A). 
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 HOPAC 3.0 (ATP and NADPH regeneration) 
The recycling of cofactors (ATP and NADPH) was an important improvement in the CETCH cycle and 
was therefore also considered for the HOPAC cycle. Especially the reversible 3-hydroxypropionyl-CoA 
synthetase (Hps) reaction is highly sensitive to changes in the ATP and ADP + Pi ratio, since the reaction 
operates close to the thermodynamic equilibrium (ΔrG’ = 11 kJ mol-1). In HOPAC 3.0, we incorporated 
the regeneration systems involving polyphosphate kinase (Pkk) and formate dehydrogenase (Fdh) to 
provide a constant recycling of the ATP and NADPH cofactors. 
In this version, the incorporation of 13CO2 showed again that acetyl-CoA is labeled once after 10 min, 
but also incorporated a second label after 30 min. This indicates, that some intermediates passed the 
cycle already two times, in contrast to HOPAC 2.0 (Fig. 33). In HOPAC 3.0 we also observed an 
accumulation of methylmalonyl-CoA. The ATP-dependent reaction of Hps was not limiting anymore 
and the methylmalonyl-CoA mutase (Mcm) became a bottleneck in this version of the pathway. This 
indicates that Mcm was inactivated over time, since the radical based reaction of this enzyme is 
coenzyme B12-dependent and might be susceptible to oxidative stress. 
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Fig. 33 HOPAC 3.0 (ATP and NADPH regeneration) (A) Topology of the HOPAC cycle version 3.0. Enzyme names are 
abbreviated according to Table 7. Addition of formate dehydrogenase (Fdh) and polyphosphate kinase (Pkk) (boxed in red) 
regenerate ATP and NADPH. (B) Dynamics of key intermediates of HOPAC 3.0 over 90 minutes. Shown are the total levels (ion 
counts) and fractional labelling pattern of six different CoA ester with color-coding according to (A). Compared to the HOPAC 
2.0 cycling efficiency slightly increased, but there is an accumulation of methylmalonyl-CoA (blue) over time. 
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 HOPAC 4.0 (Protection from reactive oxygen species) 
From HOPAC 3.0 we suspected, that the cofactor of the B12-dependent Mcm is susceptible to oxidative 
damage by ROS produced by ETF, which lead to an accumulation of methylmalonyl-CoA. Therefore, 
the next HOPAC version (HOPAC 4.0) included catalase (Kat) and superoxide dismutase (Sod) from E. 
coli to remove these ROS (Fig. 34A). These adjustments should protect the B12 cofactor, as well as other 
coenzymes, cofactors, intermediates and proteins from oxidative damage. The assay was started by 
the addition of 250 µM of acetyl-CoA and the intermediates were analyzed by HPLC-MS. The 13CO2 
incorporation showed almost the same labeling pattern of the intermediates over time as observed in 
the previous version of the HOPAC cycle. In contrast, the accumulation of methylmalonyl-CoA was 
even further increased. This indicates that the ROS protection affected the overall performance of the 
cycle, but was insufficient to protect Mcm from inactivation. Coinciding with the accumulation of 
methylmalonyl-CoA after 30 min there was a depletion of succinyl-CoA, which underscores that Mcm 
was limiting the flux through the pathway. Nevertheless, the increased performance also resulted in 
the complete labeling of a small fraction of the intermediates after 90 min (i.e. 3-hydroxypropionyl-
CoA and methylmalonyl-CoA) (Fig. 34B). This indicated that some intermediates passed the cycle 
already 2 and 1/2 times in this version. Additionally, we noticed the depletion of free CoA over time, 
which may lead to an insufficient performance of the 3-hydroxypropionyl-CoA synthetase. No side 
product formation could be observed so far that could explain the CoA depletion. The identification of 
such a side product would be important in order to devise a metabolic proofreading for its recycling. 
For example, a specific hydrolysis of an unwanted CoA derivative could replenish the CoA pool and 
help sustaining the performance of the cycle. 
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Fig. 34 HOPAC 4.0 (Protection from reactive oxygen species) (A) Topology of the HOPAC cycle version 4.0. Enzyme names 
are abbreviated according to Table 7. In this version, a superoxide dismutase (Sod) and catalase (Kat) (boxed in red) were 
added to protect the system from reactive oxygen species (B) Dynamics of key intermediates of HOPAC 4.0 over 90 minutes. 
Shown are the total levels (ion counts) and fractional labelling pattern of six different CoA ester with color-coding according 
to (A). Compared to the previous HOPAC 3.0 the labeling incorporation did not improve significantly and methylmalonyl-CoA 
accumulated even more.  There is also an observable depletion of free CoA over time. 
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 HOPAC 4.1 (further improvements) 
According to the observed bottlenecks, we started the assay of HOPAC 4.1 again with 250 µM acetyl-
CoA and supplied fresh Mcm and CoA after the first 20 min again. Addition of Mcm efficiently 
prevented the accumulation of methylmalonyl-CoA, which was observed in the previous version. The 
13CO2 incorporation improved significantly and all intermediates showed a fraction with the highest 
labeling possible after 90 min. This indicates, that some intermediates passed the cycle for at least 
three rounds of conversion at this point. The addition of CoA did not prevent its depletion in the end. 
The final concentrations was even lower than in HOPAC 4.0, which presumably resulted from the 
better overall performance in this version of the cycle (Fig. 35B). We identified an increase in the 
concentration of the oxidized dimeric form of CoA (CoAS-SCoA), which occurs simultaneously with the 
depletion of CoA. The oxidation of CoA implies an overall oxidative environment (Fig. 35C). Since the 
accumulation of methylmalonyl-CoA was prevented in this version, Mcd was able to perform more 
turn overs of the subsequent succinyl-CoA oxidation reaction. This reaction is responsible for the 
formation of ROS via ETF and might explain the increased oxidation of CoA. Additionally, the 
conversion of the free CoA pool into its oxidized form would eventually also stall the formation of 3-
hydroxypropionyl-CoA by Hps. Moreover, oxidative stress could be detrimental for enzyme 
performance in general.  
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Fig. 35 HOPAC 4.1 (further improvements) (A) Topology of the HOPAC cycle version 4.1. Enzyme names are abbreviated 
according to Table 7. Methylmalonyl-CoA mutase (Mcm) (boxed in red) and CoA was added after 20 min. (B) Dynamics of key 
intermediates of HOPAC 4.1 over 90 minutes. Shown are the total levels (ion counts) and fractional labelling pattern of six 
different CoA ester with color-coding according to (A). The addition of Mcm prevented the accumulation of methylmalonyl-
CoA compared to the previous version and increased the overall performance of the system. There is still an observable loss 
of free CoA over time. (C) The depletion of the free CoA pool is concurrent with the formation of the CoA dimer (CoAS-SCoA), 
which indicates an oxidative environment. 
  
Realization of the HOPAC cycle 
68 
 
 Conclusions 
The HOPAC 4.1 cycle is the second synthetic pathway for the fixation of CO2 in vitro and consists of 10 
core reactions. The reaction sequence is catalyzed by 15 enzymes (including cofactor regeneration and 
ROS protection) originating from 8 different organisms (including bacteria and archaea) and includes 
the engineering of enzymes towards desired reactions. The HOPAC cycle is able to perform multiple 
rounds of conversion and incorporates 13CO2 into organic molecules in a continuous fashion. 
The reaction sequence, is comparable to the CETCH cycle. While the CETCH cycle converts an initial C3 
compound (propionyl-CoA), the HOPAC cycle converts an initial C2 compound (acetyl-CoA) following a 
similar pattern of reaction types as the CETCH cycle. Hence, the energetic requirements (ATP 
equivalents per CO2 fixed) are virtually the same as for the CETCH v2.0 cycle. Nevertheless, the 
intermediates produced, the catalyzing enzymes and the thermodynamic landscape is very different. 
Additionally, the reaction sequence closely resembles the first cycle of the 3-hydroxypropionate 
bi-cycle, which can be found in the thermophilic bacterium Chloroflexus aurantiacus (Fig. 5). The major 
difference in our design is that 3-hydroxypropionyl-CoA is not reduced with NADPH to propionyl-CoA 
for an ATP dependent carboxylation by Pcc. Instead, 3-hydroxypropionyl-CoA is first dehydrated to 
acrylyl-CoA, which is then reductively carboxylated by an ECR (Fig. 35A). This shortcut in the pathway 
reduces the energy requirement by one additional ATP. Moreover, the approach of synthetic biology 
allows us to “replace” the thermophilic enzymes with more suitable candidates for the desired 
mesophilic conditions. The application of a reversible ADP-forming acyl-CoA synthetase in the HOPAC 
cycle, also reduces the requirement for ATP, compared to the AMP-forming synthetases in the 3-
hydroxypropionate bi-cycle. 
For the realization of the HOPAC cycle, we first redesigned the original reaction sequence from the 
design phase to circumvent the problematic in vitro oxidation of succinate to fumarate by a synthetic 
route via an intermediate (fumaryl-CoA) not found in nature. Therefore, we exploited the side 
reactivity of Mcd and Mch for the direct conversion of succinyl-CoA to malyl-CoA. In this synthetic 
route we successfully applied ETF as electron acceptor for the oxidation reaction, because the 
engineered Mco from the CETCH cycle was not active with succinyl-CoA. Although ETF was reported 
to react with oxygen allowing the recycling of the electron acceptor, further investigations of the 
oxygen dependent reoxidation reaction are required. As we apply 50 µM of ETF in the HOPAC 4.1, the 
pool of ETF could be completely reduced leaving the reaction of Mcd dependent on the very slow 
reoxidation rate of ETF. Nevertheless, this approach actually represents an important initial step 
towards recycling electrons for energy conservation. The electrons from the acyl-CoA dehydrogenase 
reaction could be conserved via ETF for the production of ATP and NADPH on the level of ubiquinone 
or plastoquinone of isolated organelles or in a potential host organism. 
We successfully applied enzyme engineering for the initial development of the HOPAC cycle, where 
the mutation of Pcc to accept acetyl-CoA as starting substrate was a crucial step for the operation of 
the cycle. We also investigated the engineering of Mcd toward accepting succinyl-CoA more efficiently, 
but these results were less successful in respect to the development of the HOPAC cycle. Additionally, 
the regeneration of cofactors (ATP and NADPH) as well as the protection from ROS increased the 
overall performance. Nevertheless, Mcm still seems to be the rate limiting step. We also observed the 
accumulation of the oxidized CoA dimer (CoAS-SCoA), which indicates an oxidative environment. This 
oxidative environment presumably arises from the reaction of Mcd coupled to ETF producing 
superoxide and hydrogen peroxide. This indicates that the protection from ROS via Sod and Kat might 
not be sufficient enough. Counteracting this redox state with a reducing agent like dithiotreitol (DTT) 
causes the problem of inhibiting the electron transfer efficiency from Mcd to ETF. 
 
Realization of the HOPAC cycle 
69 
 
In a next step, the primary assimilation product (glyoxylate) could be converted into a secondary 
molecule to exactly quantify the fixation efficiency of the HOPAC cycle. In the CETCH cycle, glyoxylate 
was converted with acetyl-CoA into malate via the malate synthase. This read-out module is not 
applicable for the HOPAC cycle, since acetyl-CoA is a central intermediate of the cycle. Therefore a 
different read-out module is required (further discussed in chapter 6). The realization of the second 
synthetic pathway for the fixation of CO2 in vitro increases the available options for future applications 
and allows for a parallel optimization of both pathways (HOPAC and CETCH) and their direct 
comparison (further discussed in chapter 6) 
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5. Crystal structure of (2S)-methylsuccinyl-CoA dehydrogenase 
The methylsuccinyl-Coenzyme A (CoA) dehydrogenase (MCD) is a member of the flavin dependent 
acyl-CoA dehydrogenase (ACD) family and catalyzes the oxidation of the α-branched (2S)-
methylsuccinyl-CoA into the corresponding trans-2-enoyl-CoA thioester, mesaconyl-CoA. The enzyme 
plays a crucial role in the ethylmalonyl-CoA pathway for acetyl-CoA assimilation in many α-
proteobacteria (e.g. Rhodobacter sphaeroides, Methylobacterium extorquens and Paracoccus 
denitrificans), actinobacteria (e.g. Streptomyces spp., Frankia spp.) and possibly spirochaetes (e.g. 
Leptospira spp.) (94). Other described members of the ACD family are short-chain acyl-CoA 
dehydrogenase (SCAD), medium-chain acyl-CoA dehydrogenase (MCAD), long-chain acyl-CoA 
dehydrogenase (LCAD), and very long-chain acyl-CoA dehydrogenase (VLCAD), which are involved in 
the β-oxidation of fatty acids. Additionally, isovaleryl-CoA dehydrogenase (IVD), isobutyryl-CoA 
dehydrogenase (IBD), short/branched-chain acyl-CoA dehydrogenase (SBCAD), and glutaryl-CoA 
dehydrogenase (GDH) are involved in the degradation of amino acids like leucine, valine, isoleucine, 
tryptophan, and lysine (127-130). A common feature to all of these enzymes is the presence of one 
non-covalently bound flavin adenosine dinucleotide (FAD) cofactor per active site. The α,β-
desaturation of the CoA thioester is initiated by a proton abstraction from the α-carbon by a conserved 
catalytically active glutamate and a hydride transfer from the β-carbon to the N5 of the FAD cofactor 
(131, 132). The reduced co-factor is reoxidized by two sequential one-electron transfers to electron 
transfer flavoproteins (ETF), which in turn deliver the electrons to the membrane bound electron 
transport chain for energy conservation (133). For many members of the ACD family structures were 
solved by X-ray crystallography and almost all of them form homotetramers (dimers of dimers) 
consisting of four ~43 kDa subunits (134). An exception is the VLCAD, which forms a dimer of two 
~67 kDa subunits (135). All enzymes in the ACD-family share an overall homologous fold, composed of 
an N-terminal α-helix domain, an intermediate β-barrel domain and a C-terminal α-helix domain. Again 
the VLCAD represents an exception as it comprises the central fold of ACDs, but also possesses a C-
terminal ~180 amino acid extension forming an additional α-helix domain, responsible for dimer 
stability and the anchoring of the protein to the membrane (135).  
The related family of acyl-CoA oxidases (ACO) are responsible for the β-oxidation of fatty acids in the 
peroxisomes of eukaryotes. ACOs also belong to the superfamily of ACDs and contain FAD as cofactor. 
Instead of transferring the electrons from the oxidation reaction to ETFs, however, they use molecular 
oxygen as a direct electron acceptor. Similar to VLCAD, these oxidases form homodimers that possess 
C-terminal extensions. Nevertheless, ACOs lack the transmembrane helix anchor and are thus soluble 
and not membrane bound. The catalytic domains of ACOs resemble to some extend the central fold of 
ACDs (136). 
The different members of the ACD family exhibit substrate specificities towards distinct groups of CoA-
thioesters, respectively, which are conveyed by defined active site architectures. The accommodation 
of all these different substrates within the same fold is therefore of particular interest. In SCAD (PDB 
ID: 1JQI) the active site is restricted by an isoleucine residue from helix G (137), whereas MCAD (PDB 
ID: 3MDE) possesses prolines in the same α-helix. This results in a change of the direction of the helix 
in MCAD, thereby widening the cavity to accommodate acyl-CoA thioesters of 4 to 16 carbons in length 
(138, 139). Bulkier residues in the active site of MCADs are substituted by glycines in VLCAD (PDB ID: 
3B96), opening the pocket beyond these residues to allow the accommodation of acyl-CoA thioesters 
with up to 24 carbons (135). In the case of IVD (PDB ID: 1IVH) the catalytic glutamate residue is 
substituted by an alanine and another glutamate from the opposite α-helix G is assuming its space and 
function, resulting in a lateral expansion of the pocket and enable the accommodation of the β-
branched substrate (140). Similarly, the active site cavity in IBD (PDB ID: 1RX0) is more narrow near 
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the top and more wide at the base to accept the α-branched substrate (119). In GDH (PDB ID: 3MPI) 
an arginine is important for binding of the C5 carboxylic acid moiety of the CoA thioester substrate 
(118, 141). Compared to all other acyl-CoA esters discussed above, (2S)-methylsuccinyl-CoA represents 
a substrate with mixed properties. It is short (C4) but possesses a terminal carboxylic acid group, as 
well as an additional C2-methyl branch. To rationalize the function of MCD, it is important to decipher 
how substrate specificity is conferred in MCD and how a smaller substrate like succinyl-CoA, which 
lacks the methyl branch, is excluded from the active site of MCD.  
Here we report the high resolution structure of MCD from P. denitrificans (PdMCD) that catalyzes the 
unprecedented α,β-desaturation of an α-methyl branched dicarboxylic acid CoA thioester. We used 
the structural information to rationalize the substrate specificity of MCD. This allowed us to engineer 
a MCD variant that exhibits improved catalytic efficiency with succinyl-CoA and a decreased efficiency 
with (2S)-methylsuccinyl-CoA, which is important for the development of the HOPAC cycle. For the 
CETCH cycle, an oxidase function was introduced into the MCD scaffold. The high resolution structure 
of MCD now provides a more in depth explanation for the engineered reactivity with oxygen. 
 Structure and overall topology 
PdMCD forms a homodimer, consistent with our gel filtration analysis. The protein crystallized in the 
space group P 21 21 21 with one dimer per asymmetric unit. The obtained well-ordered high resolution 
electron density map allowed to model almost the entire poly peptide chain (missing only 10 N-
terminal residues) as well as the FAD cofactor in both active sites (Table 8). 
Table 8 Data collection and refinement statistics for PdMCD crystal structure 
PDB ID 6ES9 
Ligands flavin adenine dinucleotide, Coenzyme A, sulfate 
Data collection  
 Wavelength 0.979 
 Space group P 21 21 21 
 Cell dimensions  
  a b c (Å) 81.60  105.19  138.94 
  α β  () 90.00   90.00   90.00 
 Resolution range [Å] 17.57  - 1.37 (1.42  - 1.37) 
 Number of observations  
  total 499135 (49543) 
  unique 249876 (24803) 
 Redundancy 2.0 (2.0) 
 Mean I/(I) 15.25 (1.47) 
 CC1/2 (%) 99.9 (61.6) 
 Completeness (%) 99.92 (99.97) 
Refinement  
 Rwork / Rfree 0.1760 / 0.1847 
 No. atoms  
  protein 8375 
  ligands 180 
  solvent 1389 
 Mean B-factors  
  protein 20.52 
  ligands 24.86 
  solvent 31.31 
 R.m.s deviations  
  bond lengths [Å] 0.016 
  bond angles [º] 1.41 
 Ramachandran  
  favored [%] 98.53 
  allowed [%] 1.29 
  outliers [%] 0.18 
Numbers in parentheses indicate values for highest resolution shell 
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The enzyme crystallized only in the presence of mesaconyl-CoA, the reaction product of MCDs. 
Although we could observe some additional electron density in the active sites, it was too ambiguous 
to model any ligand. Nevertheless, we observed electron densities at the surfaces of each monomer 
that allowed the modeling of the adenosyl phosphate parts of CoA or its derivative. The adenine ring 
is taking part in a cation-π stacking interactions between Arg81 and Trp476 (Fig. 36 ). This interaction 
presumably stabilizes helix H, which is involved in a crystal contact, which may explain why the crystals 
only formed in the presence of mesaconyl-CoA. (Fig. 36 and Fig. 37). 
The core fold consists of ~390 amino acids and assumes the canonical central fold known from other 
tetrameric ACDs. Therefore, we followed the conventional secondary structure labeling of ACDs for 
the α-helical domain (helices A-F), the intermediary β-barrel domain (strands 1-7) and the C-terminal 
α-helical domain (helices G-K). The only difference to the central fold of other ACDs is a ~10 residue 
long loop region connecting β-strands 5 and 6 (Fig. 37 and Fig. 38A). This loop is flanked by prolines 
(one N-terminal and three C-terminal) and contains a motif of three aspartates in a row. 
 N-terminal extension 
In contrast to canonical tetrameric ACDs, PdMCD possesses an additional ~170 amino acids long N-
terminal extension comprising helices A’-C’, a small intermediate β-hairpin motive (strands 1’ & 2’), 
followed by helices D’-E’ (Fig. 36 and Fig. 37). Superposing the monomer of PdMCD with the monomer 
of MCAD (PDB ID: 3MDE) shows, that the C-terminal ~390 residues structurally align well, but the N-
terminus is organized in an additional domain. However, when superimposing the PdMCD monomer 
with the MCAD tetramer, it becomes apparent that the N-terminal ~170 residue extension of PdMCD 
structurally mimics the dimer-dimer interface of MCAD. The α-helices A’-E’ of PdMCD align well with 
the α-helices G-K from the neighboring MCAD subunit (Fig. 38B). Exceptions are the small β-hairpin 
motive (not found in MCAD) and α-helix D’ of PdMCD, which only loosely aligns with α-helix J from 
MCAD. 
By emulating the dimer-dimer interface found in the tetrameric ACDs, the N-terminal extension of 
PdMCD is likely stabilizing the PdMCD dimer. Interestingly, all characterized ACDs exhibit a small cavity 
at the dimer–dimer interface. In contrast, the corresponding region in PdMCD is occupied by the 
unique β-hairpin structure. The hydrophilic residues in this motive form hydrogen bonds to the central 
fold of the opposite subunit lending additional stability to the dimer (Fig. 36B and Fig. 38). All residues 
from the N-terminal extension (helices A’-E’) show ca. 20% sequence identity (32.5% Sequence 
similarity) to the structurally homologous residues from the central fold (helices G-K), indicating that 
the N-terminal extension originated from a partial gene duplication. The same is assumed for the C-
terminal extension found in VLCAD that also mimics the dimer-dimer interface (135). Superposition of 
PdMCD with the structure of VLCAD (PDB ID: 3B96) demonstrates, that α-helices A’-C’ of PdMCD align 
well with α-helices L-N of VLCAD. Whereas α-helix D’ does not have a counterpart in VLCAD, α-helix E’ 
from PdMCD lines up with the α-helix O from the other subunit of the VLCAD dimer (Fig. 38). 
Conclusively, in both PdMCD as well as VLCAD the stability of the dimer is increased by mimicking 
dimer-dimer interfaces of canonical tetrameric ACDs. Moreover, the dimeric ACOs also possess a 
comparable C-terminal extension and the PdMCD dimer also structurally aligns to some extent with 
ACOs (supplementary figure SI Fig. 2). 
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Fig. 36 Overall structure of PdMCD. (A) One monomeric subunit of PdMCD consists of five domains. The central fold found in other ACDs consists of an initial α-helical domain (green), an intermediary 
β-barrel domain (pink), and a C-terminal α-helical domain (blue). The N-terminal extension of PdMCD is shown in orange with the unique β-hairpin motif in red. The labeling of the secondary 
structure elements is in accordance to other ACDs. (B) PdMCD forms a homodimer and each subunit contains one FAD (yellow). The subunits are shown in orange and cyan with the N-terminal 
extension in darker shades, respectively. Adenosyl phosphate moieties were found to be bound on the surface of each subunit between Arg81 and Trp476. This interaction presumably stabilizes 
helix H, which is involved in a crystal contact. The dimeric form of PdMCD is strengthened by the β-hairpin motif in the N-terminal extension (highlighted in the box), which forms hydrogen bonds 
to the opposite subunit. 
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Fig. 37 Sequence alignment of PdMCD, RsMCD and ACDs with known structures. The sequences were aligned and the 
secondary structure elements are indicated (α-helices with barrels, β-sheets with arrows, and turns in red). The labeling of 
the secondary structure element follows the convention for canonical ACDs. The N-terminal domain of MCD is shown in 
orange. The central fold of all known ACDs is divided into two α-helical domains (green and blue) and an intermediary β-
barrel domain (cyan). The secondary structure elements of the C-terminal extension of VLCAD is indicated in grey. Identical 
residues are shaded in gray and the active site glutamate is highlighted in black. The α-helix E shows a single amino acid 
deletion like in IVD and MCAD (indicated by a blue arrow). The Phe287 in PdMCD and Phe284 in RsMCD are shifted by two 
residues towards the C-terminus and the otherwise conserved phenylalanine or tyrosine at this position is replace with an 
alanine (indicated in red and blue letters). 
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Fig. 38 Superposition of PdMCD with other ACDs. (A) Structural alignment of a PdMCD monomer in orange (N-terminal 
domain in dark orange) with the monomer of MCAD in cyan (PDB ID: 3MDE) (1.55 Å over 350 Cα-atoms per MCD monomer). 
The central fold of ACDs is conserved in the C-terminal domain of PdMCD. An extended loop region between β-strands 5 and 
6 is indicated with an arrow. (B) Superposition of the PdMCD monomer with the tetramer (dimer of dimers in cyan and grey, 
respectively) of MCAD. The N-terminal extension of PdMCD aligns with the opposite monomer of MCAD and complements 
the dimeric interface. The unique β-hairpin motif (red) is located in a cavity at the interface, which can be found in all other 
ACDs known so far. (C) Superposition of a PdMCD monomer in orange (N-terminal domain in dark orange) with a monomer 
of VLCAD in cyan (PDB ID: 3B96) (1.85 Å over 313 Cα-atoms). VLCADs have a C-terminal extension (grey), which aligns with 
the N-terminal extension from PdMCD and also complements the dimeric interface. (D) Overlay of a PdMCD monomer with 
a VLCAD dimer (N-terminal domain: cyan; C-terminal domain: grey). The subunits of VLCAD dimers also interact via α-helix O 
(pink). This feature is lacking in PdMCD, but the neighboring subunits additionally interact via the β-hairpin motif (red). 
 
 The active site 
The cofactor FAD binds to PdMCD in a drawn-out conformation as it has been observed in other ACDs 
as well (118, 119, 135, 138). Both subunits of the dimer contribute to the binding of FAD, which adopts 
a “butterfly like” conformation in respect to the isoalloxazine ring. This conformation has also been 
observed in other ACDs and was suggested to influence the redox potential of FAD for catalysis (142). 
This bending of the isoalloxazine ring is probably caused by hydrogen bonds to the polypeptide 
backbone (O2 with amine of Phe278, O4 with amine of Thr320, and N3 with carbonyl of Ala285) (Fig. 
39) and stereoelectronic interaction of the isoalloxazine ring with aromatic residues (Phe287, Trp318, 
Phe515 and Phe534) (Fig. 40A). 
Interestingly, the Phe287 in PdMCD is shifted two residues towards the C-terminus compared to a 
conserved tyrosine/phenylalanine in other ACDs (VLCAD: Phe174, MCAD: Tyr132, SCAD: Phe128 and 
IBD Tyr136) (Fig. 37). However, in a structural superposition, the aromatic ring of the shifted Phe287 
is partially assuming the same space as the tyrosyl/phenyl rings in the other ACDs. The shift of this 
otherwise conserved residue might have functional implications as there is an alanine in the original 
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position in PdMCD, which provides more space at the base of the active site pocket (discussed below) 
(Fig. 40C). This is comparable to the structure of IBD (PDB ID: 1RX0). There, another conserved 
aromatic residue found in ACDs (PdMCD: Phe534, VLCAD: Phe421, MCAD: Tyr375 and SCAD: Tyr367) 
is replace with an isoleucine (Ile375 in IBD), which widens the cavity for substrate accommodation 
(119). Instead, the non-canonical Trp216 is oriented to partially assume the position of the 
tyrosyl/phenyl ring found in the other ACDs. 
Another important residue for catalysis is a glutamate residue in position 535 in PdMCD, which is also 
conserved on other ACDs and was proposed to act as the catalytic base for the initial proton 
abstraction from the substrate. This conserved residue is positioned between α-helix J and K in 
canonical ACDs and in a homologues position in PdMCD (Fig. 40E). Only in IVD this glutamate is 
relocated to α-helix G, but it still occupies the same space in relation to the substrate. 
A significant difference in the active site architecture of PdMCD, MCAD, and IBD is an amino acid 
deletion (Fig. 37) in α-helix E, which prevents a perturbation of this helix found in IVD, SCAD, VLCAD, 
and GDH. This results in a lateral widening of the active site to accommodate the sterically challenging 
substrates. Moreover, the same helix is shifted more than 2 Å to the back of the active site in PdMCD 
compared to IBD and MCAD, providing even more space for the terminal carboxylic acid group of 
methylsuccinyl-CoA, which likely interacts with at least two arginine residues (discussed below) (Fig. 
40). Additionally, the loop between β-strand 6 and 7 (from Leu372 to Glu380) assumes a strikingly 
different conformation in PdMCD compared to other ACDs. The differing conformation of this loop is 
stabilized by various residue interactions (i.e. Tyr375 with the backbone carbonyl of Gln198, Lys379 
with Glu279, and the backbone carbonyl of Tyr375 with Tyr243) and results in the positioning of Arg376 
within the active site via a bidentate side-on interaction with Glu380 (Fig. 40D). Arg376 may contribute 
to substrate binding, which will be discussed next. 
 
 
Fig. 39 Superposition of F0-FC electron density simulated annealing omit maps on a refined FAD and Thr320. (A) Omit map 
at 3.0 σ for the FAD cofactor and Thr320 of PdMCD. The Thr320 forms a hydrogen bond to the N5 of the FAD. The electron 
density around this residue (cyan) indicates, that the threonine can assume a different rotamer conformation (purple) where 
the hydrogen bond is broken. The FAD cofactor forms additional hydrogen bonds with the polypeptide backbone. (B) The 
isolalloxazine ring of FAD assumes a distinct “butterfly-like” conformation (angle of 165°), which can be observed in other 
ACDs as well. This conformation is assumed to indicate a shift in the electron potential of the cofactor. 
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Fig. 40 Active site architecture of PdMCD. (A) Wall-eyed stereo view of the active site residues. The acyl moiety of (2S)-
methylsuccinyl-CoA was fitted into the active site according to the conserved positioning of substrates found in other ACDs. 
The carbonyl group of the thioester bond forms a hydrogen bond to the 2’-hydroxyl of the FAD ribityl chain and the backbone 
amine of the catalytic Glu535. The C2 of the substrate is positioned below Glu535 for proton abstraction and the C3 is 
positioned above the N5 of FAD for the hydride transfer. The base of the active site cavity is lined by Arg376, Arg378 and 
Arg421 for binding of the carboxylic acid group of the substrate. (B) The interior surface of the active site shows a distinct 
pocket for the accommodation of the C2-methyl group and the base of the cavity is positively charged for the binding of the 
carboxylic acid of the substrate. (C) Overlay of PdMCD (orange) with VLCAD (PDB ID: 3B96) (cyan). The α-helix E of PdMCD is 
shifted away from the active site and a single residue deletion (as it can be found in IVD and MCAD) prevents a perturbation 
of this helix. A conserved phenylalanine/tyrosine residue in other ACDs is shifted in PdMCD. This shift allows to form the 
cavity to accommodate the C2-methyl branch of the substrate by Ala285. Moreover, Phe287 partially assumes an analogous 
position to the conserved aromatic residue in other ACDs. (D) Overlay of PdMCD (orange) with MCAD (PDB ID: 3MDE) (cyan) 
indicating a re-positioned loop between β-srands 6 and 7. This leads to the formation of a salt bridge between Glu380 and 
Arg376, which is thereby positioned within the active site. (D) Overlay of PdMCD (orange) with GDH (PDB ID: 3MPI) (cyan). 
The conserved catalytic glutamate is found in all ACDs (except IVD). In GDH a salt bridge to the substrate glutaryl-CoA is 
formed with an arginine from α-helix E. In case of PdMCD, Arg421 is in an analogous position but originates from α-helix G. 
Arg421 is held in place by Ser248 and Thr418, but the additonal Arg252 from α-helix E is in interaction distance to the fitted 
methylsuccinyl-CoA and may assume a different conformation upon substrate binding. 
 
 Substrate specificity 
For ACDs the substrate specificity within the conserved fold of ACDs is of particular interest. MCD is 
highly specific for (2S)-methylsuccinyl-CoA without detectable activity towards (2R)-methylsuccinyl-
CoA, butyryl-CoA and isobutyryl-CoA (94). Although, the enzyme accepts succinyl-CoA as a substrate, 
the rate of catalysis is ~200 fold lower than with (2S)-methylsuccinyl-CoA, suggesting that the C2-
methyl group is crucial for the correct positioning of the substrate. Analogous to other ACDs, PdMCD 
shows a cleft on the surface that extends into the active site where the binding of the CoA thioester 
takes place. Although PdMCD was crystallized in the presence of the reaction product mesaconyl-CoA, 
only very weak electron density could be observed at the binding site, which did not allow the modeling 
of CoA or a derivative. However, it is well known from other ACDs that the thioester carbonyl oxygen 
forms hydrogen bonds with the 2’-hydroxyl group of the ribityl moiety of the riboflavin and the 
backbone amine hydrogen of the catalytic glutamate that acts as a base. Additionally, the C2 of the 
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substrate is required to be positioned directly below this glutamate for efficient proton abstraction, 
whereas C3 of the substrate needs to be positioned above the N5 of the isoalloxazine ring of FAD for 
the hydride transfer (118, 119, 135, 138, 143). Following these restrictions, we fitted (2S)-
methylsuccinyl-CoA into the active site assuming the terminal carboxyl group to be planar relative to 
the carbon backbone of the molecule and parallel to the isoalloxazine ring of FAD. This would be also 
the case for the oxidized product (mesaconyl-CoA), in which the double bond would stabilized the 
planar conformation by delocalization. The modeled substrate fitted the active site surprisingly well 
(Fig. 40B), accommodating the C2-methyl branch as well as the carboxylic acid group without any 
significant clashing. 
5.4.1. C2-methyl branch 
The active site is laterally expanded forming a pocket lined by Ala285, Phe287, and Arg252, which 
provides space for the C2-methyl group (Fig. 40A). A similar pocket is not present in other ACDs where 
the alanine is substituted by conserved phenylalanine or tyrosine residues instead, which influence the 
electropotential of FAD (142). Interestingly, another phenylalanine can be found in PdMCD which is 
shifted towards the C-terminus (Phe287). As aforementioned this residue seems to partially assume a 
similar space as the conserved aromatic residue in the other ACDs (Fig. 40C). This observation 
underscores the role of Ala285 in substrate positioning and binding in MCD. The C2-methyl group of 
the fitted substrate protrudes into the cavity opened up by Ala285. The difference of the catalytic 
efficiencies between the branched and unbranched substrate might arise from a lower binding energy 
for succinyl-CoA lacking the C2-methyl group. The methyl group is likely also crucial for the precise 
positioning of the α-β-carbon bond of the substrate during catalysis. The absence of the methyl group 
allows succinyl-CoA to be more flexible and movable, which could affect its correct positioning and 
lead to unproductive binding states. A very similar observation has been made for the IBD, where 
propionyl-CoA is converted with only 5% of the relative catalytic rate compared to isobutyryl-CoA. The 
C2-metyhl branch hinders the free rotation around the α-carbon in the active site and wedges the 
substrate into position for efficient catalysis (119). 
We investigated the role of different residues for substrate specificity in the homologous MCD of 
Rhodobacter sphaeroides (RsMCD), which we previously used for engineering efforts in the CETCH and 
HOPAC cycle. RsMCD exhibits 88% amino acid sequence identity (95% similarity) in catalytic core 
domain to that of PdMCD, with nearly identical catalytic properties (supplementary figures SI Fig. 3 
and SI Fig. 4). Interestingly, substitution of Ala282 in RsMCD (corresponding to Ala285 in PdMCD) into 
more sterically demanding residues like leucine, isoleucine, and phenylalanine yielded only inactive 
enzymes. These larger residues likely prevent accommodation of the C2 branch and also negatively 
impact the interaction of the carboxyl group with Arg249 (Arg 252 PdMCD) (discussed below). In 
contrast, mutation of the alanine into valine still resulted in some residual activity with (2S)-
methylsuccinyl-CoA. The catalytic efficiency of this variant was decreased by 50% compared to the wild 
type, which was mostly due to a decreased turn over number. On the other hand, this variant exhibited 
an increased catalytic efficiency with unbranched succinyl-CoA due to a decrease in KM (Table 9 and 
Fig. 41A). This indicates, that the mutation to valine prevents efficient binding of the branched 
methylsuccinyl-CoA, but facilitates productive binding of unbranched succinyl-CoA. We also 
investigated the role of the Phe284 in RsMCD (Phe287 in PdMCD), which is shifted towards the C-
terminus by two positions compared to other ACDs and influences the redox potential of FAD. We 
additionally substituted the Phe284 with an alanine, valine or leucine within the Ala282Phe 
background of RsMCD, thus reversing the C-terminal shift. Nevertheless, these double mutants did not 
show any activity with succinyl-CoA. Interestingly, only the Ala282Phe/Phe284Ala swapping mutant 
was still able to convert (2S)-methylsuccinyl-CoA with less than 0.2% of relative catalytic efficiency 
(Table 9 and Fig. 41B). Assuming the introduced Phe282 residue adopts a similar conformation as 
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observed in other ACDs (Fig. 40C) only a small lateral cavity would be formed, still partly 
accommodating the C2-methyl group of the substrate. However, it would likely result in a shift of the 
substrate and its α-β-carbon bond away from the optimal position for proton and hydride transfer. In 
contrast, the mutation into a bulkier valine or leucine in position 284 would prevent the Phe282 to 
adapt the canonical conformation and prevent the formation of the cavity, even resulting in a 
protrusion into the active site cavity. This likely leads to the exclusion of methylsuccinyl-CoA as well as 
succinyl-CoA. 
 
Table 9 Michaelis-Menten kinetic parameters for the wild type and mutant RsMCD with either (2S)-methylsuccinyl-CoA or 
succinyl-CoA as substrate. 
 (2S)-methylsuccinyl-CoA succinyl-CoA 
 
vmax 
(U mg-1) 
app. KM 
(µM) 
kcat/KM 
(s-1 M-1) 
vmax 
(U mg-1) 
app. KM 
(µM) 
kcat/KM 
(s-1 M-1) 
RsMCD wt 79.6 ± 1.3 80 ± 5 1.0 × 106 0.31 ± 0.06 141 ± 52 2.3 × 103 
RsMCD A282V 30.8 ± 0.6 64 ± 5 0.5 × 106 0.29 ± 0.04 57 ± 20 5.3 × 103 
RsMCD A282L  n.d. n.d. 
RsMCD A282I n.d. n.d. 
RsMCD A282F n.d. n.d. 
RsMCD A282F/F284A 0.68 ± 0.03 439 ± 49 1.6 × 103 n.d. 
RsMCD A282F/F284V n.d. n.d. 
RsMCD A282F/F284L n.d. n.d. 
n.d.: no detectable activity; Ala282 and Phe284 in RsMCD correspond to Ala285 and Phe287 in PdMCD, respectively. 
 
 
Fig. 41 Kinetic properties of RsMCD wt, Ala282Val variant and the Ala282F/F284A double variants (correspond to Ala285 
and Phe287 in PdMCD). (A) Michaelis-Menten kinetic of RsMCD wt and Ala282Val variant with (2S)-methylsuccinyl-CoA and 
succinyl-CoA as substrate. The variant shows a decreased efficiency with (2S)-methylsuccinyl-CoA, but has a slightly increased 
efficiency with succinyl-CoA. (B) Michaelis-Menten kinetic of RsMCD Ala282Phe/Phe284Ala swapping mutant with (2S)-
methylsuccinyl-CoA. This mutant only achieved 0.2% of relative catalytic efficiency with (2S)-methylsuccinyl-CoA was 
completely inactive with succinyl-CoA. 
5.4.2. C4-carboxylic acid 
It is striking that the inner surface at the base of the active site cavity is positively charge, which would 
be important for securing the carboxyl group of the substrate in the correct position (Fig. 40B). A 
similar observation can be made in the structure of GDH (PDB ID: 3MPI) where the Arg87 (from α-helix 
E) is responsible for the positive charge within the active site and forms a bidentate end-on interaction 
with the carboxyl group of glutaryl-CoA (118). In case of PdMCD Arg421 is located in an analogous 
position, but originates from α-helix G (Fig. 40E). Arg421 in PdMCD is at a distance of about 4 Å to the 
fitted carboxylic acid group of the substrate theoretically able to form a salt bridge. Furthermore, 
Arg376 from the aforementioned twisted loop between β-strands 6 and 7 limits the lower base of the 
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active site and likely contributes to substrate binding (Fig. 40). Whereas Arg376 and Arg421 are fixed 
by either Glu380 or Ser248 and Thr418, respectively, a third arginine at position 252 (from α-helix E) 
has no obvious interacting residue in the vicinity (Fig. 40). It is apparently only forming a water bridge 
to Ser283 and has a fairly close contact to the catalytic Glu535. The latter, however, is a very unlikely 
interaction partner, as this would increase the pka of the catalytic base. It is therefore more probable 
that this arginine would undergo conformational changes upon substrate binding to approach the 
carboxylic acid group of methylsuccinyl-CoA to form mono- or bidentate side-on interactions. This 
would be comparable to the situation found in GDH, where Arg87 forms a bidentate interaction with 
the carboxyl group of glutaryl-CoA (118). Thus, we investigated the role of Arg252 of PdMCD by 
mutating it to alanine, glutamine and lysine. Each of these variants did not show any detectable activity 
with (2S)-methylsuccinyl-CoA or succinyl-CoA, demonstrating that this residue is essential for catalysis, 
likely by binding and correctly positioning the substrate. 
 Conclusions 
The structure of PdMCD is unique among acyl-CoA dehydrogenases with an N-terminal extension to 
the common catalytic domain and a specific activity towards the complex substrate (2S)-
methylsuccinyl-CoA. The active site architecture meats the substrates special demands by a basally 
positively charged active site to accommodate the carboxylic acid group of the substrate. We were 
able to demonstrate that the cavity formed by the Ala285 is required for the correct binding and 
positioning of the C2-branched substrate. The enzyme apparently evolved towards specifically 
preventing the oxidation of the unbranched succinyl-CoA, which is an essential intermediate in central 
carbon metabolism. The unspecific oxidation of succinyl-CoA to fumaryl-CoA would lead to a dead-end 
product. Furthermore, the hydrolysis of succinyl-CoA in the oxidative tricarboxylic acid cycle is used to 
generate an ATP equivalent and thus conserve energy. Our results show, how delicately the enzyme is 
evolved to distinguish between the presence and absence of a single methyl group. The exclusion of 
structurally similar but smaller substrates from an active site is not an easy task. The molecular basis 
for this ability probably arises from a lower binding energy for succinyl-CoA lacking the C2-methyl 
group. Therefore, the methyl group of (2S)-methylsuccinyl-CoA is likely crucial for the precise 
positioning of the α-β-carbon bond of the substrate during catalysis. 
Yet, for different metabolic engineering and synthetic-biological applications, a soluble enzyme that 
catalyzes the α,β-carbon bond desaturation of succinyl-CoA to fumaryl-CoA is of interest. Partially 
closing the putative C2-binding pocket by replacing Ala282 in RsMCD with valine allowed us to change 
substrate specificity towards succinyl-CoA, albeit at reduced catalytic rate. This indicates that there is 
a potential to reverse the evolved substrate specificity of methylsuccinyl-CoA dehydrogenase.  
Moreover, considering that the redox potential of the FAD cofactor in ACDs is precisely fine-tuned for 
the desaturation of carbon-carbon bonds of CoA thioesters and to transfer electrons onto an ETF, it is 
noteworthy, that we previously engineered the RsMCD into an oxidase (RsMCO) (see also chapter 3.3). 
RsMCO was able to accept molecular oxygen as electron acceptor instead of an ETF and catalyzed this 
reaction with approximately 1.5% of relative activity compared to the wild type dehydrogenase 
reaction (see chapter 3.3). We can now provide the structural basis for this engineered oxidase activity. 
A key mutation in the engineering RsMCO was to replace Thr317 (Thr320 in PdMCD) with glycine, 
which is conserved at this position in ACOs. The high resolution of the electron density map at the 
active site shows that this threonine in PdMCD can adopt different rotamer conformations, with one 
of them able to form a direct hydrogen bond to the N5 of the isoalloxazine ring of FAD (Fig. 39). 
Because this residue is conserved in the family of ACDs it might not only exclude molecular oxygen 
from the active site, but more importantly influence the electropotential of FAD by stabilizing the 
semiquinone state of the cofactor. This could permit the two single electron transfers to ETFs in 
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contrast to the two-electron transfer to molecular oxygen found in ACOs (144). Moreover, the 
engineered RsMCO also comprises a mutation of Trp315 (Trp 318 in PdMCD) to phenylalanine, which 
likely allows for a solvation of the active site and a modulation of the electropotential of FAD (142, 
143). Additionally, Glu377 (Glu380 in PdMCD) was mutated to asparagine, which is not in direct contact 
to FAD. This residue is conserved among ACOs and probably stabilizes the formation of the superoxide 
anion intermediate (106). 
In conclusion, the crystal structure of PdMCD presented in this study provides new insights into the 
molecular basis of reaction and substrate specificity in the ACD superfamily, and leads the way for 
engineering approaches to accommodate new electron acceptors and/or substrates at the active site 
of these highly abundant and relevant class of enzymes. 
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6. Discussion 
 
 Synthetic CO2 fixation cycles 
In this study we demonstrated the process from the theoretical design of synthetic CO2 fixation cycles 
to the realization of two candidate pathways in vitro.  
Initially, we designed promising pathways for the efficient fixation of CO2, based on CoA-dependent 
carboxylases and in particular enoyl-CoA carboxylases/reductases. The metabolic retrosynthesis 
approach included biochemically feasible conversion and reactions that require simple cofactors, such 
as CoA, NAD(P)H, ATP, or flavin adenosine dinucleotide (FAD). The starting substrate and CO2 acceptor 
molecule was regenerated via the cyclic pathway and the CO2 fixation product (glyoxylate) was 
withdrawn from the cycle via a dedicated output reaction. Following these design principles, we design 
seven synthetic pathways for the fixation of CO2. The theoretical analysis showed that these pathways 
are comparable, or even more energy efficient than naturally evolved oxygen-tolerant CO2 fixation 
pathways. From these seven theoretical designs, we assembled two pathways (CETCH and HOPAC) 
from the principle building blocks in vitro and analyzed their capability to convert inorganic CO2 into 
organic molecules. 
The CETCH and HOPAC cycle were assembled with enzymes from various sources including all three 
domains of life. Moreover, we successfully applied rational enzyme engineering to optimize the 
performance of the cycles. The synthetic cycles operated in a defined cell-free environment and were 
optimized stepwise to perform multiple rounds of conversion. Both pathways comprised similar types 
of reactions, but the intermediates and enzymes involved were different. The realization of two 
different CO2 fixation cycles allows for a future parallel optimization and comparison between the two 
systems. Whereas the HOPAC cycle is still in an earlier stage of development, the CETCH cycle was 
analyzed in more detail and optimized. An output module was established that condensed the primary 
fixation product glyoxylate with acetyl-CoA to form malate for the routine assay of the cycle. This 
module was not applicable for the HOPAC cycle, as acetyl-CoA is a key intermediate in this pathway. 
To compare the efficiency of CO2 fixation in both cycles, it will be necessary to convert glyoxylate into 
the same product. A first option would be to use an aminotransferase for the conversion of glyoxylate 
with aspartate into glycine and oxaloacetate. However, this module would still require the addition of 
“external” aspartate as amino donor. Another module includes the conversion of the primary 
assimilation product into 2-phosphoglycerate via glyoxylate carboligase, tartronic semialdehyde 
reductase and glycerate kinase (89). This module is advantageous, because it does not require the 
addition of an “external” molecule. It condenses two molecules of glyoxylate (C2) into one C3 molecule. 
However, the condensation involves the release of a CO2 molecule, which leads to an overall decrease 
of carbon fixation efficiency. We therefore want to also investigate a novel pathway that would 
conserve all the fixed carbon. In this pathway, two glyoxylate (C2) would first be converted into β-
hydroxyaspartate (C4) and eventually to oxaloacetate (145, 146). Because the last two options would 
produce a central carbon metabolism intermediate from glyoxylate, they were also considered as a 
possible solutions to connect these synthetic CO2 fixation cycles to the metabolism of a potential host 
organism in the future. 
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 In vivo transplantation 
Eventually, the in vivo transplantation of these synthetic CO2 fixation cycles will close the existing gap 
between in vitro development and in vivo realization. The implementation of “synthetic autotrophy” 
into a phototrophic and/or heterotrophic organism would represent a milestone in synthetic biology 
comparable to a “metabolic heart transplantation” (73). It will require the remodeling and adaptation 
of the central carbon and energy metabolism of the host organism. Previous attempts focused on 
implementing natural CO2 fixation pathways into Escherichia coli (67, 69) or Methylobacterium 
extorquens (147). This led to the incorporation of CO2 into central metabolites of these organisms, but 
a self-sustained growth on CO2 alone could not be achieved so far. Nevertheless, these studies already 
represent an important step towards realizing “synthetic autotrophy”. 
Interestingly, M. extorquens would be a likely host for the initial transplantation of a synthetic CO2 
fixation cycle, because of two reasons:  
(i) This organism is able to grow on methanol as a sole source for energy and carbon. It has been shown 
that the energy metabolism (oxidation of methanol) can be separated from its assimilation into the 
central metabolism. This makes M. extorquens an ideal model organism. In fact, the bacterium has 
beed recently engineered towards the incorporation of CO2 into biomass via an implemented CBB cycle 
(147). This will eventually lead to an artificial organoautorophic organism, once the metabolism is fully 
adapted to the CBB cycle and sustainable growth on CO2 is achieved. Nevertheless, this organism still 
relies on the oxidation of methanol to CO2 to gain energy, but the released CO2 is partially assimilated 
via the implemented CBB cycle for biomass formation. Accordingly, the strain could be applied to host 
one of the synthetic CO2 fixation cycles instead of the implemented CBB cycle. 
(ii) M. extorquens already possesses the ethylmalonyl-CoA pathway (148), which covers already seven 
out of the eleven core reactions of the CETCH cycle (before version 5). Hence, “only” four enzymes 
(Scr, Ssr, Hbs and Hbd) would be required to complete the reaction sequence of the synthetic cycle in 
M. extorquens. The implementation of the CETCH cycle into M. extorquens would thus also result in an 
organoautotrophic organism that builds all biomass from CO2, while deriving the required energy from 
the oxidation of methanol. 
Therefore, the metabolic engineering of phototrophs is especially interesting, as they obtain the 
required energy from light. For example, it might be favorable to substitute the inefficient CBB cycle 
by an artificial and more efficient CO2 fixation cycle in photoautotrophic organisms. The inherent 
reactivity of RubisCO with oxygen leads to the formation of 2-phosphoglycolate, which is subsequently 
detoxified in a process called photorespiration. This process involves the loss of already fixed CO2 and 
is very energy demanding, thus reducing the efficiency of the CBB cycle. Furthermore, the inefficient 
RubisCO accounts for up to 50% of soluble protein (57) to achieve sufficient flux through the CBB cycle. 
Replacing the CBB cycle (with RubisCO as central carboxylase) with a more energy efficient process, 
would not only prevent photorespiration, but also decrease the cost for enzyme synthesis.  
Conclusively, the in vivo transplantation of a synthetic CO2 fixation pathway into a phototrophic, 
lithotrophic or heterotrophic organism, would sustains the pathway with energy and redox 
equivalents. Nevertheless, it would be a major challenge to connect the artificial pathway to the 
endogenous energy metabolism of the host. The evolved balance in the energy housekeeping would 
presumably be disturbed by the pathway and requires re-adaptation. Further considering the energy 
conservation in vivo, it is worth mentioning that we engineered the methylsuccinyl-CoA 
dehydrogenase towards an oxidase reactivity for the development of the pathways in a cell-free 
environment. In a host organism, the electrons from this oxidation reaction would be conserved for 
the production of ATP via the electron transport chain. Moreover, the synthetic route via fumaryl-CoA 
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in the in vitro HOPAC cycle could be substituted by the naturally occurring oxidation of succinate to 
fumarate in the TCA cycle. 
However, the in vivo transplantation of a synthetic pathway will involve several difficulties. To achieve 
a more efficient autotrophic growth based on an artificial CO2 fixation pathway, it has to become a 
main functional part of the central metabolism and the alternative pathways would need to be 
integrated within the native metabolism. Many problems could arise from the implementation of 
artificial pathways. For instance the adjustment of gene expression levels and enzyme biosynthesis, 
stability and activity of the recombinant enzymes, disadvantageous interactions of the synthetic 
pathway with the endogenous metabolic network, and incorrect regulations. However, the 
establishment of a dependency on the synthetic carbon fixation as a sole possibility for growth, could 
presumably enable natural selection to overcome these issues. A genetically engineered organism 
depending on a synthetic CO2 fixation pathway for growth might not have a selective advantage in 
nature, but may be favorable from a biotechnological point of view (73). 
Biotechnology relies strongly on heterotrophic organisms, which grow on carbon compounds, such as 
sugars or amino acids (149-152) to yield value added products. However, the utilization of CO2 as a 
carbon feedstock in biotechnology, has lately gained significant interest. The implementation of 
artificial pathways for the fixation of CO2 might be a favorable solution for the metabolic engineering 
of autotrophs that allow the direct production of value-added chemicals from CO2.(73, 153, 154). These 
alternative pathways could be coupled to photosynthesis, reduced chemicals, hydrogen gas, or even 
electricity and provide a biotechnological and sustainable carbon capture and conversion strategy. 
 
 Synthetic biochemistry 
Further improvements of the CETCH and HOPAC cycle in a cell-free environment could eventually also 
lead to a stable in vitro system for the formation of value added products from CO2 in a synthetic 
biochemistry approach. The research field of synthetic biochemistry focuses on biologically produced 
compounds in cell free systems. A major challenge to current microbial production methods lies with 
the inherent restrictions by a living cell. The advantage of the cell-free approach is that only the 
production of the desired compound is important without considering the complexity and survivability 
of an organism. Previous studies have also shown that this could lead to higher rates and yields than 
in production strains (77, 78). In such an approach, the stability of a synthetic system is highly 
dependent on the regeneration and balancing of energy and redox equivalents (79, 80). These 
pathways start from a reduced compound and couple the energy gained from the in situ catabolic 
process to the anabolic pathway, which forms the product. Conclusively, the input molecule delivers 
the energy for the product formation. In our case, the synthetic cycles do not comprise a catabolic 
process and the input molecule is CO2, which in turn requires the generation of energy and redox 
equivalents from a different source. Although the CETCH and HOPAC cycle, in their current versions, 
comprise regenerative systems for energy equivalents, they eventually depend on a limited pool of 
“external” input molecules (ATP is regenerated with Pkk from polyphosphate; NADPH is regenerated 
from formate oxidation by Fdh). In particular, the NADPH regeneration produces additional CO2 in the 
process and is not an ideal solution for an efficient cell free process for CO2 fixation. Therefore, we are 
interested in coupling the artificial CO2 fixation pathway to isolated thylakoids from the chloroplasts of 
spinach or Chlamydomonas reinhardtii (155, 156). Thylakoids are able to provide the regeneration of 
ATP and NADPH from light via linear electron flow through photosystem II and photosystem I (Fig. 42). 
Additionally, there is a possibility to conserve the energy from the FAD dependent oxidation by the 
acyl-CoA dehydrogenase. In the HOPAC cycle the natural electron acceptor in the form of electron 
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transfer flavoprotein (ETF) was applied, but the energy is lost in the direct reduction of molecular 
oxygen. In an organism, the reduced ETF serves as an electron carrier, which can transfer the electrons 
to the ubiquinone pool in the membrane via the electron transfer flavoprotein: ubiquinone 
oxidoreductase (ETF-QO) (157). This system could be applied and engineered towards transferring the 
electrons from the oxidation reaction onto the plastoquinone pool of isolated thylakoids, where the 
energy could be conserved in the production of ATP and NADPH. Recently, we have started to 
experiment with the addition of isolated thylakoids to the CETCH 2.0 cycle, which enabled CO2 fixation 
with light as energy source. These preliminary results, demonstrate the potential for the development 
of an efficient synthetic biochemistry process for the formation of value added products from CO2 and 
light. 
Towards that end, the primary fixation product of the CETCH 5.4 cycle (glyoxylate) could be condensed 
with acetyl-CoA to malate and subsequently converted into poly(L-malate) (PMA). PMA has received 
significant interest, as it can be applied as a pro-drug or in drug-delivery systems (158). It is a water 
soluble, biodegradable, biocompatible and bioabsorbable polymer without any toxicity (159). Yet, the 
biosynthetic pathway has not been fully elucidated and the polymer can be obtained from model 
production strains (e.g. Penicillium cyclopium, Physarum polycephalum or Aureobasidium pullulans) 
(160, 161). It would be interesting to investigate the PMA biosynthesis pathway and develop a 
synthetic biochemistry process to produce PMA from CO2 and light. However, this requires also the 
sustainable production of acetyl-CoA, which might be achieved in the future by a different synthetic 
cycle that provides acetyl-CoA as primary fixation product (i.e. CHYME and CRACE cycle). 
 
Fig. 42 Scheme of the linear electron flow in the thylakoid membrane. Photosystem II (PSII) generates oxygen from water 
and the electrons are excited by light. The high energy electrons are transferred via plastoquinones (PQ) to cytochrome B6f 
which generates a proton gradient across the membrane. The electrons are further transported via plastocyanin (PC) to the 
photosystem I (PSI) where the electrons are excited once more and are able to reduce NADP+ via ferrodoxin (Fdx) and 
ferrodoxin NADP reductase (FNR). The proton gradient is used by the ATP synthase to phosphorylate ADP to ATP (adapted 
from Tarryn Miller). 
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 System modeling 
As aforementioned, cell-free reaction networks offer a range of advantages, including the absence of 
substrate or product toxicity, the absense of cell membranes and the cellular metabolism; leaving the 
operator with full control over the reaction networks. The latter includes the modification of the 
environment and enzyme composition for the optimization of the pathway and its reactions (162). 
Therefore, cell-free systems are used in a variety of applications (e.g. the synthesis of fine chemicals, 
fuels, polymers, hydrogen and even the generation of electricity). The operation of such a reaction 
network is highly attractive, since a broad spectrum of molecular conversions can be achieved with a 
high degree of selectivity. Furthermore, thermodynamically unfavored reactions can be accomplished 
by coupling them to exergonic steps in a network (163). Nevertheless, the increasing complexity of a 
cell-free reaction network leads often to a non-optimal behavior, since the interactions are difficult to 
predict and poorly understood. Therefore, a full system model, which is parameterized well enough 
might support the design and development of novel pathways. However, the parametrization is 
challenging due to nonlinear kinetics of enzymes, which are often accompanied by feedback, 
cooperative or allosteric regulation. Previous studies focused on the parametrization and optimization 
of linear pathways, which resulted in complex in vitro enzymatic reaction systems (163, 164). A full 
parametrization of the synthetic CO2 fixation cycles would enable a model assisted optimization of the 
system. 
In this study we rationally analyzed the reaction sequences for bottlenecks relying on the data from 
the individual experiments. With this approach, we were able to optimize the CO2 fixation efficiency in 
stepwise fashion. However, for further optimizations, a model-based approach could be important. It 
could enable the optimization and testing of the CO2 fixation efficiency in silico and a diversity of 
parameters can be assessed before testing and verification in vitro. The in silico model would allow to 
test the robustness of the whole system, as well as to fine-tune enzyme concentrations for optimal 
flux. Additionally, dynamic experiments could be performed, in which the perturbations of the system 
with different compounds is analyzed. 
Since the CO2 fixation pathway is circular, the stepwise incorporation of 13CO2 enables the analysis of 
intermediates during the steady-state of the reaction sequence and results in a resolution of the cycle 
numbers. Theoretically speaking, the network can be analyzed according to a linear pathway, which 
repeats the same reactions multiple times.  
Conclusively, the establishment of such a system model for a circular pathway would be highly 
interesting from a systems biology point of view. Additionally, the integration of the in silico analysis 
into the optimization process of synthetic CO2 could prove invaluable. The in vitro platform for 
synthtetic CO2 fixation cycles will advance the understanding of modulating a complex cyclic pathway 
in silico and vice versa. Finally, a well-parameterized model would certainly also support the future in 
vivo implementation. 
 
 Enzyme engineering 
In the process of establishing the artificial CO2 fixation cycles it became apparent, that enzyme 
engineering is a vital part for the development of synthetic pathways. The ongoing progress in 
synthetic pathway designs and eventually synthetic metabolisms could also drive the engineering of 
novel enzyme reactions and chemistry (87). In the course of this study, we engineered several enzymes 
towards a desired reaction. We used a relatively simple rational approach by evaluating sequences and 
active site architectures not relying on computational modeling approaches. The controlled 
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implementation of mutations into the enzymes already led to descent results without the need of 
screening large mutant libraries. Nevertheless, a further optimization of these initial obtained activities 
will certainly require more elaborate methods, like directed evolution of enzymes. Our rational 
approaches were only possible because enzyme kinetic and structural information wereavailable. For 
the engineering of Mcd, we initially used a homology model for the prediction of advantageous 
mutations. Although this was sufficient for the engineering of the oxidase (Mco) applied in the CETCH 
cycle, we required a more detailed crystal structure to understand the substrate specificity for its 
application in the HOPAC cycle. This led to the determination of the structure of the methylsuccinyl-
CoA dehydrogenase and the investigation of its substrate specificity. Therefore, a novel structure was 
added to the well-characterized acyl-CoA dehydrogenase family. Conclusively, by building synthetic 
pathways, the requirement for novel reactions also drives the understanding of enzyme-catalyzed 
reactions and the knowledge about how to engineer and control them (87).  
 
 Closing remarks 
Humans have become used to the production of CO2 as a waste product following the economical and 
technological advances of our society. The price we pay is the increasing concentration of CO2 in the 
atmosphere and the threat of global warming. On the other hand, the atmospheric CO2 can also be 
considered as an important carbon feedstock of the future. Since the beginning of life, nature has 
evolved many different strategies to convert this inorganic molecule into organic biomass. Yet, the 
scientific and industrial progress has not found comparable solutions today and the application of CO2-
fixing enzymes and pathways in chemistry or biotechnology is still limited. Conclusively, we still rely on 
natural CO2 fixation to convert the inorganic molecule into biomass. Many efforts have been made to 
improve this natural CO2 fixation process, but with limited success. The field of synthetic biology offers 
the tempting possibility to circumvent the natural CO2 fixation solutions and design optimized 
pathways in a bottom-up approach. Nature has evolved a vast diversity of enzymes to accomplish the 
catalysis of many chemical reactions and the continuous progress in biology enables us to harvest this 
potential. By freely combining different enzymatic reactions from various biological sources, 
completely novel CO2 fixation routes can be constructed that are kinetically or thermodynamically 
more favorable compared to the naturally evolved CO2 fixation pathways. Although several such 
synthetic routes have been theoretically considered, the implementation into a living organism is 
challenging. There is a lack of understanding the complex interplay between the different enzymes 
used in these synthetic networks, as well as the interference of these artificial pathways in the complex 
background of the host organism. Max Planck once said that “Insight must precede application” (165) 
and we considered that it is important to develop and understand such an artificial pathway first in a 
controlled environment. Eventually, the in vitro development of synthetic CO2 fixation pathways 
narrows the gap between the theoretical design and the in vivo application and enables the isolated 
analysis and understanding of these reaction networks. 
The results of this study have clearly proven, that it is possible to establish synthetic CO2 fixation in a 
bottom up approach to investigate and optimize the network in vitro. We were able to go beyond the 
theoretical design and demonstrated two individual CO2 fixation cycles, which are able to perform 
multiple rounds of conversion and incorporate inorganic carbon into organic molecules in a continuous 
fashion. The cycles rely on the efficient reductive carboxylation of enoyl-CoA esters. Although ECRs 
belong to the most efficient CO2-fixing enzymes known to date, they were apparently not employed 
by nature for autotrophic CO2 fixation during evolution, as far as we know. The reallocation of reductive 
carboxylation as key reaction for a synthetic autotrophic CO2 fixation cycle thus goes beyond simply 
improving or reshuffling naturally existing autotrophic CO2 fixation reactions and pathways. These 
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synthetic pathways expand the solution space of the six naturally evolved CO2 fixation pathways by 
man-made alternatives that did not require the serendipity of evolution to bring together all 
components in space and time (166). 
The here presented CETCH and HOPAC cycles are two examples for a bottom-up approach in synthetic 
biology. The successful assembly of complex systems from single biological components is part of the 
transition of biology from a descriptive discipline to a synthetic applied science. The successful 
reconstitution of a synthetic enzymatic network for the conversion of CO2 into organic products that 
is superior to any chemical process or naturally existing CO2-fixing solution opens the door for future 
applications. The in vitro pathways could be further improved in the future to become a stable 
synthetic biochemistry process as it has been shown for other artificial pathways (77, 78). This would 
enable the specific formation of value added products from CO2 in a cell free environment. Moreover, 
the coupling of the artificial CO2 fixation pathways to the energy production from light by thylakoids 
paves the way for a truly artificial and modular photosynthetic process. Finally, a future application 
includes the in vivo transplantation of these pathways into lithotrophic or photosynthetic organisms, 
breaking ground to improve CO2 fixation (167). Considering different host organisms for the synthetic 
cycles will result in a different sources of energy for CO2 fixation (e.g. lithotrophy, hydrogen or light). 
Moreover, there is the possibility to development artificial photosynthetic processes (e.g., in 
combination with photovoltaics or artificial leaves) (168) or they might form the starting point for the 
design of a self-sustained, completely synthetic carbon metabolism in artificial or minimal cells (169). 
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7. Materials and Methods 
 Materials 
Chemicals were obtained from Sigma-Aldrich (Munich, Germany) and CARL ROTH GmbH (Karlsruhe, 
Germany). Succinic semialdehyde was purchased from Santa Cruz Biotechnology Inc. (Dallas, USA) and 
Na13CO3H was obtained from Cambridge Isotope Laboratories Inc. (Tewksbury, USA). Biochemicals and 
materials for cloning and protein expression were obtained from Thermo Fisher Scientific (St. Leon-
Rot, Germany), New England Biolabs GmbH (Frankfurt am Main, Germany) and Macherey-Nagel GmbH 
(Düren, Germany). Carbonic anhydrase was bought from MP Biomedicals (Illkirch, France). Primers and 
synthesized genes were obtained from Eurofins MWG GmbH (Ebersberg, Germany) or Microsynth AG 
(Balgach, Switzerland). Materials and equipment for protein purification were obtained from GE 
Healthcare (Freiburg, Germany), BioRad (Munich, Germany) and Merck Millipore GmbH (Schwalbach, 
Germany). 
 Synthesis of CoA-thioesters 
Crotonyl-CoA, succinyl-CoA and propionyl-CoA were synthesized from their respective anhydrides. 
Methylsuccinyl-CoA and Mesaconyl-CoA were synthesized via the mixed anhydride method starting 
from the free acids and obtaining a mixture of the isomeric 2-methyl and 3-methyl branched 
thioester (170). Ethylmalonyl-CoA was produced with 15 U crotonyl-CoA carboxylase from 6 mM 
crotonyl-CoA in 5 ml reaction buffer containing 60 mM ammonium carbonate pH 8, 50 mM NaHCO3 
and 7 mM NADPH. Methylmalonyl-CoA was produced with 300 U propionyl-CoA carboxylase from 
propionyl-CoA (20 mg, 24 mM) in 1 ml reaction buffer containing 100 mM ammonium carbonate pH 8, 
250 mM NaHCO3, 25 mM ATP, 25 mM NADH, 25 mM phosphoenolpyruvate, 10 mM MgCl2 and 15 U of 
lactate dehydrogenase and pyruvate kinase each. 4-hydroxybutyryl-CoA was synthesized with 
Nmar0206 from 4-hydroxybutyrate, CoA and ATP as described in (34). All CoA-thioesters were purified 
using a HPLC (1260 Infinity, Agilent Technologies GmbH) with a Gemini® 10µm NX-C18 110 Å Column 
(Phenomenex, Aschaffenburg, Germany) as described before (171). The concentration of CoA-esters 
was quantified by determining the absorption at 260 nm (ε = 22.4 mM-1 cm-1 for unsaturated and 
ε = 16.4 mM-1 cm-1 for saturated CoA-thioesters). 4-hydroxybutyrate was synthesized from γ-
Butyrolactone (34). 
 Bacterial strains and growth conditions 
E. coli DH5α strain (Thermo Scientific™) was grown at 37°C in LB-medium and was used for cloning, 
site directed mutagenesis and DNA amplification. E. coli BL21 (DE3) (Thermo Scientific™) and E. coli 
Rosetta (DE3) pLys were used for protein expression and were grown in TB-medium. Antibiotics for 
selection purposes were used accordingly: 100 µg/ml ampicillin, 50 µg/ml kanamycin, 34 µg/ml 
chloramphenicol, 20 µg/ml Streptomycin and 50 µg/ml spectinomycin. 
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 Plasmid List 
MM Table 1 List of all plasmids used in this study. 
Vector Relevant features Source 
pET28a-PKK pET28a, His-SMc02148 (codon optimized Pkk2), kanr Gift from Andexer, Jennifer 
Nmar0206 pET16b, His-nmar0206, ampr Könneke et al. 2014 (34) 
Nmar1309 pET16b, His-nmar1309, ampr Könneke et al. 2014 (34) 
p2BP1 pLIC-SGC1, His-akr7a2, ampr Gift from Opperman, Udo 
pTE701 pET28b, His-phaJ, kanr Gift from Vögeli, Bastian 
pBB541 E. coli Chaperones GroEL, GroES, spectinomycinr De Marco et al. 2007 (172) 
pEX-A-nmar0207_opt pEX-A, nmar0207, codon optimized for E. coli, kanr Eurofins MWG 
pEX-K4-acx4_opt pEX-K, acx4, codon optimized for E. coli, kanr Eurofins MWG 
pEXP5-CT/TOPO-GDHDes pEXP5-CT/TOPO; His-gdh, ampr Gift from Boll, Matthias 
pMCH_RS_JZ06 pET16b, His-mch, ampr Zarzycki et al. 2008 (95) 
pMCL1_RS_JZ03 pET16b, His-mcl1, ampr Erb et al. 2010 (96) 
pPCS_E_lig-hyd_JZ22 pET16b, His-pcs (stop codon after V1214), ampr Gift from Zarzycki, Jan 
pPCS_Lig_JZ26 pET16b, His-pcs (stop codon after S900), ampr Gift from Zarzycki, Jan 
pPCS_E_opt pSEVA471, His-pcs (codon optimized), streptomycinr Gift from Grundling, Iria 
pJS12_Mcl2 pET16b, His-mcl2, ampr Erb et al. 2010 (96) 
pTrc-Mcr_Ca pTrc99A, Strep-mcr, ampr Kroeger et al. 2011 (173) 
JW2943 pCA24N, His-glcB, camr, ASKA collection Kitagawa et al. 2005 (174) 
JW1721 pCA24N, His-katE, camr, ASKA collection Kitagawa et al. 2005 (174) 
JW3853 pCA24N, His-yihU, camr, ASKA collection Kitagawa et al. 2005 (174) 
JW0502 pCA24N, His-glxK, camr, ASKA collection Kitagawa et al. 2005 (174) 
pET21a(+)-fdhD221A pET21, His-fdh (D221A), ampr Hoelsch et al. 2013 (98) 
pTE22 pET16b, His-mcd, ampr Erb et al. 2009 (94) 
pTE33A pET16b, His-ecm, ampr Erb et al. 2008 (92) 
pTE45 pET16b, His-epi, ampr Erb et al. 2008 (92) 
pTE71 pET16b, His-ccr, ampr Rosenthal et al. 2014 (171) 
pTE46 pET16b, His-mcm, ampr This work 
pTE380 pCDFDuet-1, His-sucD, yihU, streptomycinr This work 
pTE392 pCDFDuet-1, His-etfA, etfB, streptomycinr This work 
pTE393 pRSET B, His-nmar0207 (codon optimized), ampr This work 
pTE533 pTE100, pccA, tetr This work 
pTE534 pET28b, pccB, kanr This work 
pTE614 pCDFDuet-1, pccA, streptomycinr This work 
pTE615 pCDFDuet-1, pccA,His-pccB, streptomycinr This work 
pPccME_D407I pCDFDuet-1, pccA, His-pccB (D407I), streptomycinr Gift from Zarzycki, Jan 
pTE801 pET16b, His-mcd (T317G), ampr This work 
pTE802 pET16b, His-mcd (E377N), ampr This work 
pTE803 pET16b, His-mcd (Y378N), ampr This work 
pTE804 pET16b, His-mcd (T317G, E377N), ampr This work 
pTE807 pET16b, His-mcd (F531A), ampr This work 
pTE808 pET16b, His-mcd (F531K), ampr This work 
pTE809 pET16b, His-mcd (F531A), ampr This work 
pTE810 pET16b, His-mcd (W315F), ampr This work 
pTE812 pET16b, His-mcd (T317G, W315F), ampr This work 
pTE813 pET16b, His-mcd (T317G, W315F, E377N), ampr This work 
pTE817 pET16b, His-acx4_opt, ampr This work 
pTE818 pTE16b, His-acx4_opt (L137F), ampr This work 
pTE819 pET16b, His-acx4_opt (V138L), ampr This work 
pTE820 pET16b, His-acx4_opt ( V138I), ampr This work 
pTE821 pET16b, His-acx4_opt ( V291L), ampr This work 
pTE822 pET16b, His-acx4_opt (V291I), ampr This work 
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pTE823 pET16b, His-acx4_opt (V291F), ampr This work 
pTE825 pET16b, His-acx4_opt (T134L), ampr This work 
pTE826 pET16b, His-acx4_opt (T134I), ampr This work 
pTE835 pET16b, His-mcd (A282F), ampr This work 
pTE836 pET16b, His-mcd (A282L), ampr This work 
pTE837 pET16b, His-mcd (A282V), ampr This work 
pTE843 pET16b, His-mcd (A282I), ampr This work 
pTE849 pET28b, His-mcd (P. denitrificans), kanr This work 
pTE857 pSEVA471, His- pcs (stop codon after E1428), streptomycinr This work 
pTE859 pSEVA471, His-pcs (stop codon after N881), streptomycinr This work 
pTE860 pTE28b, His-mcd (P. denitrificans) (R252A), kanr This work 
pTE861 pTE16b, His-mcd (P. denitrificans) (R252K), kanr This work 
pTE862 pTE16b, His-mcd (P. denitrificans) (R252Q), kanr This work 
pTE863 pTE16b, His-etfA, etfB (D128N) streptomycinr This work 
pTE864 pTE16b, His-etfA, etfB (R191C) streptomycinr This work 
pTE870 pET16b, His-mcd (A282F, F284A), ampr This work 
pTE871 pET16b, His-mcd (A282F, F284V), ampr This work 
pTE872 pET16b, His-mcd (A282F, F284L), ampr This work 
 
 Cloning  
All in silico cloning was performed with Clone Manager 9 (Scientific & Educational Software). For 
purification, preparation, cloning, transformation and amplification of DNA, standard protocols were 
used (175). Plasmid isolation and PCR product purification was performed with kits from Macherey 
Nagel (Düren, Germany) according to the manufacturers protocols. 
A his-tagged version of Mcm was produced by amplifying the gene encoding Mcm by PCR from 
chromosomal DNA of R. sphaeroides using the forward primer (5’-GGA AGA GCA TAT GAC CGA AGA 
TCT CGA TGC GTG GC -3’) introducing an NdeI restriction site (underlined) at the initiation codon and 
the reverse primer (5’-GTC GGG CGG ATC CGG TCG GGT CAG C-3’) introducing a HindIII site 
(underlined) after the stop codon. The PCR product was isolated and cloned into the expression vector 
pET16b (Invitrogen) resulting in pTE46. 
The gene encoding for the succinyl-CoA reductase sucD was amplified by PCR from genomic DNA of 
Clostridium kluyveri strain DSM555 with Phusion High Fidelity DNA polymerase (Thermo Scientific™). 
The forward primer (5’-TAT ACC ATG GGC CAT CAT CAT CAT CAT CAT C-3’) introduces an NcoI site 
(underlined), and the reverse primer (5’-TTT TGA ATT CCA GGA CTT ATC CCC ATA TTT CC-3’) introduces 
an EcoRI site. The PCR product was isolated and cloned into the pCDFDuet-1 vector containing an N-
terminal 6x His-Tag. Additionally, the gene for the 3-sulfolactaldehyde reductase yihU was amplified 
by PCR from with Phusion High Fidelity DNA polymerase (Thermo Scientific™) from the ASKA collection 
vector JW3853 by using the forward primer (5’-GAA TAC AAT TGG GCA GCA ATC GCG TT-3‘) introducing 
MunI site (underlined), and a reverse primer (5’-GCC GTC TCG AGT TAC ATT TTT ACT TTG-3’) 
introducing XhoI site. The PCR product was isolated and also cloned into the pCDFDuet-1 containing 
the sucD gene resulting in the vector pTE380. 
In order to clone the genes encoding for the propionyl-CoA carboxylase, the genes were amplified from 
genomic DNA of M. extorquens AM1 by PCR with Phusion High Fidelity DNA polymerase (Thermo 
Scientific™). For pccA, a forward primer (5’-GAC CGT GCA TAT GTT CGA TAA GAT CCT GAT TG-3‘) 
introducing the NdeI site (underlined) and a reverse primer (5’-GCT ACA TAA GCT TTC AGG CGA ATT 
CCA GGA TCA C-3’) introducing the HindIII site (underlined) were used. The isolated PCR product was 
cloned into pTE100 (89) resulting in pTE533. For pccB, a forward primer (5’-GAC CGT GCA TAT GAA 
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GGA CAT CCT CGA GAA GC-3‘) introducing an NdeI site (underlined) and a reverse primer (5’-GAT ACA 
TGA ATT CTC AGA GCG GGA TGT TGT CGT G-3‘) introducing an EcoRI site (underlined) were used. The 
isolated PCR product was cloned into pET28b resulting in pTE534. In order to clone the genes into the 
pCDFDuet-1, a QuickChange® Site-Directed mutagenesis (Stratagene, La Jolla, USA) was performed on 
pTE533 to remove the NcoI site within the pccA gene. Therefore the forward (5’-GGT GCC ATC GCC 
GCA ATG GGC GAC AAG ATC-3’) and backward (5’-GAT CTT GTC GCC CAT TGC GGC GAT GGC ACC-3’) 
primer were used. Afterwards the pccA insert was amplified by PCR with Phusion High Fidelity DNA 
polymerase (Thermo Scientific™) using the forward primer (5’- CGG CTG CCA TAT GTT CGA TAA GAT 
CCT GAT TG-3‘) introducing NdeI site (underlined), and a reverse primer (5’-CAT GCG TGG TAC CTC 
AGG CGA ATT CCA GGA TC-3’) introducing KpnI site. The PCR product was isolated and cloned into the 
pCDFDuet-1 vector resulting in pTE614. The pccB gene was cut from pTE534with NcoI and SalI. The 
isolated insert was then cloned into pCDFDuet-1 containing the pccA gene, resulting in the vector 
pTE615. 
The gene coding for Mcd from P. denitrificans was amplified using chromosomal DNA as template. Two 
oligonucleotides introducing restriction sites (underlined) were designed upstream (5’-ACA TGC ATA 
TGA AGG ACA TGC CCG CGA TG-3’; NdeI) and downstream (5’-ATT ATG CGG CCG CCT AGT CCA GTA 
GCC TGC GTG C-3’; NotI) of the gene coding of Mcd. PCR was performed with Phusion® High-Fidelity 
DNA Polymerase in GC-Buffer for 35 cycles, including denaturation for 60 s at 98°C, annealing for 30 s 
at 57°C and polymerization for 2 min at 72°C. The PCR product was cloned into the pET28b vector for 
expression resulting in plasmid pTE849. 
The genes encoding for the electron transfer flavoprotein (etfA and etfB) were amplified from genomic 
DNA of R. sphaeroides by PCR with Phusion High Fidelity DNA polymerase (Thermo Scientific™). For 
etfA a forward primer introducing a BamHI site and a reverse primer introducing the HindIII site were 
used. The isolated PCR product was cloned into the pCDFDuet-1 vector. Subsequently, for the etfB 
gene a forward primer introducing an NdeI site and a reverse primer introducing the XhoI site were 
used and the isolated PCR product was also cloned into the pCDFDuet-1 vector already containing the 
etfA gene, resulting in the vector pTE392. 
The gene encoding for the 4-hydroxybutyryl-CoA dehydratase Nmar0207 was synthesized by Eurofins 
MWG (Ebersberg, Germany). The sequence was optimized for the codon usage in E. coli (chapter 7.14). 
In order to clone the gene, a BamHI and an EcoRI site were introduced before and after the gene, 
respectively. The gene was cut from the vector with those restriction enzymes and the isolated insert 
was cloned into pRSET B (Thermo Fisher Scientific, St. Leon-Rot, Germany) resulting in pTE393.  
The gene encoding for the short chain acyl-CoA oxidase 4 acx4 was synthesized by Eurofins MWG 
(Ebersberg, Germany). The sequence was optimized for the codon usage in E. coli (chapter 7.14). In 
order to clone the gene, an NdeI and an EcoRI site were introduced before and after the gene, 
respectively. The gene was cut from the vector with those restriction enzymes and the isolated insert 
was cloned into pET16b resulting in pTE817.  
  
Materials and Methods 
97 
 
 Site-directed mutagenesis  
Site-directed mutagenesis was performed with the Quick Change® (Stratagene, La Jolla, USA) method 
and protocols. For the introduction of the mutations, 60 ng of template DNA and the corresponding 
primers (MM Table 2) were used. 
MM Table 2 List of Primers used for site directed mutagenesis 
Gene Organism Template Mutation Primer forward 5’  3’ Primer reverse 5’  3’ Vector 
mcd R. sphaeroides pTE22 T317G CAACAAGACCTGGATCGGCCATGCCGCGCG
CAC 
GTGCGCGCGGCATGGCCGATCCAGGTCTTGTT
G 
pTE801 
mcd R. sphaeroides pTE22 E377N CTACCGCGGCATGAAGAACTATGAGATCGG
CTTCG 
CGAAGCCGATCTCATAGTTCTTCATGCCGCGGT
AG 
pTE802 
mcd R. sphaeroides pTE22 Y378N CGCGGCATGAAGGAAAACGAGATCGGCTT
CGAC 
GTCGAAGCCGATCTCGTTTTCCTTCATGCCGCG pTE803 
mcd R. sphaeroides pTE801 T317G, E377N CTACCGCGGCATGAAGAACTATGAGATCGG
CTTCG 
CGAAGCCGATCTCATAGTTCTTCATGCCGCGGT
AG 
pTE804 
mcd R. sphaeroides pTE22 F531A CATCCTCAACATCGCCGAGGGGGCGGCC G CCGCCCCCTCGGCGATGTTGAGGATG pTE807 
mcd R. sphaeroides pTE22 F531K GCATCCTCAACATCAAAGAGGGGGCGGCC
GAG 
CTCGGCCGCCCCCTCTTTGATGTTGAGGATGC pTE808 
mcd R. sphaeroides pTE22 W315A GCAACAAGACCGCGATCACCCATGCC GGCATGGGTGATCGCGGTCTTGTTGCC pTE809 
mcd R. sphaeroides pTE22 W315F GGCAACAAGACCTTCATCACCCATGCCGC GCGGCATGGGTGATGAAGGTCTTGTTGCC pTE810 
mcd R. sphaeroides pTE801 T317G, W315F GGCAACAAGACCTTCATCGGCCATGCCG CGGCATGGCCGATGAAGGTCTTGTTGCC pTE812 
mcd R. sphaeroides pTE812 T317G, W315F, E377N CTACCGCGGCATGAAGAACTATGAGATCGG
CTTCG 
CGAAGCCGATCTCATAGTTCTTCATGCCGCGGT
AG 
pTE813 
acx4_opt A. thlaiana pTE817 L137F GTTGCTCAACGTTCATTTTCGTCCATTCAAG
CCTGGG 
CCCAGGCTTGAATGGACGAAAATGAACGTTGA
GCAAC 
pTE818 
acx4_opt A. thlaiana pTE817 V138L GCTCAACGTTCATTCTGCTGCATTCAAGCCT
GGGTATG 
CATACCCAGGCTTGAATGCAGCAGAATGAACG
TTGAGC 
pTE819 
acx4_opt A. thlaiana pTE817 V138I CAACGTTCATTCTGATCCATTCAAGCCTGG CCAG CTTGAATGGATCAGAATGAACGTTG pTE820 
acx4_opt A. thlaiana pTE817 V291L GTTAGCCGTGTCATGCTGGCCTGGCAACCT
ATC 
GATAGGTTGCCAGGCCAGCATGACACGGCTAA
C 
pTE821 
acx4_opt A. thlaiana pTE817 V291I CGTTAGCCGTGTCATGATTGCCTGGCAACC
TATC 
GATAGGTTGCCAGGCAATCATGACACGGCTAA
CG 
pTE822 
acx4_opt A. thlaiana pTE817 V291F CGTTAGCCGTGTCATGTTTGCCTGGCAACCT
ATC 
GATAGGTTGCCAGGCAAACATGACACGGCTAA
CG 
pTE823 
acx4_opt A. thlaiana pTE817 T134L GATGCCAGTTGCTCACTGTTCATTCTGGTCC G ACCAGAATGAACAGTGAGCAACTGGCATC pTE825 
acx4_opt A. thlaiana pTE817 T134I GATGCCAGTTGCTCAATCTTCATTCTGGTCC
ATTC 
GAATGGACCAGAATGAAGATTGAGCAACTGG
CATC 
pTE826 
mcd R. sphaeroides pTE22 A282F GATCCTGCCGACCTTCGTCTTCACCGAG CTCGGTGAAGACGAAGGTCGGCAGGATC pTE835 
mcd R. sphaeroides pTE22 A282L GATCCTGCCGACCCTCGTCTTCACCGAG CTCGGTGAAGACGAGGGTCGGCAGGATC pTE836 
mcd R. sphaeroides pTE22 A282V GATCCTGCCGACCGTCGTCTTCACCGAG CTCGGTGAAGACGACGGTCGGCAGGATC pTE837 
mcd R. sphaeroides pTE22 A282I GATCCTGCCGACCATCGTCTTCACCGAG CTCGGTGAAGACGATGGTCGGCAGGATC pTE843 
mcd R. sphaeroides pTE835 A282F, F284A CCGACCTTCGTCGCCACCGAGCCGAAC GTTCGGCTCGGTGGCGACGAAGGTCGG pTE870 
mcd  R. sphaeroides pTE835 A282F, F284V GCCGACCTTCGTCGTCACCGAGCCGAAC GTTCGGCTCGGTGACGACGAAGGTCGGC pTE871 
mcd R. sphaeroides pTE835 A282F, F284L GCCGACCTTCGTCCTCACCGAGCCGAAC GTTCGGCTCGGTGAGGACGAAGGTCGGC 
 
pTE872 
mcd P. denitrificans pTE849 R252A CTCGCTGGGCACCGCCAGCGAGATCGC GCGATCTCGCTGGCGGTGCCCAGCGAG pTE860 
mcd P. denitrificans pTE849 R252K CTCGCTGGGCACCAAAAGCGAGATCGCGG CCGCGATCTCGCTTTTGGTGCCCAGCGAG pTE861 
mcd P. denitrificans pTE849 R252Q CGCTGGGCACCCAGAGCGAGATCGC GCGATCTCGCTCTGGGTGCCCAGCG pTE862 
pcs Erythrobacter  pPCS_E_opt Stop codon after E1428 CTGTTCACTACTCTGTAAATCCAAGCTGGC GCCAGCTTGGATTTACAGAGTAGTGAACAG 
 
pTE857 
pcs Erythrobacter pTE857 Stop codon after N881 CTTCTACCCTGCGTAACTGAGAGTCTCTGGA
CGAAC 
GTTCGTCCAGAGACTCTCAGTTACGCAGGGTA
GAAG 
pTE859 
etfB R. sphaeroides pTE392 D128N GCAAGCAGGCCATCAACAATGACATGAACG 
 
CGTTCATGTCATTGTTGATGGCCTGCTTGC 
 
pTE863 
etfB R. sphaeroides pTE392 R191C GATGAACGAGCCGTGCTATGCCTCGC 
 
GCGAGGCATAGCACGGCTCGTTCATC 
 
pTE864 
 Heterologous enzyme production and purification 
7.7.1. General protocol 
All enzymes were purified according to the following protocol if not described otherwise. E. coli BL21 
(DE3) were transformed with the expression plasmid (MM Table 1) and grown over night on LB-agar 
plates containing the antibiotic(s) necessary for selection. The grown colonies were used to inoculate 
1 L TB medium for the expression culture. The cultures were grown at 37°C to an OD600 of 1.5 and 
induced with 0.25 mM IPTG. The protein was produced over night at 21°C. The cells were harvested 
by centrifugation at 5000 rcf for 10 min and resuspended in lysis buffer (20 mM Tris-HCl pH 8.1, 
500 mM NaCl, 10% Glycerol). Resuspended cells were stored at -20°C. Cells were lysed by 
ultrasonification and the lysate was cleared by ultracentrifugation at 50,000 rcf for 45 min at 4 °C and 
subsequently filtered through a 0.45 µm filter. The cleared lysate was loaded onto a 1 ml HisTrap FF 
(GE Healthcare, Freiburg, Germany) and unbound protein was removed with 20 ml of 20 mM Tris-HCl 
pH 8.1, 500 mM NaCl, 75 mM Imidazole. The protein was eluted in 20 mM Tris-HCl pH 8.1, 500 mM 
NaCl and 500 mM Imidazole. The protein was either desalted with a HiTrap 5 ml Desalting (GE 
Healthcare, Freiburg, Germany) column in 20 mM Tris-HCl pH 8.1, 200 mM NaCl or by a HiLoad 16/600 
Superdex 200 pg (GE Healthcare, Freiburg, Germany) size exclusion column in 20 mM Tris-HCl pH 8.1, 
150 mM NaCl. Elution fractions were concentrated with Amicon Ultra-4 centrifugal filters (Merck 
Millipore, Darmstadt, Germany). The concentration was determined on a Nanodrop 2000 (Thermo 
Scientific, St. Leon-Rot, Germany). The purified proteins were stored in 20% glycerol at -20°C up to 
several month if not mentioned elsewise. 2 mM MgCl2 was added to enzymes containing magnesium. 
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7.7.2. Succinyl-CoA reductase (SucD) and succininc semialdehyde reductase (AKR7a2) 
The general expression and purification protocol was applied. The enzymes were stored in 20% glycerol 
at -20°C for up to two weeks. 
7.7.3. Ethylmalonyl-CoA mutase (Ecm) and methylmalonyl-CoA mutase (Mcm) 
The expression and purification was conducted using the general protocol mentioned above. 
Additionally, these two enzymes were always purified by size exclusion FPLC as mentioned above. 
These proteins were stored with additional 2 mM of coenzyme B12 and 20% glycerol at -20°C for up to 
several month 
7.7.4. Acyl-CoA oxidases (Mco and Pco) 
For expression, E. coli Rosetta (DE3) pLys was transformed with the expression plasmid (MM Table 1) 
and grown on LB-agar plates over night at 37°C. The grown colonies were used to inoculate 1 L TB-
medium containing additionally 10 mg/L riboflavin. The culture was grown at 37°C to an OD600 of 1.5 
and induced with 0.25 mM IPTG. The protein was produced for 4h at 25°C and the cells were harvested 
as described above. For protein purification, the general protocol above was applied. Note that Pco 
can only be concentrated up to 1.2 mg ml-1. The proteins were stored in 20% glycerol at -20°C for 
several weeks. 
7.7.5. 4-hydroxybutyryl-CoA synthetase (Nmar0206) and 3-hydroxypropionyl-CoA synthetase 
(Nmar1309) 
The general protocol as mentioned before was applied. Additionally, the BL21 (DE3) cells were also 
transformed with a plasmid (pBB541) for expression of the chaperone proteins GroES and GroEL from 
E. coli (172). All purification buffers contained 50 mM MOPS pH 7.5, 500 mM NaCl, 5 mM MgCl2 and 
5 % v/v Glycerol. For the lysis, protease inhibitor (SIGMAFAST™ protease inhibitor (Sigma-Aldrich, 
Munich, Germany)) was added according to the provided protocol. Unspecific bound protein was 
washed with only 50mM of Imidazole. During concentration, the glycerol concentration was step wise 
increased to a final concentration of 20% and the protein was stored at -20°C for only up to three days. 
7.7.6. 4-hydroxybutyryl-CoA dehydratase (Nmar0207) 
The culture was grown in TB medium at 37°C aerobically to an OD600 of 4. The culture was transferred 
to a sterile Schott Bottle and cooled down with closed lid to 21°C. 100 µM of Fe(II)SO4, 100 µM 
Fe(III)citrate, 20 mM fumarate and 0.25 mM IPTG were added and the lid was closed firmly. The 
protein was produced under microaerobic conditions over night at 21°C. The following purification was 
performed aerobically as mentioned in the general protocol above, but all buffers contained 500 mM 
NaCl. The purified protein was stored in 20 % glycerol at -20°C for several weeks. 
7.7.7. Electron transfer flavoprotein (EtfAB) 
For expression, E. coli Rosetta (DE3) pLys was transformed with the expression plasmid (MM Table 1) 
and grown on LB-agar plates over night at 37°C. The grown colonies were used to inoculate 1 L TB-
medium containing additionally 10 mg/L riboflavin. The culture was grown at 37°C to an OD600 of 1.5 
and induced with 0.25 mM IPTG. The protein was produced for overnight at 21°C and the cells were 
harvested as described above. For protein purification, the general protocol above was applied, but 
the unspecific bound protein was washed off with only 15 mM of imidazole. The protein was stored 
with 20% glycerol at -20°C for several weeks. 
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7.7.8. Malonyl-CoA reductase (Mcr) 
E. coli BL21 (DE3) were transformed with the expression plasmid pTrc-Mcr_Ca and grown over night 
on LB-agar plates containing 100 µg/ml. The grown colonies were used to inoculate 1 L TB medium for 
the expression culture. The cultures were grown at 37°C to an OD600 of 1.5 and induced with 0.25 mM 
IPTG. The protein was produced over night at 21°C. The cells were harvested by centrifugation at 
5000 rcf for 10 min and resuspended in lysis buffer (50 mM MOPS pH 7.5, 200 mM KCl, 10% Glycerol). 
Resuspended cells were stored at -20°C. Cells were lysed by ultrasonification and the lysate was cleared 
by ultracentrifugation at 50,000 rcf for 45 min at 4 °C and subsequently filtered through a 0.45 µm 
filter. The cleared lysate was loaded onto a 1 ml StrepTrap HP (GE Healthcare, Freiburg, Germany) and 
unbound protein was removed with a buffer containing 50 mM MOPS pH 7.5, 200 mM KCl. The protein 
was eluted in 50 mM MOPS pH 7.5, 200 mM KCl with 2.5 mM desthiobiotin. The protein was desalted 
with a HiTrap 5 ml Desalting (GE Healthcare, Freiburg, Germany) column in 50 mM MOPS pH 7.5, 
200 mM KCl. After the addition of 20% glycerol, the protein was stored at -20°C for several month. 
 Crystallization of Mcd from P. denitrificans 
Competent E. coli Rosetta pLys (DE3) were transformed with the plasmid pTE849 and 1 liter cultures 
were grown at 37°C in TB medium with 50 µg kanamycin ml-1 to an OD ~1 Expression was performed 
at 20°C over night after induction with 250 µM IPTG. The cells were harvested by centrifugation at 
5000 rcf for 10 min and resuspended in 2 times the volume of lysis buffer (20 mM Tris-HCl pH 7.9, 500 
mM NaCl, 10% Glycerol). For the crystallization, the Mcd from P. denitrificans was purified as follows. 
Cells were lysed by ultrasonification and the lysate was cleared by ultracentrifugation at 50,000 rcf for 
45 min at 4 °C and subsequently filtered through a 0.45 µm filter. The cleared lysate was loaded onto 
a 5 ml HisTrap FF column (GE Healthcare, Freiburg, Germany) and unbound protein was removed with 
20 ml of 20 mM Tris-HCl pH 7.9, 500 mM NaCl, 75 mM Imidazole. The protein was eluted in 20 mM 
Tris-HCl pH 7.9, 500 mM NaCl and 500 mM Imidazole and subsequently desalted with a HiTrap 5 ml 
Desalting (GE Healthcare, Freiburg, Germany) column in 20 mM Tris-HCl pH 7.9, 250 mM NaCl. The His-
Tag was removed by Thrombin (T4648, Sigma-Aldrich, Munich, Germany) mediated proteolysis (1 mg 
Thrombin per 10 mg Mcd) for 2 h at room temperature. The digested protein was passed through a 
1 ml HisTrap FF column (GE Healthcare, Freiburg, Germany) and the flow through was collected. The 
digested protein was further purified via a HiLoad 16/600 Superdex 200 pg (GE Healthcare, Freiburg, 
Germany) size exclusion column in 20 mM Tris-HCl pH 7.9, 200 mM NaCl. Elution fractions were 
concentrated with Amicon Ultra-4 centrifugal filters (Merck Millipore, Darmstadt, Germany and the 
protein concentration was determined on a Nanodrop 2000 (Thermo Scientific, St. Leon-Rot, 
Germany). 
Crystals were grown at 16°C using the sitting-drop vapor diffusion method. The Mcd protein adjusted 
to a concentration of 20 mg/ml in a buffer containing 20 mM Tris-HCl pH 7.9, 200 mM NaCl with a final 
concentration of 1.5 mM FAD and 3 mM mesaconyl-CoA. The protein solution was mixed in a 1:1 ratio 
with the crystallization buffer containing 30% PEG 5000 MME, 100 mM Tris pH8 and 200mM LiSO4. 
Crystals were soaked in 30% glycerol before the being plunged into liquid nitrogen for freezing. X-ray 
diffraction data were collected at the European Synchrotron Radiation Facility (ESRF) in Grenoble, 
France (beamline: ID29). The data was processed with XDS (176) and the CCP4 software package (177). 
The structure was solved using molecular replacement using Phaser-MR- and AutoBuild-programs of 
the Phenix software package (178). The structure of a putative acyl-CoA dehydrogenase (PDB ID: 4N5F) 
served as search model for the molecular replacement. Additional manual modeling and ligand fitting 
was performed using COOT (179). Because the FAD cofactor assumed a bend (butterfly like) 
conformation for the isoalloxazine ring the molecular restrains for the refinements had to be modified. 
The isoalloxazine ring was therefore separated into two planes along the N5/N10 axis of central 
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pyrazine ring. Additionally, the restrains for the bond angles over N5 and N10 were relaxed. Water-
picking and further refinements were done by Phenix. The atomic coordinates (PDB ID: 6ES9) and 
structure factors have been deposited in the Protein Data Bank [http://www.pdb.org/]. 
 Activity assays 
7.9.1. Activity assay of sulfolactaldehyde reductase (YihU) 
The activity was determined at 30°C in 150 µl of 100 mM MOPS pH 7.2 buffer containing 10 mM MgCl2, 
10 mM KCl2, 1 mM MnCl2 and 200 µM NADH and 7.8 µg purified YihU. Different concentrations of 
succinic semialdehyde (from 2 mM up to 100 mM) were used to start the reaction. The consumption 
of NADH was observed at 360 nm (Δε = 3.1 mM-1 cm-1) with a Cary 60 UV-Vis spectrophotometer 
(Agilent Technologies GmbH, Waldbronn, Germany) 
7.9.2. Activity assay of succinic semialdehyde reductase (AKR7a2) 
The activity of AKR7a2 was measured in a phosphate buffer (100 mM, pH 7.4) containing 0.2 mM 
NADPH and 2 μg AKR7a2. The reaction was started by addition of succinic semialdehyde and the 
reaction was followed at 28 °C and 340 nm (Δε = 6.22 mM-1 cm-1) with a Cary 60 UV-Vis spectrometer 
(Agilent Technologies GmbH, Waldbronn, Germany). Michaelis-Menten kinetic parameters were 
determined by varying the concentration of succinic semialdehyde from 2.4 μM to 480 μM. 
7.9.3. Activity assay of medium-chain fatty acid CoA ligase (AlkK) 
The activity of AlkK was measured in 450 µl of a 50 mM Tris-HCl buffer pH 7.8 containing 0.5 mM CoA, 
1.6 mM ATP, 2 mM MgCl2, 0.8 mM phosphoenolpyruvate, 0.5 mM NADH, 10 U myokinase , 6 U lactate 
dehydrogenase, 4 U pyruvate kinase and 7.2 µg purified AlkK. Different concentrations of 4-
hydroxybutyrate were used to start the reaction. The consumption of NADH was observed at 30°C and 
360 nm (Δε = 3.1 mM-1 cm-1) with a Cary 60 UV-Vis spectrophotometer (Agilent Technologies GmbH, 
Waldbronn, Germany). 
7.9.4. Activity assay of propionyl-CoA carboxylase (PccAB) 
Carboxylation activity was measured in 200 µl of 100 mM HEPES pH 8.0 buffer containing 2 mM ATP, 
5 mM MgCl2, 100 mM KHCO3, 0.25 mM NADPH, 0.65 µg purified propionyl-CoA carboxylase. The 
reaction was started with different concentrations of propionyl-CoA and the consumption of NADH 
was followed at 30 °C and 340 nm (Δε = 6.22 mM-1 cm-1) with a Cary 60 UV-Vis spectrophotometer 
(Agilent Technologies GmbH, Waldbronn, Germany). 
7.9.5. Activity assay of propionyl-CoA carboxylase D407I variant 
Carboxylation activity was measured in 150 µl of 50 mM Tris pH 7.5 buffer containing 0.5 mM ATP, 
8 mM MgCl2, 40 mM KHCO3, 0.2 mM NADH, 1 µl carbonic anhydrase (0.2 mg/ml), 24.6 µg Mcr and 
either 2.8 µg of Pcc (D407I) or 3.4 µg wt Pcc. The reaction was started with different concentrations of 
acetyl-CoA and the consumption of NADPH was followed at 30 °C and 340 nm (Δε = 6.22 mM-1 cm-1) 
with a Cary 60 UV-Vis spectrophotometer (Agilent Technologies GmbH, Waldbronn, Germany). 
7.9.6. Activity assay of crotonyl-CoA carboxylase/reductase 
Carboxylation activity was measured in 100 µl of 100 mM phosphate buffer pH 8.0 containing 3 mM 
NADPH, 100 mM NaHCO3 and 0.39 µg of Ccr. The reaction was started by addition of crotonyl-CoA and 
the consumption of NADPH was followed at 30°C and 340 nm (Δε = 6.22 mM-1 cm-1) with a Cary 60 UV-
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Vis spectrophotometer (Agilent Technologies GmbH, Waldbronn, Germany). Michaelis-Menten kinetic 
parameters were determined by varying the concentration of crotonyl-CoA from 0.025 mM to 1.6 mM. 
7.9.7. Activity assay of crotonyl-CoA carboxylase/reductase (R152A) 
Carboxylation activity was measured in 100 µl of 77.5 mM Tris pH 8.0 containing 2.1 mM NADPH, 
53.7 mM NaHCO3 and 0.87 µg of Ccr (R152A). The reaction was started by addition of crotonyl-CoA 
and the consumption of NADPH was followed at 30°C and 340 nm (Δε = 6.22 mM-1 cm-1) with a Cary 
60 UV-Vis spectrophotometer (Agilent Technologies GmbH, Waldbronn, Germany). Michaelis-Menten 
kinetic parameters were determined by varying the concentration of crotonyl-CoA from 0.27 mM to 
4.3 mM. 
7.9.8. Activity assay of glycerate kinase (GlxK) 
The activity of GlxK was measured in a coupled assay in potassium phosphate buffer (50 mM, pH 7.3) 
containing 10 mM MgCl2, 0.5 mM ATP, 2.5 mM PEP, 0.2 mM NADH, 6 U lactate dehydrogenase, 4 U 
pyruvate kinase and 0.18 µg of GlxK. The reaction was started by addition of glycerate and 
consumption of NADH was followed at 30°C and 340 nm (Δε = 6.22 mM-1 cm-1) with a Cary 60 UV-Vis 
spectrophotometer (Agilent Technologies GmbH, Waldbronn, Germany). Michaelis-Menten kinetic 
parameters were determined by varying the concentration of glycerate from 15.625 μM to 1000 μM. 
7.9.9. Activity assay of methylsuccinyl-CoA oxidase (Mco) 
Oxidase activity screening of the enzyme variants was performed by product (mesaconyl-CoA) 
detection with HPLC-MS (1260 Infinity, Agilent Technologies GmbH)/MS (6130 quadrupole MS, Agilent 
Technologies GmbH) using the method described before (41). The assay was prepared in 250 µl of 
80 mM ammonium carbonate buffer containing 50 mM NaHCO3 pH 7.5, 600 µM NADPH, 110 U 
crotonyl-CoA carboxylase/reductase (Ccr), 75 U ethylmalonyl-CoA mutase (Ecm), 2200 U epimerase 
(Epi) and 15 µg methylsuccinyl-CoA dehydrogenase (Mcd) variant. The reaction was started with 
400 µM of crotonyl-CoA and samples were withdrawn at 5 min and 30 min. The reaction was quenched 
in a final concentration of 1% HCl. The Michaelis-Menten parameters were determined by a 
spectrophotometric assay on a Cary 60 UV-Vis spectrometer (Agilent Technologies GmbH, Waldbronn, 
Germany) by observing the formation of mesaconyl-CoA at 30°C and 290 nm (Δε = 3.1 mM-1 cm-1) 
starting with different concentration (from 2.5 – 250 µM) of (S)-methylsuccinyl-CoA. The reaction was 
performed in 100 µl of 37.5 mM phosphate buffer pH 7.5 containing 120 µg of Mcd variant. 
7.9.10. Activity assay of methylsuccinyl-CoA dehydrogenase wt and variants 
The activity of Mcd from P. denitrificans (PdMcd) and R. sphaeroides (RsMcd) was determined using 
the protocol based on the reduction of ferrocenium as electron acceptor, which has been described 
before (94, 180). The reaction was followed at 300 nm (adjusted Δε300=2.75 mM-1 cm-1) on a Carry 60 
UV-Vis Spectrophotometer (Agilent Technologies GmbH, Waldbronn, Germany) and 30°C. The reaction 
mixture (0.1 ml) contained 50 mM potassium phosphate buffer (pH 7.5), 0.25 mM ferrocenium 
hexafluorophosphate. For the assay with succinyl-CoA, the assay contained 1.6 µM of the RsMcd wt or 
the RsMcd Ala282Val variant (corresponds to Ala285 in PdMcd). This assay was started by the addition 
of different concentrations of succinyl-CoA (10 µM – 800 µM). For the activity of the enzymes with 
(2S)-methylsuccinyl-CoA, the reaction contained additionally 7.5 µM of ethylmalonlyl-CoA mutase and 
3 µM of epimerase. The following enzyme concentrations were used in this case: 0.008 µM RsMcd, 
0.01µM RsMcd Ala282Val (corresponds to Ala285 in PdMcd), 1.9 µM RsMcd Ala282Phe/Phe284Ala 
(corresponds to Ala285/Phe287 PdMcd) or 0.007 µM PdMcd wt. The assay was started by addition of 
varying substrate (ethylmalonyl-CoA) concentrations (10 µM – 1600 µM).  
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7.9.11. Activity assay of short chain acyl-CoA oxidase (ACX4) 
Activity of the oxidase variants was measured with a spectrophotometric assay on a Cary 60 UV-Vis 
spectrophotometer (Agilent Technologies GmbH, Waldbronn, Germany). Product formation from 
propionyl-CoA (Δε = 2.0 mM-1 cm-1) and 4-hydroxybutyryl-CoA (Δε = 1.6 mM-1 cm-1) was observed at 
30°C and 290 nm. The reaction was performed in 150 µl phosphate buffer (45 mM, pH 7.5) and was 
started with various concentrations of propionyl-CoA or 4-hydroxybutyryl-CoA. 
 HPLC-MS based enzyme assays 
7.10.1. Assay of Mco (Mcd W315F, T317G, E377N) and Mcd T317G) with succinyl-CoA 
The assay of Mco and Mcd T317G was performed in a reaction mixture (0.25 ml) containing 100 mM 
(MOPS) (pH 7.5) and either contained 172.5 µg of Mco or 172.5 µg of Mcd T. The reaction was started 
with the addition of 750 µM succinyl-CoA. Samples (40 µl) were withdrawn at certain time points and 
the reaction was quenched in 4 µl of 40% formic acid. 
7.10.2. Assay of Mcd with ETF (titration) 
The assay of Mcd wit ETF was performed in a reaction mixture (0.25 ml) containing 50 mM (MOPS) (pH 
7.5), 50 mM NaCl, 40.5 µg KatE, 303 µg SodB and 5 µM of Mcd wt enzyme. Four different reaction 
conditions were prepared with either 2 mM ferrocenium hexafluorophosphate, 5 µM ETF, 50µM ETF 
or 250 µM ETF as electron acceptor. The reaction was started with the addition of 500 µM succinyl-
CoA. Samples (30 µl) were withdrawn at certain time points and the reaction was quenched in 3 µl of 
40% formic acid and 1 µl of polyphosphate (500 mM). 
7.10.3. Assay of ETF variants 
The assay of the ETF variants was performed in a reaction mixture (0.25 ml) containing 50 mM (MOPS) 
(pH 7.5), 1.8 mM ferrocenium hexafluorophosphate, and 34 µg Mcd A282V variant. Two different 
reaction conditions were prepared with either 13.6 µg of Mch or 15.6 µg of PhaJ as hydratases. The 
reaction was started by the addition of 682 µM succinyl-CoA. Samples (40 µl) were withdrawn at 
certain time points and the reaction was quenched in 4 µl of 40% formic acid and 1 µl of polyphosphate 
(500 mM). 
7.10.4. Assay of the potential fumaryl-CoA hydratases for the formation of malyl-CoA 
The assay of the hydratases was performed in a reaction mixture (0.275 ml) containing 91 mM (MOPS) 
(pH 7.5), 250 mM NaCl, 250 mM KCl and 5µM Mcd wt. Three different reaction conditions were 
prepared with either 50 µM of ETF wt, 50 µM of ETF D125N or 50 µM of ETF R188C. The reaction was 
started by the addition of 500 µM succinyl-CoA. Samples (30 µl) were withdrawn at certain time points 
and the reaction was quenched in 3 µl of 40% formic acid and 1 µl of polyphosphate (500 mM). 
7.10.5. Assay of Mcd and Mcd variants with succinyl-CoA and (2S)-methylsuccinyl-CoA 
For the assay of the Arg252Ala/Gln/Lys variants of Mcd from P. denitrificans (PdMcd), single variants 
of Ala282Val/Leu/Ile/Phe of Mcd of R. sphaeroides (RsMcd) (corresponds to Ala285 in PdMcd) and the 
double variants of RsMcd (Ala282Phe with Phe284Ala/Val/Leu; corresponds to Ala285 and Phe287 in 
PdMcd) the reaction mixture (275 µl) contained 91 mM 3-morpholino-propanesulfonic acid (MOPS) at 
pH 7.5 and 1.8 mM ferrocenium hexafluorophosphate. The assay with succinyl-CoA contained 34µg of 
enzyme and was started with the addition of 680 µM succinyl-CoA. The assay with the natural 
substrate contained 1 µg Mcd variants, 110 µg ethylmalonyl-CoA mutase and 13 µg epimerase. To start 
the reaction, 680 µM ethylmalonyl-CoA was added. Samples (30 µl) were withdrawn at certain time 
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points and the reaction was quenched in 3 µl of 40% formic acid. The samples were analyzed by HPLC-
MS described below. 
 CETCH cycle assays 
7.11.1. Assay of CETCH 1.0 (discontinuous) 
The discontinuous assay of the first CETCH cycle was performed in 250 µl of 180 mM ammonium 
formate buffer pH 7.5 containing 1 µl carbonic anhydrase (0.2 mg/ml), 1 mM ATP, 2 mM NADPH, 
50 mM NaHCO3, 0.5 mM CoA and 300 µM propionyl-CoA. All samples (35 µl each) that were withdrawn 
from the assay were quenched in formic acid with a final concentration of 2%. Between each addition 
of the following enzymes, the reaction mixture was incubated at 30°C for 10 min before taking a 
sample. First, a negative control sample was taken and the assay was started with the addition of 0.2 U 
PccAB. After sampling, 0.12 U Mcm, 2.2 U Epi, 0.62 U SucD, 0.02 U AKR7a2 and 0.14 U Nmar0206 were 
added and the assay was further incubated. Afterwards 0.14 U Nmar0207 and 2.1 U Ccr were added 
and the sample was withdrawn after 10 min. Subsequently, 0.07 U Ecm, 0.04 U Mcd and 100 µM 
ferrocenium hexafluorophosphate were added before further incubation. Eventually, 9.9 U Mch and 
0.09 U Mcl1 were added and the reaction was incubated for 10 min at 30°C before withdrawing the 
last sample. The samples were analyzed for CoA-esters with the method described below. 
7.11.2. Assay of CETCH 1.0 (continuous) 
The continuous assay of the first CETCH cycle was performed in 600 µl buffer (124 mM ammonium 
formate, pH 7.5) containing 1 µl carbonic anhydrase (0.2 mg/ml), 5 mM ATP, 6.5 mM NADPH, 10 mM 
MgCl2, 0.5 mM CoA, 50 mM NaHCO3, 100 µM ferrocenium hexafluorophosphate and the enzymes with 
the corresponding amounts (MM Table 3 and MM Table 4). The reaction was started with the addition 
of 300 µM propionyl-CoA and incubated at 30°C. Samples (35 µl each) were withdrawn from the 
reaction mixture and quenched in formic acid with a final concentration of 2%. The samples were 
analyzed for CoA-esters with the method described below. 
7.11.3. Assay of CETCH 2.0 
The assay of CETCH 2.0 was performed in 400 µl buffer (125 mM ammonium formate, pH 7.5) 
containing 1 µl carbonic anhydrase (0.2 mg/ml), 5 mM ATP, 6.5 mM NADPH, 10 mM MgCl2, 0.5 mM 
CoA, 50 mM NaHCO3 and the enzymes with the corresponding amounts (MM Table 3 and MM Table 
4). The reaction was started with the addition of 225 µM propionyl-CoA and incubated at 30°C. 
Samples (35 µl each) were withdrawn from the reaction mixture and quenched in formic acid with a 
final concentration of 2%. The samples were analyzed for CoA-esters with the method described 
below. 
7.11.4. Assay of CETCH 3.0 
The assay of CETCH 3.0 was performed in 550 µl buffer (118 mM ammonium formate, pH 7.5) 
containing 1 µl carbonic anhydrase (0.2 mg/ml), 5 mM ATP, 6.5 mM NADPH, 10 mM MgCl2, 0.5 mM 
CoA, 50 mM NaH13CO3, 1 mM acetyl-CoA and the enzymes with the corresponding amounts (MM 
Table 3 and MM Table 4). The reaction was started with the addition of 250 µM propionyl-CoA and 
incubated at 30°C. Samples (40 µl each) were withdrawn from the reaction mixture and quenched in 
formic acid. After the 1 min and 2 min samples, 250 µM propionyl-CoA was additionally added. In 
general, all samples were quenched in formic acid with a final concentration of 2%. After the 30 min 
and 90 min samples, 1 mM of acetyl-CoA was added. The samples were analyzed for CoA-esters and 
malate with the method described below. 
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7.11.5. Assay of CETCH 4.0 
The assay of CETCH 4.0 was performed in 600 µl buffer (114 mM ammonium formate, pH 7.5) 
containing 1 µl carbonic anhydrase (0.2 mg/ml), 0.75 mM ATP, 4 mM NADPH, 2 mM MgCl2, 0.5 mM 
CoA, 50 mM NaH13CO3, 0.1 mM coenzyme B12, 5 mM ascorbic acid, 1 mM acetyl-CoA and the enzymes 
with the corresponding amounts (MM Table 3 and MM Table 4). The reaction was started with the 
addition of 150 µM propionyl-CoA and incubated at 30°C. Samples (35 µl each) were withdrawn from 
the reaction mixture and quenched in formic acid to a final concentration of 2%. After the 30 min and 
90 min samples, 1 mM ATP and acetyl-CoA each was added. The samples were analyzed for CoA-esters 
and malate with the method described below. Note that the buffer concentration from CETCH 1.0 to 
4.0 slightly varied, due to the dilution of the assay to the desired volume from a 200 µM stock buffer. 
In the following assays, the buffer concentration was fixed to 100 mM. 
7.11.6. Assay of CETCH 5.0 
The assay of CETCH 5.0 was performed in 600 µl buffer (100 mM ammonium formate, pH 7.5) 
containing 1 µl carbonic anhydrase (0.2 mg/ml), 2 mM ATP, 4 mM NADPH, 5 mM MgCl2, 0.5 mM CoA, 
50 mM NaH13CO3, 0.1 mM coenzyme B12, 5 mM ascorbic acid, 1 mM acetyl-CoA, 20 mM polyphosphate 
and the enzymes with the corresponding amounts (MM Table 3 and MM Table 4). The reaction was 
started with the addition of 150 µM propionyl-CoA and incubated at 30°C. Samples (30 µl each) were 
withdrawn from the reaction mixture and quenched in formic acid to a final concentration of 2%. After 
the 5 min, 15 min, 30 min and 60 min samples additional enzymes were added each (Ecm: 18 mU, 
Mcm: 60 mU and Nmar0206: 72 mU). Additionally after the 60 min sample, 1 mM of acetyl-CoA was 
added. The samples were analyzed for CoA-esters and malate with the method described below. 
7.11.7. Assay of CETCH 5.1 
The assay of CETCH 5.1 was performed in 520 µl buffer (100 mM ammonium formate, pH 7.5) 
containing 1 µl carbonic anhydrase (0.2 mg/ml), 2 mM ATP, 4 mM NADPH, 5 mM MgCl2, 0.5 mM CoA, 
50 mM NaH13CO3, 0.1 mM coenzyme B12, 5 mM ascorbic acid, 1 mM acetyl-CoA, 20 mM polyphosphate 
and the enzymes with the corresponding amounts (MM Table 3 and MM Table 4). To test the influence 
of different Ccrs, either 3.11 U/ml Ccr (M. extorquens), 1.0 U/ml Ccr (K. setae) or 1.5 U/ml Ccr (L. 
borgpetersenii) was added. The reaction was started with the addition of 150 µM propionyl-CoA and 
incubated at 30°C. Samples were withdrawn (30 µl each) from the reaction mixture and quenched in 
formic acid to a final concentration of 4%. After the 5 min, 15 min, 30 min and 60 min samples 
additional enzymes were added each (Ecm: 18 mU, Mcm: 60 mU and Nmar0206: 60 mU). Additionally 
after the 60 min sample, 1 mM of acetyl-CoA was added. The samples were analyzed for CoA-esters 
and malate with the method described below. 
7.11.8. Assay of CETCH 5.2 
This assay was performed in the same way as CETCH 5.4 (see below). Additionally, the assay buffer 
contained 10 mM CaCl2. The samples were analyzed for CoA-esters and malate with the method 
described below. 
7.11.9. Assay of CETCH 5.3 
The purified enzymes for the CETCH 5.3 assay were pooled (double amounts of the assay; except 
Nmar0206, which was already stored in 25 mM MOPS pH 7.5 buffer) and the total concentration was 
determined by Nanodrop 2000 (Thermo Scientific, St. Leon-Rot, Germany). The storage buffer was 
exchanged to 25 mM MOPS pH 7.5 containing 250 mM NaCl and 10% Glycerol by using an Amicon 
Ultracel 10K centrifugal filter (Merck Millipore, Darmstadt, Germany) to wash the enzymes multiple 
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times. The enzyme solution was concentrated to the same concentration as before the buffer 
exchange. The assay was performed in 520 µl buffer (100 mM ammonium formate, pH 7.5) containing 
1 µl carbonic anhydrase (0.2 mg/ml), 2 mM ATP, 4 mM NADPH, 5 mM MgCl2, 0.5 mM CoA, 50 mM 
NaH13CO3, 0.1 mM coenzyme B12, 5 mM ascorbic acid, 1 mM acetyl-CoA, 20 mM polyphosphate, 
20 mM formate, the enzymes (exchanged buffer) and Nmar0206 with the corresponding amounts 
(MM Table 3 and MM Table 4). Samples were withdrawn (30 µl each) from the reaction mixture and 
quenched in formic acid to a final concentration of 4%. After the 60 min sample, 1 mM of acetyl was 
added to the reaction mixture. The samples were analyzed for CoA-esters and malate with the method 
described below. 
7.11.10. Assay of CETCH 5.4 
The assay of CETCH 5.4 was performed in 520 µl buffer (100 mM MOPS KCl, pH 7.5) containing 1 µl 
carbonic anhydrase (0.2 mg/ml), 2 mM ATP, 4 mM NADPH, 5 mM MgCl2, 0.5 mM CoA, 50 mM 
NaH13CO3, 0.1 mM coenzyme B12, 5 mM ascorbic acid, 1 mM acetyl-CoA, 20 mM polyphosphate, 
20 mM formate and the enzymes with the corresponding amounts (MM Table 3 and MM Table 4). The 
reaction was started with the addition of 200 µM propionyl-CoA and incubated at 30°C. Samples were 
withdrawn (30 µl each) from the reaction mixture and quenched in formic acid to a final concentration 
of 4%. The samples were analyzed for CoA-esters and malate with the method described below. 
7.11.11. Further assays of CETCH 5.4 
For further investigation of the CETCH 5.4, the assay was performed using the protocol and conditions 
mentioned above for CETCH 5.4. To test the effect of the protecting agents for oxidative damage, 
either catalase, coenzyme B12 or ascorbic acid was replaced by water. Further, the addition of 50 mM 
NaH13CO2 was omitted and replaced by water to check if carbon fixation can be achieved at ambient 
CO2 concentration. To investigate why the production of malate ceases, either 5 mM ATP or 200 µM 
propionyl-CoA was added to the reaction after 60 min to restart the process. Additionally one assay 
contained 500 µM malate before the start of the assay. Samples were withdrawn (30 µl each) from the 
reaction mixture and quenched in formic acid to a final concentration of 4%. Malate was quantified 
using the method described below. 
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7.11.12. Lists of enzyme activities and amounts in the CETCH cycle 
MM Table 3 List of enzyme activities in CETCH assays. 
Rxn 
Nr. 
Abbr. Tag 
U ml-1 in 
CETCH 1.0 
U ml-1 in 
CETCH 2.0 
U ml-1 in 
CETCH 3.0 
U ml-1 in 
CETCH 4.0 
U ml-1 in 
CETCH 5.0 
1 pco Pco - - - - 1.71 
12 pcc PccAB 2.41 2.30 2.41 1.02 - 
2+8 ccr Ccr - - - - - 
2+8 ccr Ccr (R152A) 10.9 10.5 11.2 5.3 4.2 
3+9 epi Epi 3.67 5.50 2.00 3.67 3.67 
3 mcm Mcm 0.40 0.30 0.28 0.42 0.60 
4 scr SucD 2.91 2.88 2.16 3.60 2.17 
5 ssr AKR7a2 0.10 0.11 0.10 0.10 0.10 
6 hbs Nmar0206 0.61 0.61 0.58 0.90 0.80 
7 hbd Nmar0207 0.48 0.42 0.28 0.52 0.39 
9 ecm Ecm 0.29 0.28 0.16 0.29 0.28 
10 mco Mco - 0.14 0.13 0.13 0.13 
10 mcd Mcd 0.20 - - - - 
11 mch Mch 16.50 24.75 20.18 16.50 16.50 
12 mcl Mcl1 0.50 0.75 0.50 0.50 0.50 
13 mas GlcB - - 0.72 1.10 1.10 
14 mct Mcl2 - - - 1.10 1.10 
- fdh Fdh - - 0.76 0.75 0.93 
- pkk Pkk2 - - - - 0.92 
- kat KatE - - - 1174.00 1761.00 
 
Rxn 
Nr. 
Abbr. Tag 
U ml-1 in 
CETCH 5.1 
U ml-1 in 
CETCH 5.2 
U ml-1 in 
CETCH 5.3 
U ml-1 in 
CETCH 5.4 
1 pco Pco 1.73 1.73 1.73 1.73 
12 pcc PccAB - - - - 
2+8 ccr Ccr - 3.11 3.11 3.11 
2+8 ccr Ccr (R152A) - - - - 
3+9 epi Epi 4.23 4.23 4.23 4.23 
3 mcm Mcm 0.58 0.58 0.58 0.58 
4 scr SucD 2.95 2.88 2.95 2.88 
5 ssr AKR7a2 0.10 0.10 0.10 0.10 
6 hbs Nmar0206 0.80 0.80 0.80 0.80 
7 hbd Nmar0207 0.94 0.92 0.94 0.92 
9 ecm Ecm 0.28 0.28 0.28 0.28 
10 mco Mco 0.13 0.13 0.13 0.13 
10 mcd Mcd - - - - 
11 mch Mch 19.04 19.04 19.04 19.04 
12 mcl Mcl1 0.50 0.50 0.50 0.50 
13 mas GlcB 1.01 1.01 1.01 1.01 
14 mct Mcl2 0.76 0.76 0.76 0.76 
- fdh Fdh 0.73 0.74 0.73 0.74 
- pkk Pkk2 0.74 0.74 0.74 0.74 
- kat KatE 1523.9 1523.9 1523.9 1523.9 
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MM Table 4 List of enzyme amounts in CETCH assays 
Rxn 
Nr. 
Abbr. Tag 
µg ml-1in 
CETCH 1.0 
µg ml-1in 
CETCH 2.0 
µg ml-1in 
CETCH 3.0 
µg ml-1in 
CETCH 4.0 
µg ml-1in 
CETCH 5.0 
1 pco Pco - - - - 143 
12 pcc PccAB 101 99 100 43 - 
2+8 ccr Ccr - - - - - 
2+8 ccr Ccr (R152A) 128 124 132 62 50 
3+9 epi Epi 8 13 5 8 8 
3 mcm Mcm 20 15 14 21 30 
4 scr SucD 100 99 75 124 75 
5 ssr AKR7a2 27 29 25 26 25 
6 hbs Nmar0206 303 306 291 450 400 
7 hbd Nmar0207 18 16 11 20 15 
9 ecm Ecm 42 40 23 42 40 
10 mco Mco - 1350 1309 1342 1333 
10 mcd Mcd 34 - - - - 
11 mch Mch 11 17 13 11 11 
12 mcl Mcl1 100 150 101 100 100 
13 mas GlcB - - 20 30 30 
14 mct Mcl2 - - 0 6 6 
- fdh Fdh - - 545 533 667 
- pkk Pkk2 - - - - 77 
- kat KatE - - - 100 150 
 
Rxn 
Nr. 
Abbr. Tag 
µg ml-1in 
CETCH 5.1 
µg ml-1in 
CETCH 5.2 
µg ml-1in 
CETCH 5.3 
µg ml-1in 
CETCH 5.4 
1 pco Pco 144 144 144 144 
12 pcc PccAB - - - - 
2+8 ccr Ccr (see methods) 29 29 29 
2+8 ccr Ccr (R152A) - - - - 
3+9 epi Epi 10 10 10 10 
3 mcm Mcm 29 29 29 29 
4 scr SucD 102 99 102 99 
5 ssr AKR7a2 25 25 25 25 
6 hbs Nmar0206 400 400 401 400 
7 hbd Nmar0207 36 35 36 35 
9 ecm Ecm 40 40 40 40 
10 mco Mco 1279 1300 1314 1300 
10 mcd Mcd - - - - 
11 mch Mch 13 13 13 13 
12 mcl Mcl1 99 99 99 99 
13 mas GlcB 28 28 28 28 
14 mct Mcl2 4 4 4 4 
- fdh Fdh 523 528 528 528 
- pkk Pkk2 62 62 62 62 
- kat KatE 130 130 130 130 
 
  
Materials and Methods 
108 
 
 HOPAC cycle assays 
7.12.1. Assay of HOPAC 1.0 
The assay of HOPAC 1.0 was performed in 300 µl buffer (50 mM MOPS, pH 7.5) containing 1 µl carbonic 
anhydrase (0.2 mg/ml), 3 mM ATP, 3 mM NADPH, 3 mM MgCl2, 0.5 mM CoA, 50 mM NaH13CO3 and 
the enzymes with the corresponding amounts (MM Table 5 and MM Table 6). The reaction was started 
with the addition of 500 µM acetyl-CoA and incubated at 30°C. Samples (30 µl each) were withdrawn 
from the reaction mixture and quenched in 3 µl of 40% formic acid. The samples were analyzed for 
CoA-esters with the method described below. 
7.12.2. Assay of HOPAC 2.0 
The assay of HOPAC 1.0 was performed in 300 µl buffer (50 mM MOPS, pH 7.5) containing 1 µl carbonic 
anhydrase (0.2 mg/ml), 3 mM ATP, 3 mM NADPH, 5 mM MgCl2, 0.5 mM CoA, 50 mM NaH13CO3, 
0.1 mM coenzyme B12 and the enzymes with the corresponding amounts (MM Table 5 and MM Table 
6). The reaction was started with the addition of 250 µM acetyl-CoA and incubated at 30°C. Samples 
(30 µl each) were withdrawn from the reaction mixture and quenched in 3 µl of 40% formic acid. The 
samples were analyzed for CoA-esters with the method described below. 
7.12.3. Assay of HOPAC 3.0 and HOPAC 4.0 
The assay of HOPAC 1.0 was performed in 300 µl buffer (50 mM MOPS, pH 7.5) containing 1 µl carbonic 
anhydrase (0.2 mg/ml), 3 mM ATP, 3 mM NADPH, 5 mM MgCl2, 0.5 mM CoA, 50 mM NaH13CO3, 
0.1 mM coenzyme B12, 20 mM formate and, 20 mM polyphosphate and the enzymes with the 
corresponding amounts (MM Table 5 and MM Table 6). The reaction was started with the addition of 
250 µM acetyl-CoA and incubated at 30°C. Samples (30 µl each) were withdrawn from the reaction 
mixture and quenched in 3 µl of 40% formic acid. The samples were analyzed for CoA-esters with the 
method described below. 
7.12.4. Assay of HOPAC 4.1 
The assay of HOPAC 1.0 was performed in 300 µl buffer (50 mM MOPS, pH 7.5) containing 1 µl carbonic 
anhydrase (0.2 mg/ml), 3 mM ATP, 3 mM NADPH, 5 mM MgCl2, 0.5 mM CoA, 50 mM NaH13CO3, 
0.1 mM coenzyme B12, 20 mM formate and, 20 mM polyphosphate and the enzymes with the 
corresponding amounts (MM Table 5 and MM Table 6). The reaction was started with the addition of 
250 µM acetyl-CoA and incubated at 30°C. After 20 min 19 µg of Mcm, 0.5 µl CoA (100 mM) and 2 µl 
of coenzyme B12 (5 mM) were added. Samples (30 µl each) were withdrawn from the reaction mixture 
and quenched in 3 µl of 40% formic acid. The samples were analyzed for CoA-esters with the method 
described below. 
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7.12.5. List of enzyme activities and amounts in the HOPAC cycle 
 
MM Table 5 List of enzyme activities in HOPAC assays 
Rxn 
Nr. 
Abbr. Tag 
U ml-1 in 
HOPAC 1.0 
U ml-1 in 
HOPAC 2.0 
U ml-1 in 
HOPAC 3.0 
U ml-1 in 
HOPAC 4.0 
U ml-1 in 
HOPAC 4.1 
1 pcc Pcc 0.02 0.00 0.00 0.00 0.00 
1 mpc Pcc D407I 0.00 1.05 1.05 1.05 1.05 
2 mcr Mcr 0.68 0.68 0.68 0.68 0.68 
3 hps Nmar1309 0.30 0.60 0.60 0.60 0.61 
4 ech PhaJ 318.27 636.53 636.53 636.53 636.53 
5 ccr Ccr 1.61 6.16 6.16 6.16 6.16 
6 mcm Mcm 0.55 1.27 1.27 1.27 1.27 
6 epi Epi 7.92 7.92 7.92 7.92 7.92 
7 mcd Mcd 0.89 0.99 0.99 0.99 0.99 
8 mch Mch_RS 301.50 301.50 301.50 301.50 301.50 
9 mcl Mcl1 0.51 0.53 0.53 0.53 0.53 
- fdh Fdh - - 0.91 0.91 0.91 
- pkk Pkk2 - - 0.98 0.98 0.98 
- kat KatE - - - 1267.92 1267.92 
- sod SodA - - - n.a n.a 
- sod SodB - - - n.a n.a 
14 etf EtfAB n.a. n.a n.a n.a n.a 
 
MM Table 6 List of enzyme amounts in HOPAC assays 
Rxn 
Nr. 
Abbr. Tag 
µg ml-1 in 
HOPAC 1.0 
µg ml-1 in 
HOPAC 2.0 
µg ml-1 in 
HOPAC 3.0 
µg ml-1 in 
HOPAC 4.0 
µg ml-1 in 
HOPAC 4.1 
1 pcc Pcc 249 - - - - 
1 mpc Pcc D407I 0 950 950 950 950 
2 mcr Mcr 68 68 68 68 68 
3 hps Nmar1309 500 997 997 997 1015 
4 ech PhaJ 51 103 103 103 103 
5 ccr Ccr 15 56 56 56 56 
6 mcm Mcm 28 63 63 63 63 
6 epi Epi 18 18 18 18 18 
7 mcd Mcd 2960 3290 3290 3290 3290 
8 mch Mch_RS 201 201 201 201 201 
9 mcl Mcl1 102 106 106 106 106 
- fdh Fdh - - 653 653 653 
- pkk Pkk2 - - 81 81 81 
- kat KatE - - - 108 108 
- sod SodA - - - 52 52 
- sod SodB - - - 404 404 
14 etf EtfAB 330 2964 2964 2964 2964 
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 UPLC-MS analysis 
7.13.1. UPLC-high resolution MS of CoA esters 
CoA esters were analyzed using an Agilent 6550 iFunnel Q-TOF LC-MS system equipped with an 
electrospray ionization source set to positive ionization mode. Compounds were separated on a RP-18 
column (50 mm x 2.1 mm, particle size 1.7 µm, Kinetex XB-C18, Phenomenex) using a mobile phase 
system comprised of 50 mM ammonium formate pH 8.1 and methanol. Chromatographic separation 
was carried out using the following gradient condition at a flow rate of 250 µl min-1: 0 min 0% methanol; 
1 min 0% methanol, 3 min 2.5% methanol; 9 min 23% methanol; 14 min 80 % methanol; 16 min 80% 
methanol. Capillary voltage was set at 3.5 kV and nitrogen gas was used for nebulizing (20 psig), drying 
(13 l min-1, 225°C) and sheath gas (12 l min-1, 400°C). The TOF was calibrated using an ESI-L Low 
Concentration Tuning Mix (Agilent) before measurement (residuals less than 2 ppm for five reference 
ions) and was recalibrated during a run using 922 m/z as reference mass. MS data were acquired with 
a scan range of 200-1200 m/z.LC-MS data were analyzed using MassHunter Qualitative Analysis 
software (Agilent) and eMZed (181). 
7.13.2. UPLC-high resolution MS of malic acid 
The quenched samples were centrifuged for 10 min at 17,000 rcf, to remove precipitated proteins. The 
samples were diluted 1:4 in H2O for the injection into the HPLC-MS system. Standard curves for 
quantification (2 µM, 10 µM, 25 µM, 50 µM, 100 µM, 150 µM) were prepared. Malic acid was 
separated and detected using an Agilent 6550 iFunnel Q-TOF LC-MS system equipped with an 
electrospray ionization source set to negative ionization mode. The LC conditions were adapted from 
a previously reported method (182). The modified LC method is as follows: The analyte was separated 
on an aminopropyl column (100 mm x 2 mm, particle size 3 µm, 100 Å, Luna NH2, Phenomenex) using 
a mobile phase system comprised of 95:5 20 mM ammonium acetate pH 9.3 (adjusted with ammonium 
hydroxide to a final concentration of approximately 10 mM) / acetonitrile (A) and acetonitrile (B). 
Chromatographic separation was carried out using the following gradient condition at a flow rate of 
250 µl min-1: 0 min 85% B; 7 min 0% B, 14 min 0% B; 15 min 85% B; 17.5 min 85% B. Column oven and 
autosampler temperature were maintained at 15°C. The ESI source was set to the following 
parameters: Capillary voltage was set at 3.5 kV and nitrogen gas was used as nebulizing (20 psig), 
drying (13 l/min, 225 C) and sheath gas (12 l/min, 400 °C). The QTOF mass detector was calibrated prior 
to measurement using an ESI-L Low Concentration Tuning Mix (Agilent) with residuals and corrected 
residuals less than 2 ppm and 1 ppm respectively. MS data were acquired with a scan range of 50-600 
m/z. Autorecalibration was carried out using 113 m/z as reference mass. Subsequent peak integration 
of the malic acid isotopologues was performed using eMZed (181). 
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 Optimized sequences 
 
Optimized sequence of 4-hydroxybutyryl-CoA dehydratase from N. maritimus (nmar0207_opt) 
5’-GGATCCATGGCCAATGTCCTTAAAACCATCCGTAGTGGGGACGACTACATTGAGTCACTGCGTGGTCGTGACCTGAAAGTCTATCTCT
TTGGCGAGTTGGTTAAGGAACCGGTTGATCATCCCATGATTCGCCCGTCGATTAACGCGGTAGCGGAAACCTACGACTTAGCTCTGCGTG
AAGAAGCGCTTGCGTCAGCCGATTCGTCAATCACTGGTCTGAAAGTAAATCGCTTCCTGCATATCGCTGAATCCGCCGAGGATCTGGTTC
TGCAAAACAAAATGCAGCGTAAACTGGGCCAGAATACCGGCACCTGTTTTCAGCGGTGTGTGGGCATGGATGCAATGAACTCGCTGCAT
AGTACTACCTTCGAAATCGATGAAAAGCACGGTACGGACTATCACAAACGGTTTCTGGAGTTCGTGAAGATGGTGCAGCAAGAGAATCT
GGTGATTGGCGGAGCAATGACCGATCCGAAAGGCGATCGCAGCAAAGGTCCCTCCGAACAAGATGATCCGGATCTGTTTACCCGCATTG
TGGATACAGACGAGAAAGGAGTGTACGTGAGTGGCGCGAAAGCACACCAGACGGGCTGTATTAACAGCCATTGGATTATCTTAATGCC
GACGATTCGTTTGACAGAAAGCGATAAAGATTGGGCGATTGTCGGTGCCATTCCAGCCGATGCGAAAGGCGTGACGTATATCTACGGTC
GTCAAAGCTGCGATACTCGCAGCATGGAGGAAGGGGATATCGATGATGGCAACGCGAAATTTGGTGGGCAGGAAGCGTTGATCATTCT
GGATCGCGTTTTCATCCCGTGGGACAAAGTGTTTATGCATGGCGAATACGAATTTGCCAGCATGCTGGTTGAACGCTTTACGTGCTATCA
TCGTCGCAGCTATGTGTGCAAAACGGGTCTGGGTGATGTACTGATCGGTGCAGCGGCTACCATTGCCGACTATAATGGCGTCCCTAAAG
TTTCGCACATCAAAGACAAAATTATCGAGATGACCCATCTCAACGAAACCATTTTCGCAGCGGGTATTGCATCCTCTCATCAAGGGCAGA
AAATGAAATCAGGAGTATATCTGAACGATGATATGCTCGCCCAGGTCTGCAAACACAACGTAACACGCTTCCCGTACGAAATCTCTCGCT
TAGCACAGGACATTGCTGGCGGCCTGGTCGTGACGTTGCCTTCTGAGAAGGACTTTCGTCACCCAGAAGCCGGTCCTTTGCTTAAGAAAT
ATCTGGCGGGTCGCAAAGGCGTGGACGTTGAAAACCGCATGCGCATTCTGCGGTTAATCGAAAATATGACACTTGGCCGTAATGCTGTT
GGATATCTGACCGAGAGTATGCATGGTGCTGGGTCGCCACAGGCACAACGCATTCAGATTCAGCGTCAGATGCAAGTTGGGTATAAGAA
GAATCTCGCGAAGAATTTAGCCGGCATTACTAACGATGTGGAAGAACCGAAAGAATCCAGCGAATACTTCAAACGCGTCTTTAAAACCA
AAGACTCTGTCCTGTAAGAATTC-3’ 
 
Optimized sequence of short chain acyl-CoA oxidase 4 from A. thaliana (acx4_opt) 
5’-CATATGGCAGTGTTATCGTCAGCGGATCGTGCGTCTAACGAAAAGAAAGTGAAATCCAGCTATTTCGATCTTCCGCCTATGGAGATGT
CTGTGGCCTTTCCACAAGCAACACCAGCCAGCACTTTTCCACCGTGTACGAGCGATTACTATCACTTCAACGATCTGCTCACCCCGGAAGA
ACAGGCGATCCGCAAGAAAGTGCGCGAATGCATGGAAAAGGAAGTAGCTCCGATCATGACAGAGTACTGGGAGAAAGCCGAATTTCCG
TTTCACATTACCCCGAAACTGGGTGCAATGGGAGTGGCTGGTGGGAGCATCAAAGGCTATGGATGCCCCGGCTTGTCGATTACCGCGAA
TGCTATTGCCACCGCAGAGATTGCACGCGTTGATGCCAGTTGCTCAACGTTCATTCTGGTCCATTCAAGCCTGGGTATGCTGACCATCGCT
TTGTGTGGCTCTGAAGCGCAGAAAGAGAAATACTTACCGTCCTTGGCGCAACTGAACACTGTAGCGTGTTGGGCCCTGACGGAACCGGA
TAACGGCTCTGACGCGTCGGGTCTGGGTACCACAGCAACCAAAGTTGAAGGCGGTTGGAAAATCAATGGTCAGAAACGCTGGATTGGC
AATAGCACGTTTGCGGATCTGCTCATTATCTTTGCCCGTAATACGACGACTAACCAGATTAACGGCTTTATCGTGAAGAAGGATGCTCCA
GGCCTGAAAGCGACCAAGATTCCGAACAAAATCGGTCTGCGCATGGTTCAGAATGGCGACATTCTTCTGCAGAACGTGTTCGTTCCGGA
TGAGGATCGCTTGCCCGGCGTCAACTCCTTCCAAGACACCAGTAAAGTGTTAGCCGTTAGCCGTGTCATGGTTGCCTGGCAACCTATCGG
AATTTCGATGGGCATCTACGACATGTGTCATCGCTATCTGAAAGAACGGAAACAGTTTGGTGCTCCTTTAGCGGCCTTCCAGCTGAATCA
ACAGAAACTTGTGCAGATGCTGGGGAATGTACAAGCGATGTTTCTTATGGGCTGGCGTCTGTGCAAACTCTATGAAACGGGCCAGATGA
CTCCCGGACAGGCTTCGCTGGGGAAGGCATGGATTAGTTCCAAAGCCCGTGAAACCGCGTCATTAGGTCGTGAACTGCTGGGCGGCAAT
GGGATTCTGGCAGACTTTCTGGTCGCCAAAGCGTTCTGCGATTTGGAACCGATCTATACCTATGAGGGGACTTACGACATTAACACCCTC
GTAACCGGTCGCGAAGTCACGGGTATTGCGAGTTTCAAACCGGCAACACGCAGCCGGCTGTAAGAATTC -3’ 
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8. Supplementary information 
 Gibbs free energies use to calculate Gibbs free energy profiles  
Gibbs free energy values of all reactions for natural and the designed synthetic CO2 fixation pathways 
were calculated or taken from literature with their respective standard deviation if applicable (n.a = 
not applicable). ΔrG’m: Gibbs free energy under standard conditions; ΔrG’ custom: Gibbs free energy 
under defined conditions (see Fig. 8). 
[a]: calculated with eQuilibrator 2.0 (http://equilibrator.weizmann.ac.il) (88); [b]: taken from Fuchs et 
al. 2011 (6); [c]: estimated based on values given by eQuilibrator 2.0 for various short- and medium-
chain CoA-ligases; [d]: estimated based on the value used for succinyl-CoA + NADPH ⇌ succinic 
semialdehyde + NADP+; [e]: estimated based on the value used for succinic semialdehyde + NADPH ⇌ 
4-hydroxybutyrate + NADP+; [f]: estimated based on values given by eQuilibrator 2.0 for glutaryl-CoA 
+ ubiquinone ⇌ glutaconyl-1-CoA + ubiquinol and succinate + ubiquinone ⇌ fumarate + ubiquinol; [g]: 
estimated based on values given by eQuilibrator 2.0 for acrylyl-CoA + H2O ⇌ 3-hydroxypropionyl-CoA, 
fumarate + H2O ⇌ malyl-CoA and mesaconyl-CoA + H2O ⇌ methylmalyl-CoA/citramalyl-CoA; [h]: 
estimated based on values given by eQuilibrator 2.0 for malyl-CoA  ⇌ acetyl-CoA + glyoxylate, 
methylmalyl-CoA ⇌ propionyl-CoA + glyoxylate and citramalyl-CoA ⇌ acetyl-CoA + pyruvate; [i]: 
estimated based on the value used for 4-hydroxybutyrate + CoA + ATP ⇌ 4-hydroxybutyryl-CoA + ADP 
+ Pi; [j]: estimated based on the value used for 4-hydroxybutyryl-CoA ⇌ crotonyl-CoA + H2O; [k]: 
estimated based on the value given by eQuilibrator 2.0 for vinylacetyl-CoA ⇌ crotonyl-CoA; [l]: 
estimated based on the value used for crotonyl-CoA + NADPH + CO2 ⇌ ethylmalonyl-CoA + NADP+; [m]: 
estimated based on the value given by eQuilibrator 2.0 for 3-hydroxybutyryl-CoA ⇌ crotonyl-CoA + 
H2O; [n]: estimated based on the value used for methylsuccinyl-CoA + ubiquinone ⇌ mesaconyl-CoA + 
ubiquinol; [o]: estimated based on the value given by eQuilibrator 2.0 for ethylmalonyl-CoA ⇌ 
methylsuccinyl-CoA; [p]: estimated based on the value given by eQuilibrator 2.0 for butyryl-CoA + 
ubiquinone ⇌ crotonyl-CoA + ubiquinol 
 
A) CETCH cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 crotonyl-CoA + NADPH + CO2 ethylmalonyl-CoA + NADP+ -26.1 ±17 -30.4 ±17 [a] 
2 ethylmalonyl-CoA  methylsuccinyl-CoA 0 ±0 0 ±0 [a] 
3 methylsuccinyl-CoA + UQ mesaconyl-CoA + UQH2 -25.5 ±6.7 -25.5 ±6.7 [a] 
4 mesaconyl-CoA + H2O methylmalyl-CoA 3.3 ±3.7 3.3 ±3.7 [a] 
5 methylmalyl-CoA propionyl-CoA + glyoxylate -1.6 ±16.4 -5.6 ±16.4 [a] 
6 propionyl-CoA + ATP + HCO3- methylmalonyl-CoA -8.2 ±10.3 -20.7 ±10.3 [a] 
7 methylmalonyl-CoA succinyl-CoA 0 ±0 0 ±0 [a] 
8 succinyl-CoA + NADPH succinic semialdehyde + CoA + NADP+ -3 ±5.4 -10.2 ±5.4 [a] 
9 succinic semialdehyde + NADPH 4-hydroxybutyrate + NADP+ -24 n.a. -24 n.a. [b] 
10 4-hydroxybutyrate + CoA + ATP 4-hydroxybutyryl-CoA + ADP + Pi 10 ±16.1 10.4 ±16.1 [c] 
11 4-hydroxybutyryl-CoA  crotonyl-CoA + H2O -7.7 ±15.6 -7.7 ±15.6 [a] 
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B) HOPAC cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 acrylyl-CoA + NADPH + CO2 methylmalonyl-CoA + NADP+ -26 ±17.6 -30.4 ±17.6 [a] 
2 methylmalonyl-CoA succinyl-CoA -7.6 ±4.1 -7.6 ±4.1 [a] 
3 succinyl-CoA + ADP + Pi succinate + ATP + CoA 1.1 ±2.6 0.6 ±2.6 [a] 
4 succinate + UQ fumarate + UQH2 -21.6 ±7.1 -21.6 ±7.1 [a] 
5 fumarate + H2O malate -3.4 ±0.6 -3.4 ±0.6 [a] 
6 malate + ATP + CoA malyl-CoA + ADP + Pi -5.8 ±7.1 -5.4 ±7.1 [a] 
7 malyl-CoA glyoxylate + acetyl-CoA -3 ±5.8 -6.9 ±5.8 [a] 
8 acetyl-CoA + ATP + HCO3- malonyl-CoA + ADP + Pi -9.9 ±6.5 -20.7 ±6.5 [a] 
9 malonyl-CoA + NADPH malonic semialdehyde + CoA + NADP+ -3 ±5.4 -10.2 ±5.4 [d] 
10 malonic semialdehyde + NADPH 3-hydroxypropionate + NADP+ 4.6 ±3.4 -0.9 ±3.4 [e] 
11 3-hydroxypropionate + ATP + CoA 3-hydroxypropionyl-CoA + ADP + Pi 11.2 ±16.1 11.6 ±16.1 [a] 
12 3-hydroxypropionyl-CoA acrylyl-CoA + H2O 0 ±3.8 0 ±3.8 [a] 
 
C) CHYME cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 crotonyl-CoA + NADPH + CO2 ethylmalonyl-CoA + NAPH+ -26.1 ±17 -30.4 ±17 [a] 
2 ethylmalonyl-CoA + UQ ethylidenemalonyl-CoA + UQH2 -21.6 ±7.1 -21.6 ±6.3 [f] 
3 ethylidenemalonyl-CoA + H2O hydroxyethylmalonyl-CoA -0.8 n.a. -0.8 n.a. [g] 
4 hydroxyethylmalonyl-CoA malonyl-CoA + acetaldehyde -3.8 n.a. -7.77 n.a. [h] 
5 malonyl-CoA + NADPH malonic semialdehyde + NADP+ + CoA -4.6 ±8.8 -11.8 ±8.8 [a] 
6 malonic semialdehyde + NADPH 3-hydroxypropionate + NADP+ -19.1 ±5.8 -24.5 ±5.8 [a] 
7 3-hydroxypropionate + CoA + ATP 3-hydroxypropionyl-CoA + ADP + Pi 11.2 ±16.1 11.6 ±16.1 [a] 
8 3-hydroxypropionyl-CoA  acrylyl-CoA + H2O 0 ±3.8 0 ±3.8 [a] 
9 acrylyl-CoA + NADPH propionyl-CoA + NADP+ -56.6 ±16.9 -62 ±16.9 [a] 
10 propionyl-CoA + ATP + HCO3- methylmalonyl-CoA + ADP + Pi -8.2 ±10.3 -20.7 ±10.3 [a] 
11 methylmalonyl-CoA succinyl-CoA 0 ±0 0 ±0 [a] 
12 succinyl-CoA + NADPH succinic semialdehyde + CoA + NADP+ -3 ±5.4 -10.2 ±5.4 [a] 
13 succinic semialdehyde + NADPH 4-hydroxybutyrate + NADP+ -24 n.a. -24 n.a. [b] 
14 4-hydroxybutyrate + CoA + ATP 4-hydroxybutyryl-CoA + ADP + Pi 10 ±16.1 10.4 ±16.1 [c] 
15 4-hydroxybutyryl-CoA  crotonyl-CoA + H2O -7.7 ±15.6 -7.7 ±15.6 [a] 
16 acetaldehyde + CoA + NADP+ acetyl-CoA + NADPH -4.4 ±2.4 2.7 ±2.4 [a] 
 
D) CRACE cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 crotonyl-CoA + NADPH + CO2 ethylmalonyl-CoA + NADP+ -26.1 ±17 -30.4 ±17 [a] 
2 ethylmalonyl-CoA  methylsuccinyl-CoA 0 ±0 0 ±0 [a] 
3 methylsuccinyl-CoA + NADPH methylsuccinic semialdehyde + NADP+ -3 ±5.4 -10.2 ±5.4 [d] 
4 methylsuccinic semialdehyde + NADPH 4-hydroxy-3-methylbutyrate + NADP+ -24 n.a. -24 n.a. [e] 
5 4-hydroxy-3-methylbutyrate + CoA + ATP 4-hydroxy-3-methylbutyryl-CoA + ADP + Pi 10 ±16.1 10.4 ±16.1 [i] 
6 4-hydroxy-3-methylbutyryl-CoA 3-methyl-but-3-enoyl-CoA + H2O -7.7 ±15.6 -7.7 ±15.6 [j] 
7 3-methyl-but-3-enoyl-CoA 3-methylcrotonyl-CoA -7.7 ±16.5 -7.7 ±16.5 [k] 
8 3-methylcrotonyl-CoA + HCO3- + ATP 3-methylglutaconyl-CoA + ADP + Pi -15.4 ±6.3 -26.3 ±6.3 [a] 
9 3-methylglutaconyl-CoA + H2O hydroxymethylglutaryl-CoA -3.1 ±3.7 -3.1 ±3.7 [a] 
10 hydroxymethylglutaryl-CoA acetyl-CoA + acetoacetate -34.7 ±15.9 -38.7 ±15.9 [a] 
11 acetoacetate + CoA + ATP acetoacetyl-CoA + ADP + Pi 11 ±2.8 11.5 ±2.8 [a] 
12 acetoacetyl-CoA + NADPH 3-hydroxybutyryl-CoA + NADP+ -13.2 ±2.5 -18.7 ±2.5 [a] 
13 3-hydroxybutyryl-CoA crotonyl-CoA + H2O 3.8 ±3.3 3.8 ±3.3 [a] 
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E) FUMES cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 fumaryl-CoA + NADPH + CO2 carboxysuccinyl-CoA + NADP+ -26.1 ±17 -30.4 ±17 [l] 
2 carboxysuccinyl-CoA + NADPH formylsuccinate + CoA + NADP+ -3 ±5.4 -10.2 ±5.4 [g] 
3 formylsuccinate + NADPH hydroxymethylsuccinate + NADP+ -24 n.a. -24 n.a. [h] 
4 hydroxymethylsuccinate + CoA + ATP hydroxymethylsuccinyl-CoA + ADP + Pi 10 ±16.1 10.4 ±16.1 [i] 
5 hydroxymethylsuccinyl-CoA itaconyl-CoA + H2O 3.8 ±3.3 3.8 ±3.3 [m] 
6 itaconyl-CoA mesaconyl-CoA -7.7 ±16.5 -7.7 ±16.5 [k] 
7 mesaconyl-CoA + H2O methylmalyl-CoA 3.3 ±3.7 3.3 ±3.7 [a] 
8 methylmalyl-CoA propionyl-CoA + glyoxylate -1.6 ±16.4 -5.6 ±16.4 [a] 
9 propionyl-CoA + ATP + HCO3- methylmalonyl-CoA + ADP + Pi -8.2 ±10.3 -20.7 ±10.3 [a] 
10 methylmalonyl-CoA succinyl-CoA 0 ±0 0 ±0 [a] 
11 succinyl-CoA + UQ fumaryl-CoA + UQH2 -25.5 ±6.7 -25.5 ±6.7 [n] 
 
F) HITME cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 hydroxycrotonyl-CoA + NADPH + CO2 hydroxyethylmalonyl-CoA + NADP+ -26.1 ±17 -30.4 17 [l] 
2 hydroxyethylmalonyl-CoA  hydroxymethylsuccinyl-CoA 0 ±0 0 0 [o] 
3 hydroxymethylsuccinyl-CoA itaconyl-CoA + H2O 3.8 ±3.3 3.8 3.3 [m] 
4 itaconyl-CoA mesaconyl-CoA -7.7 ±16.5 -7.7 16.5 [k] 
5 mesaconyl-CoA + H2O methylmalyl-CoA 3.3 ±3.7 3.3 3.7 [a] 
6 methylmalyl-CoA propionyl-CoA + glyoxylate -1.6 ±16.4 -5.6 16.4 [a] 
7 propionyl-CoA + ATP + HCO3- methylmalonyl-CoA -8.2 ±10.3 -20.7 10.3 [a] 
8 methylmalonyl-CoA succinyl-CoA 0 ±0 0 0 [a] 
9 succinyl-CoA + NADPH succinic semialdehyde + CoA + NADP+ -3 ±5.4 -10.2 5.4 [a] 
10 succinic semialdehyde + NADPH 4-hydroxybutyrate + NADP+ -24 n.a. -24 n.a. [b] 
11 4-hydroxybutyrate + CoA + ATP 4-hydroxybutyryl-CoA + ADP + Pi 10 ±16.1 10.4 16.1 [c] 
12 4-hydroxybutyryl-CoA + UQ hydroxycrotonyl-CoA + UQH2 -27.8 ±17 -27.8 17 [p] 
 
G) HYPA cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 hydroxycrotonyl-CoA + NADPH + CO2 hydroxyethylmalonyl-CoA + NADP+ -26.1 ±17 -30.4 ±17 [l] 
2 hydroxyethylmalonyl-CoA  hydroxymethylsuccinyl-CoA 0 ±0 0 ±0 [o] 
3 hydroxymethylsuccinyl-CoA itaconyl-(C1)-CoA + H2O 3.8 ±3.3 3.8 ±3.3 [m] 
4 itaconyl-(C1)-CoA itaconyl-(C4)-CoA 0 ±0 0 ±0 [o] 
5 itaconyl-(C4)-CoA + H2O citramalyl-CoA -4.5 ±3.1 -4.5 ±3.1 [a] 
6 citramalyl-CoA acetyl-CoA + pyruvate -6.8 ±15.3 -10.8 ±15.3 [a] 
7 acetyl-CoA + ATP + HCO3- malonyl-CoA + ADP + Pi -9.9 ±6.5 -20.7 ±6.5 [a] 
8 malonyl-CoA + NADPH malonic semialdehyde + NADP+ + CoA -3 ±5.4 -10.2 ±5.4 [a] 
9 malonic semialdehyde + NADPH 3-hydroxypropionate + NADP+ 4.6 ±3.4 -0.9 ±3.4 [a] 
10 3-hydroxypropionate + CoA + ATP 3-hydroxypropionyl-CoA + ADP + Pi 11.2 ±16.1 11.6 ±16.1 [a] 
11 3-hydroxypropionyl-CoA  acrylyl-CoA + H2O 0 ±3.8 0 ±3.8 [a] 
12 acrylyl-CoA + NADPH propionyl-CoA + NADP+ -56.6 ±16.9 -62 ±16.9 [a] 
13 propionyl-CoA + ATP + HCO3- methylmalonyl-CoA -8.2 ±10.3 -20.7 ±10.3 [a] 
14 methylmalonyl-CoA succinyl-CoA 0 ±0 0 ±0 [a] 
15 succinyl-CoA + NADPH succinic semialdehyde + CoA + NADP+ -3 ±5.4 -10.2 ±5.4 [a] 
16 succinic semialdehyde + NADPH 4-hydroxybutyrate + NADP+ -24 n.a. -24 n.a. [b] 
17 4-hydroxybutyrate + CoA + ATP 4-hydroxybutyryl-CoA + ADP + Pi 10 ±16.1 10.4 ±16.1 [c] 
18 4-hydroxybutyryl-CoA + UQ hydroxycrotonyl-CoA + UQH2 -27.8 ±17 -27.8 ±17 [p] 
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H) CBB cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 ribulose-1,5-bisphosphate + CO2 + H2O 2 3-phosphoglycerate -37.8 ±7.5 -37.3 ±7.5 [a] 
2 3-phosphoglycerate + ATP 1,3-bisphosphoglycerate + ADP  18.7 ±0.9 17 ±0.9 [a] 
3 bisphosphoglycerate + NADPH glyceraldehyde-3-phosphate + NADP+ -18.3 ±1 -23.2 ±1 [a] 
4 glyceraldehyde-3-phosphate dihydroxyacetone-phosphate -5.5 ±1.1 -5.5 ±1.1 [a] 
5 dihydroxyacetone-phosphate + glyceraldehyde-
3-phosphate 
fructose-1,6-bisphosphate -2.4 ±4.4 1.6 ±4.4 [a] 
6 fruct e-1,6-bisphosphate + H2O fructose-6-phosphate + Pi -28.5 ±4.3 -28 ±4.3 [a] 
7 fructose-6-phosphate + glyceraldehyde-3-
phosphate  
xylulose-5-phosphate + erythrose-4-
phosphate 
10.2 ±3.8 10.2 ±3.8 [a] 
8 erythrose-4-phosphate + dihydroxyacetone-
phosphate 
seduhep ulose-1,7-bisphosphate 3.3 ±5.6 7.3 ±5.6 [a] 
9 seduhep ulose-1,7-bisphosphate + H2O seduheptulose-7-phosphate + Pi -25.1 ±2.4 -24.6 ±2.4 [a] 
10 seduheptulose-7-phosphate +glyceraldehyde-
3-phosphate 
xylulose-5-phosphate + ribose-5-phosphate -4.5 ±4.5 -4.5 ±4.5 [a] 
11 ribose-5-phosphate ribulose-5-phosphate 2 ±1.5 2 ±1.5 [a] 
12 xylulose-5-phosphate ribulose-5-phosphate 3.4 ±2.3 3.4 ±2.3 [a] 
13 ribulose-5-phosphate + ATP ribulose-1,5-bisphosphate + ADP -24.2 ±4.5 -25.9 ±4.5 [a] 
 
I) 3HP bi-cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 acetyl-CoA + ATP + HCO3- propionyl-CoA + ADP + Pi -9.9 6.5 -20.7 6.5 [a] 
2a malonyl-CoA + NADPH malonic semialdehyde + NADP+ + CoA -3 5.4 -10.2 5.4 [a] 
2b malonic semialdehyde + NADPH 3-hydroxypropionate + NADP+ 4.6 3.4 -0.9 3.4 [a] 
3a 3-hydroxypropionate + CoA + ATP 3-hydroxypropionyl-CoA + ADP + Pi 11.2 16.1 11.6 16.1 [a] 
3b 3-hydroxypropionyl-CoA  acrylyl-CoA + H2O 0 3.8 0 3.8 [a] 
3c acrylyl-CoA + NADPH propionyl-CoA + NADP+ -56.6 16.9 -62 16.9 [a] 
4 propionyl-CoA + ATP + HCO3- methylmalonyl-CoA + ADP + Pi -8.2 10.3 -20.7 10.3 [a] 
5+6 methylmalonyl-CoA succinyl-CoA 0 0 0 0 [a] 
7 succinyl-CoA + malate malyl-CoA + succinate -4.8 7.4 -4.8 7.4 [a] 
8 succinate + UQ fumarate + UQH2 -21.6 7.1 -21.6 7.1 [a] 
9 fumarate + H2O malate -3.4 0.6 -3.4 0.6 [a] 
7 succinyl-CoA + malate malyl-CoA + succinate -4.8 7.4 -4.8 7.4 [a] 
10a malyl-CoA acetyl-CoA + glyoxylate -3 5.8 -6.9 5.8 [a] 
1 acetyl-CoA + ATP + HCO3- malonyl-CoA + ADP + Pi -9.9 6.5 -20.7 6.5 [a] 
2a malonyl-CoA + NADPH malonic semialdehyde + NADP+ + CoA -3 5.4 -10.2 5.4 [a] 
2b malonic semialdehyde + NADPH 3-hydroxypropionate + NADP+ 4.6 3.4 -0.9 3.4 [a] 
3a 3-hydroxypropionate + CoA + ATP 3-hydroxypropionyl-CoA + ADP + Pi 11.2 16.1 11.6 16.1 [a] 
3b 3-hydroxypropionyl-CoA  acrylyl-CoA + H2O 0 3.8 0 3.8 [a] 
3c acrylyl-CoA + NADPH propionyl-CoA + NADP+ -56.6 16.9 -62 16.9 [a] 
10b propionyl-CoA + glyoxylate methylmalyl-CoA 1.6 16.4 5.6 16.4 [a] 
11 methylmalyl-CoA mesaconyl-CoA + H2O -3.3 3.7 -3.3 3.7 [a] 
12 mesaconyl-CoA (C1) mesaconyl-CoA (C4) 0 0 0 0 [a] 
13 mesaconyl-CoA  + H2O citramalyl-CoA -3.1 3.7 -3.1 3.7 [a] 
10c citramalyl-CoA pyruvate + acetyl-CoA -6.8 15.3 -10.8 15.3 [a] 
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J) 3HP/4HB cycle 
Rxn Substrates Products ΔrG'm  
(kJ mol-1) 
ΔrG'custom  
(kJ mol-1) 
Source 
1 acetyl-CoA + ATP + HCO3- propionyl-CoA + ADP + Pi -9.9 6.5 -20.7 6.5 [a] 
2 malonyl-CoA + NADPH malonic semialdehyde + NADP+ + CoA -3 5.4 -10.2 5.4 [a] 
3 malonic semialdehyde + NADPH 3-hydroxypropionate + NADP+ 4.6 3.4 -0.9 3.4 [a] 
4 3-hydroxypropionate + CoA + ATP 3-hydroxypropionyl-CoA + ADP + Pi 11.2 16.1 11.6 16.1 [a] 
5 3-hydroxypropionyl-CoA  acrylyl-CoA + H2O 0 3.8 0 3.8 [a] 
6 acrylyl-CoA + NADPH propionyl-CoA + NADP+ -56.6 16.9 -62 16.9 [a] 
7 propionyl-CoA + ATP + HCO3- methylmalonyl-CoA + ADP + Pi -8.2 10.3 -20.7 10.3 [a] 
8 methylmalonyl-CoA succinyl-CoA 0 0 0 0 [a] 
9 succinyl-CoA + NADPH succinic semialdehyde + CoA + NADP+ -3 5.4 -10.2 5.4 [a] 
10 succinic semialdehyde + NADPH 4-hydroxybutyrate + NADP+ -24 n.a. -24 n.a. [b] 
11 4-hydroxybutyrate + CoA + ATP 4-hydroxybutyryl-CoA + ADP + Pi 10 16.1 10.4 16.1 [c] 
12 4-hydroxybutyryl-CoA  crotonyl-CoA + H2O -7.7 15.6 -7.7 15.6 [a] 
13 crotonyl-CoA + H2O 3-hydroxybutyryl-CoA -3.8 3.3 -3.8 3.3 [a] 
14 3-hydroxybutyryl-CoA + NADP+ acetoacetyl-CoA + NADPH 13.2 2.5 18.7 2.5 [a] 
15 acetoacetyl-CoA + CoA 2 acetyl-CoA -25.9 1.7 -28.2 1.7 [a] 
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 Michaelis-Menten Kinetics 
 
SI Fig. 1 Additional Michaelis-Menten kinetics of enzymes characterized in this study (see Table 4 and Table 7 for values) 
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 Crystal structure of MCD 
 
SI Fig. 2 (A) Superposition of a MCD monomer in orange (N-terminal domain in dark orange) with an ACO monomer (PDB ID: 
1IS2) (4.82 Å over 591 Cα-atoms). The central fold is also conserved in ACOs and the structures aligns to some extent. (B) 
Overlay of a MCD monomer with the dimer of ACO in cyan. 
 
 
SI Fig. 3 The sequence alignment of the MCDs of Paracoccus denitrificans and Rhodobacter sphaeroides shows an overall 
identity of 77.8% and a similarity of 86.1%. The catalytic core domain (without the N-terminal extension) shows 88% identity 
and 95% similarity in the amino acid sequence. 
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SI Fig. 4 Michaelis-Menten kinetics of the MCDs of Rhodobacter sphaeroides and Paracoccus denitrificans with (2S)-
methylsuccinyl-CoA as substrate. Both enzymes show very similar catalytic properties. 
 
 
 131 
 
 
  
 132 
 
 
Acknowledgments 
133 
 
9. Acknowledgments 
 
  
 
  
  
 
Curriculum vitae 
  
 
  
 
 
